var title_f9_13_9424="Normal adult wrist lateral radiograph";
var content_f9_13_9424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral view of wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral radiograph of a normal adult wrist shows the outlines of scaphoid, lunate, and capitate bones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9424=[""].join("\n");
var outline_f9_13_9424=null;
var title_f9_13_9425="Color Doppler cord gastroschisi";
var content_f9_13_9425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse section of a 14 week fetus with gastroschisis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 258px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAECAUEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5gYjAwo/KkLYPQZHtTBkrx1oGCNuOcdag6x5bkfKv5UhPP3V/Kmtjqc4oJ9fwoE7DucHAX8qVSB/Ap9iKj7YJJ+lIME8f/roFoS7uQNo/KlLf7K57cVHxgZPFJjggmgokLHA+UfiKQNzwoP4VGTjIBOAcUL1GBx3NBN7slGD/AAqD7CpI229OPwqOPIwR27VZRnIHy0jopRW5fsbuRMKNjZ6bugrZFpdTogjhiZye2Dn3rmwzDqMVuaNrt/azxeU+QDwoRSf5V00pL4Wdbcre6dn4c8NXks0T+RET3Bk24H0712Oo+Hz9jbehWRcEFG4I7VX8J6j9ri8ySWHdwVZ8ZB+grrdWv5vsD+SFjZOmE3bhXXyo8yrWnza7nlStNDclbi3jJjf5CRjFX2vopYgl3wncp8xqhrN4by6ZJkbg5zgBTWM8VsXT9+FQclQ+MVldLY7VT57OWjLdxJY25LQl5DnglSB+J7V1nhO90AxF72RRNjlGiLgD1zWBDDFNaYgUnPQ4zmss+GNQknLgBVPOwI3I96FKzugnShUjyydjvvEUnh69tiltJCkmOCkB3D8a49YNZt9x067uPLHTMmzj8a1tM06bTFWRw0siEFSELY+ua2G8Sam7CP7O23GS32UdPrVOV1qcyg6ekNV5nC6lea6cxzXswOOglBH51iCe6+1oJ55JAeDk9K9VuNUlFqRPDCPZoVBrnri7tLmXy5DaKw67dqkfjWbjG+pvSrStblJ9C1CLT4S5jRzjOWPT8qbrnjWO6tGhSBWf7uFc4+lZ8z6YrZdp2K4wYXB/StC38RabZQGOO1vckZ3vbKwrS8dkzJ07vncbs4e7upAS1xaJjHUtms7MVxMFVQgY+nSvV9N0seKnWS4WGK2BwNwWI/lmuk/4VfoKReYs7K49J1P9KiVNvqbLFU4e7JWfkeYW/h/TPsiytdRFzj5TGf5g16jpL+GfD/hW3Gr6Fb6qn3gdxRQfxrkfFmi2GkWrm3kuzN0G19w/ACtPwNpvgTVrW3s9U1HxXNqDj54Yg2xT+AwB9afuxVramNW80p3djtvDHifSL5Li5Gmb7JQFFok2FiH1ro53srz7Lc2NukdjjLW6Nnf+NZ+m6X4V8L+cPtV+LRccGISH8cD+dXrm5tb63SXRkItT91plKH8BWqSv7x5dR21hsc7reo+EZpZoINCWC/HBYTkkH6V5Z4vs5osSxW1x5A/jbp+Fel6ppVvLfJCr+W0zYklRfnX36VBq/hPwbeq1hN4j8TTXYHCiNhGD6ZK7cfjTlyRVkjehUknzX/U5bwB4V8QP4fvb1PD968VyuYpFIIYevXNdF4FfxRoljJF4a0i7lKORKFhUkN3BJNaGi2OieH9MWxn8d+LLYAYEFqCwX2+VTXP3Nr4g0u4muPB+v6v/AGbOd7y3MoSRm7/KRmsYqT0SNZyU9ZPR97nY3Mj63qcFrrkotNRfn7LI4EzH0CirOuXKW1kunahbT6LZbtiPfSgCb/dOc1w3hPTNQ8QeIftfiPV7+ymteYtQiKu//fXaui8TeHF1++srZfFuq6tbb/mNzEG8sj+6ABzWjlJaNHN7Ompay/ryNwH+w9Oks7LTtRhtpU3G7k+aIjHZic189+K57JZ7hoCsrkkHDA59zivofxj4SutK8LyPqHjrWUtljysMix7TxwOBmvAPBfiDT9A1C8fVvClrr6S/ce4bBHuMjoaym046Kx2YRNNyTv8A15nnuV/ur+VFez/8LA8Lf9En0j/v4P8ACiuLk8z0Paz/AOff5HgZJx1oyG5HJoYA9OvpTTknBP5UHmttDtw/DvQxGPmB9OKQD0xilfOfQUDvoN46enFKCfbNKWPI9qZg4+lMl6bDyfYUgPH1pRnnjHFABA47UitWIW/KkGe3WkwcUo4I55pk3u9SZVZSflz9asRzkdYwRUUc5TAPbirUbq44x+dJHdRS+zId5gccqB9K1dFjYXCPHGsp/ukkVVsdjXCLIyqhbqeK9V0PwtZzwxTJewBiM8SFsfhXVShfVs1q1FTWpW0m01KNQ3k28MYGcwy5YfhXQW63c7JBcXs+1h9zqKRLu40GXfb3Ns4YbCFXdkfQ0+Xxte7vLlgkKnnIt1H61s5JHG1OeqSJV8FvOheJhPnqHIGPYVl6h4KuYkMh0+3C9MAgkGtG18ZrHHxDMjdThVwPwzTpfGouS0RRgPV1A/rUPlYL28WclHjTLoF7l7cDjCx5FdJZeIYLe1ZpIReZH3y7Lj8MVVA0iW4E9x9oWQn/AJ6Dp7VrWkOl3MEiRvJIjDplciqirdQqzi7cyOZn8fZnKpaqFLdd7flgiqE/jS6L7YIyoHXEn9MVZ1PwpcRyvLb+WqE52ySFjj24qtIJbaBR9njZ1GPuVEpM3jGg7cquNlvL7VNyO20NxuzuzWTL4WmUtKJFmHPBX/69StfXOSv2YDnsuB+Fb+g+fIwaRY1AHI3Y5/GpXvPVXLnP2S00OZs7GO0mBuZPsygfeK9a6iw1LRFQRSSwXLjphiBWlqzS3EIjEVmxxgnI4qppPhWOWTzZ/LjTPRHXr6citVFrY5pVoVFeba9CeXTo7hFk0+NYyeQQd3862fDFqImc6u6um7glduPyqc2Twx+VaOruBgZPA/KuX1Ox1iIs89wUQnhY5jzVtW1sc8Z+0XLe35nSeNNR0S206TyjA9yPuIHOW962vhZPob+GXktdXsNH1WfImeWQSOB9DwK8nu5gMpOGnbuWy1c5eXd3FKxs4VtUP8UZ2lj61Dlbc6Vheanyps+mY4dG+zz6fL4k0wLKMyTswXzT3zVfUtf0DS4IbTT57W58ocNFcAKfoDXzparf3B8y7u7lm4+8+7IrotISCLY9wyygHhHTr71Sm3oc8sEoq7dz1e28WXV1qUIsojHFxlX2vj3rp5PEl7P9os/EFxANMKZWRVES/TPXNeRv4ptNOBNnZWe8DlzlG/SsPU/E2q6qrrFdzww/3Vk4P4Gm4r1M1h5Seisj2fwpeW+l6dJH4X8Q6FpVpuZjDdYkdvfJOa878e+Ift2rublvtflnHmWpChj6gCvNjY3M96dkryOOWJANenfDvwdPqjq09usqA4yVHy+9TG+ptOlCj78pXLvw31bUtUuJdLsYpLMFTtlvIBsx9RyTXcX/AIIuo9EGns7NqUpJN5CzpEPy5FdzonhHRtItxLcW8DOgzuaLBB/CqOu/EHw/pe6GO7ikdTjyhuGP0pL7zklNyleCOC0n4a6xo7y3Oo61DfxlNoV5pGx+DZrjJPhzqWr6pPBBqWl2oJyzTTEdfTiu41L4jteyMthbFR3CzD+ormNWh1/VgJLfSzbtj/Xl0Y/rVuK5bMuEqvPzN2uZH/Cidb/6GTw9/wB/zRTf+ET8W/8AP9J/35jorD2f9f0zt+sVP+fi/r5Hz4eSCTxSY5wDz6GlyR0GOOtNOW+8a5TBsUkDggfnS/e6gE0hGDgD8KQcDjucUBcUdBgigqSRxQBjnAGe9C9ueM9+9IEhTkjGe1N57ZHHpSk9uB9acD1z1oHuR556cUEHHtTjkDgUhPbg4pkWJIly4yBWpZ2ySZw6p9az4JWUjHzL9K19OmtDkXUTNk/eVsYq6dm9TuocttDQtdHLIsrSjZnGcd63dMvb1Jks4L+dCTwin/61ZOnWP2q48uKeFFyCA03GP8a9B0TwgrhJWmj81cZdLoYI/EV0qN9jadWNNWmy9pfh7WIolnn0w3CE5Ejyjn61dm1DTYkdb7T7ZJAcDLM3PvWrdR3FnZYinjYKuAvngg8fWuNvhuZZJUbcxyQOQKTfLscsX7XWRavLf7dHu0zSQP8AajPB/M1zc9jd2szPcWJxnnMgH9a6bSvFEFgCsqlgp4xHyK6zR/E2hz5d4XZn+ZgbcEj2p6MftalLTl0+ZwFpa2F5Kn2y0RvRWk/wrt9Ms9KhhVbeOOIgdgTir+oapoEkZe2hdJhnk26qK5uDVLa0nEtw0ioDyFGR+Wa0jZHNUlKr0a8jVvdJv5j5lpdMrEfwxgk1wetf2zaO0ct3Ih5/1kak/pXok3jnS4rcNEWJx8u6AkfpXHz6zb65fH7XDhA3BiUg/rVO0la5NDng7yjoYmnwhHP2y+SRSuTitOHTdIugjC8hifoN4Y/pXRyPoosWhtBMZSOrwDI/GuG1HTrqO586CWRYwckebgH8KzcLG0arqPsams+G7u3haXTrqKVuoSOHmuNmbWLKcm6uFiGcnfGMV0jeLUsR5NwRvwB0Ymue1XxFDdkhUEox/ED1/GnzQRrShVekjV0vxhewDy7WB5pRxuiVdp/CtK4vtW1FhJdpIi+6Bf5Vz2jTXUgV7O0iAHXBwa2b68ulgzNmMEdVbNVzcy3B0lGXupX/ABNS01WwsYiLmZFfpzIAR+dct4lvtOvn/wBGwzdchs1z+r3MUzuWkMshPUjpWdBII3DBmHPas3NN8p0U6PI+fqbNhHfO5FomXJ4XGeK7Lw/4H1y7kWe/xBGeSjowJHtV7wHpd3eRRXNtZvjjEnH5ivSpdI1M2haXVbqBQOVEecfQ1SptanLiMbryqxw154T0OFcXUku9eX2T459Oa4bxNYQs6ppUN0EU8sxP866PXdVt4dRMDyi9CnDMy7SPrWout6KkC7IYWY8sFLrz+IpSd9ApOULSd2ef6RpxhlVruVfL7kMQ1eqaV42g0ezSO3DfJwCItxP5GuF1ONL2cvDuiHYfexXYfD5tMLpYP4IOu3SYMlwkwUqvuCazTfQ0xCjOKcv0N211rV/EaeY08kMB/gDMpI/OpLvTZREPKQyPnrKmR+NWPGGr+HdBuYodJitbaUDMlusp3Rn0Oaj8L+Jxqd+kc8Mi2BOGZnG38wM10JpbnlSjP4oqyM5tQk07Bnt7IkcEmLJq/H8TbXSoStlZw3s5H/La2YKD9c12+reFvB2o2Jax0q3v7kdEhmO8H868+v8AwDrKbja+HdRKHoqMvA9OtRJ3WmhpT5G/eHf8Lg1j/oDaT/3w1Fc7/wAIV4l/6FnVvzX/ABorO3mdfLR8v6+Z887T1Hp1oztxnmg8HPpQQMgkCuMy22FY5zx+BpG+6Mnp6UcDsCKAN2FHHfmge4+OPe3FS/ZTjAPB602MEHgD61bQlsYAzQrHVSpRktUU2t2zjBI+tL5L4bgj3zXq3wx0qza6DX9qZGyDnCkD/vqvpnQvCWg6haAlVJK8krGMfkK6PYaXbOarUhTnypXPg4p36U3ywM8H8q+2PEnwI8NairSwwzJM3O9ZQoz9AK8N+IXwZv8Aw5HLc2kkUtuozt3l2x9AtZuk+jHGdOb7M8dQ4AAHSrtpEJXAJC54z6VBJC8TlXUqw4KsMEU9QQeKzWj1O2krbnS2GkQPljdKoyMHGcGus0m7kgX7OzGeLoBwAK4fStQS34nDEZ/hArs9H1TRJpVBF4WPULGMZrtjJPYKqdu6OwsfD82qIj20yoTyVVAdpqa98Mazaw5bT7i6THLqQB/OpND1aC13taxziPI270wOlX7zxtqkC4is7ORe29m5+tNxT1OL2lS9keaalaala3eZNLnji9HUH9c1d03xLpenoftWiTtIowAJcGtTUPEetXpLXOnaSIjwQrMT+tZ4WykBN6skbnn5ISwo5bbG/PzK019zZl6hrcOrz4tbV7WMngH5vzqe08KXVwplj1K2QEcAxEn6e1WhpOls6yQXl2D1IMYFdNokWlwBRqGp3uzuI4d2R70ku451uWNqenyOLutNns/klnilwegOOKLC4sEGJcQt0O6UV7ppV34PaNIorWKc45Mtn8x+pxVbV/D+h6irJb6bZoxGNwgUEfTNWlrocssWtp3PIpprGMGS3v4Q3oGzmuV1bV7mRiouosH26j616ZqHwouZnZrW8kQHsWjAFcnrvgttDG/UJy6jnqrEflTktNTejVpN6O79Dh5GIYtMwk5BGDVeSaSYYwuF7hRW7dXOkwr8kaSOPWIqawrqdZXJijSIH+7xXNOSR3x13Q2KWRXO2Qrng84rXtre3eLE9wWJ7K+Oay7WON8KXDO3Yg1u6fpSiUeaBj6Zq6cbq7JnKxTvrO0jGYt/HXLDrWSyqRlSMZ7muzubDTfLJYgem5Twa5XVLeKGUiBgVPIwOKmpG2o4VOZFrT/EF5pqKltIARznLf41ox6/rGsP5LXcqBjz5crKf51yKjn5hmuj8PpcBg9taSYA5kzx+tRTm5PVkOMXrY6q38HhkWZ5bne3XMmcn34rk9alksrt4RJJlT/fyK2tR8Q67FEVfUGEQ/h2LXKX17NeOWuZd5z1wB/KtKk1ayQqUKi1m7lux1m4gfKiN+MfOT/jXs3w/wDHfhOPw29lr13c6VfSEhpNOt234/3+a8COOgq1axyHJB24rOM5PRBVowqfEek+JX8GyeILU6TrOt3FlI3+kzXUO+QfTPNdhoOt+GNOukXT728Glbf3ktxbkysfbHSvKLWysoohJdSxSsFzgkqf0qul9bQSt5JwM8YPFa8so7mUqMai5bv+vkfRd5400GHSpn8OajeTX+35fMiMY/PArzC88deMElcrrt/GOSVW4yFrirnXrhlConA6HAOa0fA+seE4JblvG2j3mqFz+5FvLsCDvkAjmk5LqTHC+zTaV/x/yNX/AITvxd/0MV//AOBJ/wAKKuf258If+hJ1v/wLP/xdFT7WPb8R2l/z7/BHiHHTpQw9Rml4AwOvpSE9+oHGK5zmduoYJ6DFKARg9zTgu5uPun1qVYye9I0jTb2HRuFP/wBeug8JRWtxrECXzKsRPfpWXZ6c9ycx4OOOTXY6H4Se6YNAzCZexYACt6MJXTsdDfLBqTsfQXhv4eaLqNlG9lPbo2OoiLc/ia6uHwzrfh2FW0+5W6hXnykgWMn8a8b8KQeINGnjDXEvl9lWZ2B+uK9o0LWr6SNVmUbO5ZmJP511uMtzxajSdua4qeM72DCanYT2bdAZJVIP5CsXxZrtzfWbrZTMeMEIQK6y9sV1CEsE+fHB6Vy19pV5aPmeGBoic7t2T+VEeVGbbZ8/+LvDVzqN89xLbTM5/iznNctceHY7U5lDADqWyBX0fqVtBcxEIi7vdQBj8a8z8S+XaK6zwW23PXbnP0qZRitT0sPiJStE4nTtK0S6+SXUrWJugDMRmujsPD8NrsezuoJlAxhUPP41zV9pY1ACSwVPMJ4AAT8ahgsPEFlIu64mSPOcLcf/AF6iMl2OucHL7fyZ217rV9YW7JJC0ikcZAxXK33jDVeApQJyNvlqeK6PQJbyRW+2wxT4HBkOTipdV0Z7shrXTbRG6kLgA1o4uWqZz05U6btOK9TjYvFepxux2rlj18sH8q6PTNd1DUQFks7qbuWjRQP0qhcaPqFkrSy6ZahB1JkBxVfTNZYTBQqw5P8AyxY1PLJbs6H7OavBI37rTNUOXg0y7CH+Noy1cxPrF7YTFZ38t88q0db154h16Nf3FzcpCOpeXHFL4WsbTxPej7W5mfOCWj3kH8aLNvQhNQi5VErFfT/Ft15iGCSIFjgnywTW0LvVdXXEmpWcSdQZI8fyr0iw+GOhJCGkt0RvXyAKp6r4M0m3G2G9kTjAVYBir5H3OR4mlf3Y2+Ry9roV+8JEmqWcjHoVLcVn6p4Td90t1qFsSBn/AFjDP51qXVrd6azfYr5nQdc4XiszU/E8UMSx3VvE8mDgl+TRypbjjUqN3gY/9h2LfLI8YwMHEgrOvPD2iDeTcqjLyf8ASF5qxLaXWtYktEeFMjmLvUU3hQrETdTO7deYhUStbY64t396fyMCU6TZBxBJK0o6YIYfnWdcarNISqhVT9anv9HFruLzAYGfu1jyKFbAYEeorllJo67ddyykiOv75pySeinIp8dq1wwWBJCcfx9KrQSmNw2TwexrSfWrryhGkrhQOnH+FOMlbUpq+wsenywcOsO7IyCwNPRZl4+0eWF67ZKzJbmeZtzsSfWrOnWsck6fapo0j6nccZq1UvokJK25bgsbnUrlILQSSu+AMgkZ/KvRfDXwO1nVCsl7NBFEeojl+b9VrpvhhqmlaZEqaZZyhgcNMs+5Prg17rpWoxyW6vcX1uQRkKSARVOMd2ebiMXNPlirHi3/AAoXSbKLfc3d8zY7OjAH8qwdS+G2jWQZxd6goXqQF/wr3zX/ABPoemWzNdTwnjnEq18/fEP4i/bvNg00ssTHGTGjrj69RVR5UuxhTqV6krJnC+IY9E08GC1uL2WcdfMQY+mRXNWkRkcvtG0HvV21eyim82csXJ3cEU7UNV+0MRaRNt9WUE1Dve57EE0rFd9stxmWUxxquQQP0rs/BfgvWPFVnM3hywtbmOI7WmmlEbZ645rz4RMz4ZHyecAV1/h7R9YuWP2OSW0Rh2Z48/lSUZT2CrU5I72Oh/4U/wCMv+gXbf8AgWtFN/4QjWf+gnL/AOBMlFP2M/6f/AOX67L+dfc/8zxcLnripBHyMUwZ6dsVYRSBXKZU4p9BBEc9M1LHA7H5Rn2rQ0WKC6vEiuGYAnHFeqaL8PhLAk8TZJ/hYKAa3p0eZXNZzp0tzzrQdLv5rhWgKRseAXFeyeCfD0zyp9uYEjjzHUhav6P4TEEmy6tol44ddrZ/KuujUWEalEWUdweAK66a5FoeficT7TSJ2fh3Q1igGZYpVP8AzzBwBXRf2RZeWd0ZViODuIxXA2Gtz4H2CYkqMmNiVWi4+JUdgu3W44Ldh12s78evApS5nqmckI30sdRfldLUC2uYQF6R5BNW7LVbadAryxCU9V3DP5V5NqHiXTfFd5FHpWr3Cz7vuQoyZ/EjpTr3UptJ1OExRq8iYDsW5HvwKfKmtQkpRdj0HxTpqXdtIUhnmY/woT6e1eMeINA1wSusej3sijvHBur1C08cNFCr3NsiL2YyHJ/DFa0XieG8tfMiO0nrtLf4Vm29jWnPkfNY+W9QtpLOffNF9mnU5Mcw2sD9KrReKLxN0d0puIxyPKhUY/HrXs/j3xV4asndr/wrp2pz95JG+b+VcBH8RfC8sipD8PNOAVsFhLnA/KkvdZ6cKjqRT5L/AHGFZanaSnfJb3agHpjH/wBaut0fVdIeNYw5t3P8U7qAf1q5NpngfVpVupfFMOlRSKC1rHB8sR7jJ61nXfhL4dPlR8QoVA6N9mBNP2jj1MZxjU6Nfeamp31vFFiC7s5nI4COr/pXnGuWVxPKJEtuc5yEK10dr4S8Exzbrb4jJu7bbTBroodC0N4I40+I/nzudsduLUbpD2UDrRz33Y6aVJ+7+T/yOA0u1u5I1V1jQDoJOo+tdDY6fcQKSZ7BNwyCJNpNS6r4G8dW7hbTSLmRGOUfcmW/DPFQW3w68dXEobVdKukOOpMbcfgacXYufLNX51Y1LPVbnT5FZbsSbuoMpcD9a63T/GMaw5mQFhxwgP8AM1yLfDrxLDGWt9MmkPU8KpP61BD4H8W+Yr3ehTR2hYB5mdcIO5IzVczWljmlToyV+Y7i98dK0LrBaRmTHG62GP51xnjnRtW1Oe2Lw2bJNEJUeKExjnqO/NdXpdp4MtARdeJ9NmlXg5UrtPp1roZb7Qr6ytrTSvEVpJcw52CIFiV9PaplLVCp2pptLXozx+w8I63HhEuLaJMZA8xhn9KW98EahOCJbgBu2y4Iz+ddVrGs39jcvCb4fKfvbV/liufvPEJYf6XqkLFs5RlAJ/IUNI0jUrS95fkcve+AJokL3M4UAZ4nVq4fVLBbWZkiMjhepIr1eBNOv1zJp7zHs4kIFJc6LbKAyQtGQcYZs0vYqS0OiOKcXae542qjPOasB4lX/Vgn1OeK6zXpjZblhhw2fv4BArmbnV76SNo2lVkIxjy1/wAKwkow0OuM5OPNYpvIu7gAewoVTJ0x+JqEZJyakVCTgfpWSuyuZs2dJ1zVdJaP7Le3UUan7iSkCuzsPFPinUowIbmVw3GfNAP05rjdJtVil82c9BnG4DP511tl4ttrWLCQPgcElFIrqikt2YVoX+GKbHavp+uTx79SvbpiBnY7hl/SuU1SC4hIUDfGfvHGK29X8bPdIyxhcdBmIDj865S71Oad2bPB7Y4pTcegUYTS9+yHLBEEBYgn3p0YllkCWqDdns33qz2kZmyxq9YajNAwEYj68EqOKiMk9Do9DptB0m/WQSSWLSYHTeOa9O8MHT5rJxrviZvDbg8RCMOzAdycGvNtNGoaow3TQxoOpyVH6V0aaMqgiGHUdQkHJ+yIZ1B9yOldKtbc4K/vP3vw/wCCejeb4M/6KUP+/P8A9aivOPsV7/0AdU/8AWoqb+Zj7CP9W/yPEAe3OfapkLY2gk+tRjgDjk1PEOBiuBm9OOpNFknr0ruPB2qywSRQyhvJJGSpwf1NcrpkMElwFuGKg9MDNdzpWjWyPGY5pgp5wY85rpoxa1OiryqPLI9q0i4zaRvaTRDIGNwDYprzXIuj9vgu7mLPzGG2Cg/T2rkdFM2mXCMBPLDnIy+0D2IFezeGtZ8NajCq3KQGUcMpDNg/lXXKSseFKHK/Ip+GLHQXO+JZo5G5YTXIJH4Zro73RNNvofLcqwxjhxU8nhzRbkeZp8cNux/ijh5P51mPb3mkTHfG1zD2d2C49sCs+a+zJ6nNDwTHpWpteWaxFRzh2LsPoKyNU1ye2uX+0WqmIf3IQT+OTmvQRqivbvJ5KgjOcNmvE/Hfj/QtNu5GVYNRud21oY5WUr9TjFDml8RpCnKpLRXOltvE+lzgBrW8Vv7zRKB/OmNeabJLx9oUnoDKAPx5rK8HeI/CviJI1uIrOG5floizPt+pwK7s+FvCNxGHf7E7Y6lCaT5WtCnHkdmmjz3XNHtNVQBncjtskFcRe+F4bCcvbyru64lk4r2LUPC9v5R/sXUYoFHQQwcZ/E15d4w8P69FMXls5bkA8OSMEfQUmrdDooVW3y82hgy65facTG66fND3CxhzWlod9YasDHNp05cHrHbiuYCPbSYutN+fOSN+PxrufD3iqzsI1T7IkYPVmuAD/Kqil1N60Wl7kfuGXekWEMeYLW5Rs5y0e0GsS8mWBwyq4mU5V1GCCO4NdjqviiyvbdkW9iRWHds4/GuTjS3e5+a5QgfxGqlGNjGlOf2iFZ9cvyG/tvVgw6H7W449uahvh4ktmLnxFqZUc4N85P8AOtn+09PtVKm7Qkfw9CD+Vc5rWpteE/ZbyMHptVc/nWbgkjop1Zyla1l6Gp4f1jV7iYi41rU1UHnN0wH867H/AISmHT123WoancqMDYJTKv5ZrxyZdUjXoZVJyGCjimWeqvZy/wCkIw6dsGhT5VZo0qYZVXe+h7Lb+K/DtzId1pNnODmxBNdr4TuNHvJ2mth5Oe3kLHXhVn4msWwJCAvAILf/AFq67w94q0WPUbZUEckzNhQrcfTpSVRN7nHVwzivdTPWdX06xmDtLFCc9CyrmvKvGOjadHISGKux4I2j+VJ8QfEGoSagYLOzuPu4DmNTj865jwz4Zu9Wuy91FJIxPORz+lF3eyQ6NPlXtJSsjp/Cml2Srua5vFXdg4Xcp/GuvuLbSAgUNNO7DgPAee3Wul8J+AdPitk3wNyoyspcY/WuvPhrRrZQZWSPA5zMwq4zsrM5as+eV0z5x8VadaOsghj2Fs4xGRivMb3R1ikbErsTyCUr6/8AEEXhi3gkZ51kYD7iXQBP5mvE/FOracWddNs7mIdN0m1x+lTKCkdOHxM17tjx/wAtbfPmW2/jGWJFVBcBGJCqv0zW7rVxdXJczSo654Cpg1gtE2T8jHHfFZzi4/CenFtomF6XxuG7HrSzXDNGAihAeuO9QCJ4zkqV56kVKiSS/d2j3NPeOu41d7lfljyKmSN3yqqT9BT/ACigBdlwOuDzXtnwX8Va7N5ekWFl4etbGBd7XWowbS4z0DZ+Y1mopbiqTdOPMeLPZMqnLjIGcYqrnY3QE16h8eNfj1PxL9ntoEjhhGDIsYVZD6qR1Fcv8MvPHi+0eytrW6ulyY4rpN0ZPqwqXbmsgjNunz2KemavLEiiWYrGP4a7Xw78SdQ8LWjxaJI8Uch3MI9vJ9eRXuWsrJrPhSXR7uHw8utzrt3QoEhj+pxnNeTt8AtdKkjXdA5Gf+Poj+lau8VZnNGtSqp8+hW/4Xn4i/5+Lv8A7+L/APE0U3/hRevf9Bjw/wD+Bh/worK8u5f+yHim3HUGpYIwzgA4z6mnJG2MEZq3aWLzToiKQWPUis4q7NI03ud14M8N3kqJLGYdpPQqS34cV7DpHgXSdSt9tz9pSQDH+u8tc1geBvtek2caXFoZomUbZHfYK7q31TTblEWWaO0kBBAB35/SvRsrHkV683PR/cJaeEIdGZdzSS2/ZYWLH8zW3Y6BpN9GRby3EMp4Ae4CH8hVu2sbu9iBtNUkkhI6CLGaZb+DJvtnnyMol673iBP86T00OW7buV7vw1rGmgSaZdxSAHOJZ5XB/AVc07xXc2bCDW7bJx1jtmK4+pNdLDHf2cI2ObgqPuqoXNYmu6tH8y6rosnPQyzD8+KlJSG3Y0V8Q6Pc2bSGKRU7jygK8V+M134KurWOK8SW3LtkNawx+Z9TXVeIo7a+0trezli0+OVec/MRXFn4O2F4hkZ45Xbq6K6598ZqZ03sjow1SmnzTdvQ574Yf8IhBryR6Pc6lLcydryNAgH1zX0Pb3McFsBKti6HoECs35Zr551D4IvHI7R61FAn9xrdmK/jmpvDPgW58PX/AJ9n4zsopFYB43tiSR6c9KzjzLRo6ayo1PejPXz/AK/Q9u1e+0eWPE322LH/AD7xYGa4jWrzSFkCwz6g2P8Anrjj65Nar6uEtCJbyCcDrtG3J9hXjnxB1LTbybabcbgfmYy5H1FbNW1Ry0abqSsdzFDbSyF4oreQ9zKEJrQhW1ijHn2mncdlhViDXjGmpo8KLLHdQJIvIBkJya3rLxjeWYX7PbXM8I6Mipj9RVR8zeph5fZf6HZ61qulQI5ewCgDqLMYrg9Y8SaeiMqQqOOMQbatXXxDWRCl3aXKk8Euyj+QrlNQvtO1SbMj7cn+J+1Epq2jNKNBxfvxf3lW4U6lICk0qZ6Ag0kekLbygzT3Sg94xzXUaAbSyRBassi9SFfPP41d1Lxhp8CeXcQSTgnBRJVyPrxWU3FK7OqMpuXLGOhzyz6dZwYkuLsr6suTXO6vNZ3JU2jzN6l1AqTXr6HU74y21u8Mf91myaqJGB/DXDUrX0PUoYbqV1Xb1Ga0fDM3k+IbBogTIJVwMZ5zVWRR0Ax70y1aSLUbeSFgkiSKVY9Ac1FN3aZVeHLGyPSPiB4lkstePlWsEhZQS7Ej9BUOheO54pAILaKOTONyFx+tQeO7W1W8s7m4YySyqDIU7n29Kf4f12y0u6Jt7G745DEKwB9ea9V01d6ng6Spr3bndw+KfEuo2oazmurceqXBB/JqqXOr+KY+NQ1e9ZCeplDfyFXoPiIzwqv2Scsey2yE1FPqlzqp3S6Xfqh9bbH8qcUr6HM7pWcUkcrfatcTMVkupZSD/EOh9az54b+5PFzKAw6DFdDezWtmC/8AZ2o7xwP9GLVztzqWqXe6KOO3gtu3mRFJBVcyW5tBSlrFW9SNdKRV/wBLGcHlmFU9R0aERu9jgYGSyjgfnUV3pt2w3QNJKRzgEt+gqtHbaq4UzQGONexR1P6iou9rHSklrzGV9k1CeQqPMPblsCtaw8JaxMu7ymRPUYP9a39HvdGspFN59sE3ptBz+daWo+MdNhgYWqyKR2aHg/rUuEV8TG61Vu1OJx974RubdQ0xkBP+wMfzrb8IeMtD0OzlsfE2gjxEsRxb+dIFWEdwBj9a5XVdcvNUcxkgoT8u0Ff61Vj0pyhaY7e/UVhKX8hu6blH96a2peJrDUvFsOo3OjqdIiOE00SkKEHRd2Kmk8U28Hi+DVvDumrodvHgNDA5YsufmGT0JHFcpcKkchVCSB3NQDJGSeKz5nfUHCK08j2PW/iF4ZvrS4i0bw6dMvLkfvrpp9zP9a4KW/SEEK4c4znfWRpyp567mx/KvT/CPjCz8KWc8aaFpOoNKSzS3cW5hx0z6VstVqQ4+zXuq/zOI/4SEesn5rRXon/Cz7T/AKFTwz/4Cn/Cilyv+kTep/I/vMTwZZW97EjFIggGDgLuIr0u0+H2i6lEGVryKQjAKuF/pXz/AOENUXT79WkcohIw3ZT619JeGNbNxZxv56zgDkxYxn64raCUo3OLFSqQlzRehBp3hzUvDDyDdBc25IwZWaVwP5VusNOvEVHE0cuOWSMIAfrWj/a6zrjcLXtiRgcmsHWNKku5g9viUHn5EyBWiWhwSk5Su2DaXq1ndCXSr2SSMclbi8YD8hXQ6X4r12FQl3a2ZC4yQ0jfzrg5G1XR5w8O6M56vGGz+ddd4f8AE32pVS4kTzhwQdoJ/CiyYSbSudWPFtwpHm2sSk+garEevxX0m2ezt2wcfPGW/nVGKU3AwqlV9etX7awbIcNk9elLliiLsztd0+3vgCsEaMvOEQCubkFzpzERSP5Z6Aymu8lCqT5hX6k4rmfEVppt9C8c1zA5IxtWXFCelgOR1m7v5gVTaGI6iXBrzTULXWjdSm6u7iCIHho5CxNbOuS3ehX5bS5oEjHQEeZkfU966Dwn4tnu1AvAjg8fIEWkkpHVFypR5lqjiv7GmmgD/wDCQauwP8LPxXJ67pktrMwmd7j3kOc19IyXlnJEBsAY+u3864nxwIJ9IuWJRjGCwyRgU5R0NKGKfOlY+d7vIcqIgoB7VoWN7cqojRcDGPv1CbmRo3nuNjseECADafU06zvtQhwY2gAzn/Ur/hXN7SK3Z7ipVJ6RiOvI1lQyXMjL+GapxRWXmLm6kC55/dV1lj4r1GzhUQLbmQf89IFYD8KszeMNXu4THcx6ayHrizUf0rOWIjHb+vxN4YDETdrfj/wCv4a8Ntr00iaNq12HjXc6pHsAH4kVzGr2P2S+khR3lZTlmkG1s+9aJUiV3i3IWOfkJA/SoXtw2cg5781y1MSpHfTymcG3cyodzMVVcnvUpkA4Jwanlt0BJGfzqnIpH3Q3Hc9KzVp7CnCdBWZp6Joeo6/cNDpUInkQbmG9VwPxNbTfDzxLDcW8zaapAcblWdOOfXNbPg7xHfwWyRPDbPgYQxwAED0JHWutTWppZIFFtKhdgP8AU8fTrXfRw6tc8TGYupGTikiPxhplnZLZvdxow2jIYZ2nHQetczFPobTbCsMWT3RjtrqfidLM0NmsEUjZHLKh2j6muCt7SXzxJI0Yj7jgE12ufK7Hm0afPBSbPVvClx4Ms41ee4tJZDjJdHGP0rrpPFnhSFdsKWbA+juP6V574Zn0yBQiw3bzEDJMIYfga7IQfaYVPkQ7O26MBsVLd9bnJNJPVMoax4o0m6/dW2nRkN0eOZsfyrhtbtUupDKMpj+Hrn8a7u90eFhhIcP6J0rJl0LUYseWkEinrvJBx9MUKLe46dSMdVocxoV8ml4MenyzPk4ZH2/zq3rutXlzbFWtZ4oyM8uGzVvUbS6sraR3hgHOTtbk+9cPf3kdxPtNzNGM8iNsg1fPyqx0QpqrLmsc/wCIJbNJiZFZpzzksc1heZ5jA7toB6Z/Wu/j0PSmLSzS3M8h/haMEH8aW6g0u2gwlrAWXgZgxn8awlG7O+FdLRJs8/F1JEWCt074/lUc93LP/rZCw+mK2NUubZ3wLaNAOPljxismQxGT93ENvuDWMovudKdyoTkYANMYEnOK05LV9gaOJQD3DVTYHBBAFRKHLuJxuRqSOCK7r4e+Cbfxbb3ct34j0zRhCdqrdt8z8ZyBnpXEpjjI49q3NJt4ghaRVkY9OOlVBXFKMuX3XY7/AP4VTpn/AEPugfk3+NFYPlL/AM8x/wB8iitbRMf338/4I85i4IB4P1r0Dwdd6zDGhtnYwA5x55Xj6VxEIDnGDk9K9I8HWWqrsn0+EuTjI8gsKVGNtRVbRp2f4ndaV4kPEd9DsI4yu5z+JNara6Bj7Bc3jt/d5RQKXTZrzyjFqMEu8gjiMIDVa/0C6uf3lm6RKOxBya6r9zxmo83Yu2+rXF5OizxJMcbf3pYgc10dpbQ/fNrDCW4zEnJrH8JyzabcCO+0u9uTu/1kSBVH4mvYNJGl3UCnb5TkA7HkGaUnbUzlvY4MusfEF9dK/TacgVe0u51lJmckyW4HBafn8q7y60i1uYwowVPUq2Kw5tFg08StGQm7qzHP86mM0S4u5yWs+Kr+13tPpcEkQH3mmJJ/ACudbxFa6lMscVnFDKW6Rqxz+Yrp9TidkO2e1KexBNcD4gjvbVzMJrXbnOAnI/GqfkXC0tGX9Z0N7pN00S4/2gDXn+saVe6Y7vbySID18s4xVyTx6LINDKrOwzjYqkA/nWPqfiB9QiZ0juEU8kMgwfyrKR20YVYvVaDrHxJJbuEvL2WNe7Nlufwp2oazDc2zbb6e4VhgoyED61U0yK0uIgbmCY8/wsBVu5udMssNbo6sBgrKwNS72OtKPNpHU43U7SGY5t9kfOcAVmgeS2wnJHXFdhcX0V+6p5XDHqkYrlL2IxahKu0gA9K4MQranvYGbejL1rEkkY/eqp7jbWhHHGq4IDYPQ9KZpsBMG4x9eBxVyS2kCZ257YxXmzqvY+poUr6sRbaB/mOEK+gzmqc8VuGI3Zz0wMVYKujYCPjvkV0ng25DXvk3UFr5R6loBv8AzY4FKm+Z2HiJKlBytex59fLGo+Rxj6dK6z4d6JZX8E9xq5TyAQELoWz68A17tY2+iIisRZDPZzDU0y6MBhJ7KNcdFliGa9ehRSd7nxGPzaVS8Ywa+ZwEUfhTTflhubfz+mPLYf5NX7RV1DaLNzsz1T/A1q3eg6VfTFop4WbuI5kP8qvaZoFvY/MhbHX5pOD+Fdyv0Pnqkk9db+Y7UfD8t3YIm9tpxkMvX8M1z8/gKyPzy20bsOvyYz+tehXOrmytkKxB1AAOI91VX1O7ulOIIEUjgmMqaqzfQyU3FaOxxN3d2/h2JUg0hU9Ss2CKksfEY1DI+0fYwOzANt/HFW9WtknlL3A3EH+Gsu3v7OzYCOPJz/HFlafJLoLni1qtTq7C6062TNxqkF0/Xk7ai1jxakEfl2Omy3TEYDRSjH61lR64bhtn2KFE/vJFip2EQVCYyCM9sChRJbSZw2vQ654hSVZ7eeG3Jz5LoCfzFcvD4KuoJv8ARtNu855IGf5mvSNU1Wa2Q/Zo7fAP/LQ/4GuYufFtxbODMIAc4IDN/jRJ8p10Z1GrQVi7o/hLVGRAwNuD18yPkVp33hGKEeZqOo2PlqOd6Mn65rmp/iVMo8uBWeQjAJZx/I1j3esX2tHFxcTrH12CQkH86FWvoV9Xqt3loaGtW/g+wAYLDdPnkQ3RzmuT1bxLYmPyLKwuYlGQrNIrH+VT3K2aDBi8x8/fZO4rktakeSX5YVjUf3e9ROTSujso0U/iu/Vli51V5I8tsLEYIwKxJnDuSe5pnzGlVTmuWdRz0OtK2iQ+PGMjrXpXw9l8KRaZMninR9cvrt3+Q2j7YwuOO/X3rz6yaGOUGYAr3yK9Z+H+i634h0+Wfw1o8dxDGdjSGcJ83sDVU0kTiHaGunzsb32Pwd/0Add/7/n/ABorb/4Rrxr/ANAj/wAmFora8e55vNL+b/yY+W4HIAOTkCvTfhx4sfT7mNLi5kEQ48ss2D+VeYRYIGO9XbaV4HV432kdDWFKbizuUFUhyyPtHwxq2k6vaeY1shI/iMTHPvyKs3Ol2yTecs8nlZ+55eBXzH4P1mNmVGkmEg6qsjAfXrXqGnz3M8G1HVQeRvY8D35rsTctUePWw/snZnq8NtEyMUdtnXlSKzdV1dNLhZvIiO3+Nm6fkK5Szt/EMYElpd6UAD9x97H+dWLiS9mRl1D7MTjGIgQB+dNJvc52lHZjp/iQ6qDFdN9Ec/4Vb1bxbfJoZnl3yCReC8pGP0rgdX09I3RgQULDOzkj8qu+ONVurPSbS0tVgCkD5pItx6euaLJK5qo80oxj1OS1fxHrMblrXVbkKxyAAMD26VTtdY1jUJ1jvL64ZMjO5gcfhiqU891dPiT7OMf3Bg1JY6bFeSAmeRZM4wp4rNJt6HpcsIx1SOr0/wACRak6yiZmLHILQD5vXvXYW3hLyLXYuhJcoBjcSBn9eKyfD2j30McZt50lKjjfK3p7V1VoNcjQK4syuOzvWup5s6jbte5y+qaFbxxHfpENiR6PnH45rzXxJpVkZi0V2vB6GPgfjXuV7b300eGWwbIzy+c/nXlXj/TdTtoZXIsdpBP7vGawq6K524GbdTlueeRXUNldxxWt8ZFYjdLtKhPw710N9o+mTkXMPiSG6nIyYlgZSPxriLePe/UZz61uadaNlXDqo+vNePXraWZ9jg8K7qV/yO10qC0hsVMk8QPUkscmpp7uxTjH7zsd/X36ViiL90qq5IJyQKLzdHC8xUZHSvP5m3ofQwUYr3jdgsb+5iLW1vczKeflHGPXpXNa/cy2rGO5jZW/uvj+VNHivUrWIrDM0YYYwsjDj865XVdRlu52kmcs56knNdFOnzbM5MVilSTvYLu+jduVUH2rMmuFJztJ+lQTydTmq28tgce9etRwd1dnyWLzOUnynpngPxZo+kwOJLCK2m43TGc5f6DBxXUH41WqPsbSbm4RTw32kKP/AEGvHtB0G812WRLHyS0fJDvtz9K6jRPBdzBcCXUQhKEMI0YMD9a9L6rokn8zwp1oTk3Na+p9F6J4hub3Q4dQh024BdciPepIFVNS8TawFfbY3an2CH+lQadqMll4ZWVYIzsH3RkgD0rGufiTYQJ/x5xSSDtLE4/WlNKJzU4ym/diZF9qvim8uMLpd/Gh6yFEwfyrU0OBz8+radc3DHPy52Ee1VT8T43Xauk2WwjqA+aWPxrHesN0EcI9Yw9RGUe5tUpVLW5UvQ7GG/s7eJB/Yt5EF6EzAkVj+ItT+2RPFbbIVPy7ZcE1j3usW8kRYX1wDg5DKcGuL17xAYWItsyjtkleacpJE0sPKTItd8NM5aU3tuueTkNXJtosaTYe/t5B6KxBqQ3l3qFyVub+dIz1AfOPwrqNBsNIg2ySyyXjZyRJCMD8ayaTPU5pUo+87/Ig8O6HHKy7EyAfvbiQR613Vpo9ta2++V1zjpuIOPWqqK+wjTLUQqx42Db+VYes22skEvqN0qHt1ArRe6tNTjnJ1pauxY142yeYsRyR3HINM0v4TT67areT+KNBs/MGVieX5gPfnrXDXVxPbzkXGqyjHqhPNek/CXwrq9xFJq8ngq38SWtxzDNcXKR7cdwprKbTOnldKGkv6+Zw3jXwiPB98lrJd22ou4yJLXJUfnVLwj4fm8U60um2L29tJtLtJdHCAV3Xj3RNVm8Xpptppzi+nTctgrAeUPQHoRVDwJbavpnjebSL3w9JqV1sO/TjMkfHqWPBpbPyLVV+yun71i7qXwem0KxfUb3X9EmjiG4xwznefYA1kp4kisLYRaZLNAMclXKDP/ATzXsGr6NpdpYS32q/ChLOKEbiRco+/wD75rhZ/H/w4wUPw2TfjA/fAVLdkZ06jqbpyt6f5mL/AMJVdf8AP/df9/z/APFUVY/tzwf/ANE5X/wMNFLmL0/k/Ff5niinkEVOsnHPSqeDxj8qljBJwcD8a57akU6jWh1Hgq/srTWY5NQWMwZ6yAlR9cV9ReEJ/B+q2kYgewfj7qRsTXyBbwlmCggZ9TXpXgmeSzmjPnusfAHkuQSPzrsoXtqzLGUuePM90fUa+EoJQJNNu/KGOAkH+NULvwheqrb52kXHJKAVneH3nltleG6fLDIWS4x/I1sJJ4ijORFZmHp/rHdjW75l1PJSTMVPCsUc6GWRCueRtxUPibS7O4dIZoopUUZVTXV2d/dCbZd28QGOSsbE/rWF4jfSrkyo1xqCzHjEahQPxov3DXdHh/ifRBFdSm1g+z46AHIrmoH1mzkAjvGjXPQKv9a9N1Hw3KkjS2LNOc5P2iese5vJbBwt1aWjt0ysZYik6fVM9KliPd5bXItF8Ra+gVVu2nH90IoP8q66LxXrvkjzdJu5sDn5kUfyrEsrlbpsWkcSP1+VNmTWjDZ69nfHaW8o/wBqZv8ACm00tzGThJ/CkZes+I78Ev8A2Nc2zEY3uyn+lcN4g1zVJ7KSKW6CQnIMbIpz+OK9Wnt/FkkGLbQtFYkcNNOxIP0xXl/iHwP4lWWa71FLbYDuKQzZC/QVxYhtI9TLlTcley+ZxtpHlgCM10uklYXyEIz24NM0CGK3uG3wpIy9RIvArrII4Gj3yRohHTaleFVkpM+4w9LljY6/xR4TgsINEn0u6klttRjGGlA+Vzjjj61k/Ffw9B4fdNMsZZLh/KV5nkUfKx7DHtXp3w/ay1zwtZxXDgjRrnzhkY+XBI/D/CuD8d3QvZNQ1SfmKX51bsoHAH5YronCCjzQW55mGrVXX9nVb9y9/Nt6fgeQ6xYG3jjHQ471zF2uCckVsarqRuZMs5IHAzU/hTwjrHjGa6j0SBJjbKGkLsEAznA57nBrow9OUtkRmVelCHvSOQlH90cVAvVg2QM1qTROkjWzRlZ1fYUxyCOMfnXufww+F9hHaR3+qqlzPKAfLeJXRfp7179OCULbHyGLqKElK9zyr4a6i1nfzxQxNLJKo2oh5NegX93qklvuRJrQAcF4wa9bbwjodkjPDZ28Dd2itVUn8qwNbj0iBGVp5QPQxHmqlNciSOKFS9S/Kc1ZTXc/hKVYNRS4u+TvSMMy+2O1ceba4vGiW4nVmHU7NufrivQbC50mPRb1bYls53ExEE/nXkurTyhyLS6lQZPCNgCuSUmehQhzN2VjvdL0DQIwG1Ca3LYzxc7K3oD4VtQFjkg6c/6WCTXj+lSP9pX7fM8megcZzXp/hnRrK8II0y2Oe55NVHXZGWIjyfHJsm1OTRbiFljRivZlkBOPWuB1uzsZVYQxyZHqf1r2G68N26QZexhVF5GAK5HUbOE3Gy00+OWQnAQfLTlG5nQrKL0ueVrpEcpP7qXOeecVWuNOSFsAumO26vW08Ja9MMw6VHEuOCJ1NVH+Hl85Z7+1bP8AdLKc/kaz5L9Dv+txWrZ5jaXV4JBHbNMQp7MSa05RdyRfvhKuB0JI5r0E6DBYYUWSWzjoVX+dT2uhrf3Km5ujsH8LR5/lVezaMnjYM8VvoLl5mAhlYA/3Cat2N14h06322d3qVpCP4Y5XjH5A19C2+i+HdNjMt1Jbg45MiMuawvEVz4aS3aSEW87kfdDMP51EqMd5MI45zdoxPDpL6/e8F1c3l810P+WzSsXH45zV+w1aWG589ry5FyTzOJD5mPTdnNaGvTi4ci2tfKU9MNkGuUdAjEN94Vn8OqPQiuZanazeItRuoGQ63qMq4A2S3blT7YzWFNbX160hs7Ka4CffaCMyAH3I6VinI5xgGux8IfEvxN4R02Ww0G9it7dyXIMCMdxHXJGalzaWwpR5V7m5jbtW/wCfS6/78NRXS/8AC3PG/wD0Gf8AyBH/AIUVHtP6/pk3q9l/XyPLWI4z1xSq20+g+maQ8jH50ZI6A8+9QeenZ3LkLnIya7LwXNarMBeW5nQEZy+0AVxMLHcOOM1s6VJKJP3Tc8YGcVtRdmdq9+DVz6T8O2ejvtfSrqyilxkxpliPxNej6Vrctkoju1Z1/v5Cj8q+WdK1a/gbZG8ibe8bkfyrtNH8RXTrueWWVl7Sszf1rsT51Y8irhpQd73PpOHVNOu4SVmh98SZx7Vy/iqwtZIS8Tqwzn5K4uG7nGhNOjvG7j5QGwR/hXCXmq+Ifnj86crnoboml7Nx2MYJTdtjY1WbUdPlaWyDxIDyXhDD86rz6288BF1dxZbr8oX/APVWQlxrUi/6QoZVH8cpOKp31vcu265jQDplWzTvJdDojCL0bRbXUIobsNbahaRSZyCWBx+Feh+Hde8ReQrR6xazRADCLbCvM9J0XRLm4/027uYznkLb5A/HFeseG9O0yG2jFlf3UgAwA0eKTtLcVZqOkfyNpfFGpJFma3mlbt5carmuI8a/EWKwHl32mXxcjA+6o/E12OpoIEOGaQj+HpXgfxXe+/tCP7Tb+VA3K4fdXHXfLG6O3LKUatVRmLppt9ZvJbppkjYndtc4P04rcm0y2MLYuINxGeJOtec6XP5brhyvbIro4r93jVRMwI43DrXhzld6o/RcNStFcrNq1Fxp5lS1ucRyLhtkh5HvU+r60ieHpYtm4bMEgAZrESZVUh7tnXH3WHesvXpQ1iiBkYZ6AVdG6YYqHMji7x8ucZ/E19MfBnQNS0XwVo0unRQrc6hdpd3zzELi35woz3xj86+Z55BHKDsV8HoRwa6Xxp8Q9X8U3VhLII7BLOAQJHaZVT7kZ69K9zB2tbufCZtCVWVltfU6L47eH00P4h6hJGoSG9P2qLHA5PzY/HNeWPf3EbbYp5gM5wHIrp/GfjrU/FUumtqzROLGHykKJtLDvu9elc9FfWm8+ZZQHHqWr07RcOWe55nNOKSuXfD+o341KJoLiRmUEgO5IP4Zr1PTdZuJrZVv2iQ4wcELgfjXkkdzG0oNigjkJ42EjFPnkvo2zLNNkju+c1z+09nC0Vf0On2Cq6tn0DpUtlPoV1FlCgzuZZAxH4iuLTSLAOWhkjCZ/wCemTWV8P8AUZ7rSL/TfKHKlvPZySPYL0/HNcXPqFzDO6RXcxCsQDnHesJ1NEx0aDUpRTPobwfPoulgG6O4n0lTH616XpfjLQyUhgUbun34+P1r4503V3Nwv265dov+mnzCvUvDWv8Agq0jR5xYzSdW8xHX/wBlpKopbmNbCOOqu2fSa6zZzjKIZMnou00x5LZ+UtmBPQtGK8mj+LHhewh/0OGzGBwqSMM/+O1nXvxsabKWGnBT0DLcZ/mKenQ51h6r3R67MxBIgiAJ9U/wqIaE99H/AKW8EcTDnaxVq8VHxH8RzkNHeSwA+m1h/KtC18VeIr0r9p1WTYefmiTH54qkpvYmVHlXvM9UfwZocSs0lxISP71yD/OuM8Vx6PpYP2drtpOf9X8wI/CoYblZk3X0yyA8klf8BVDUNY0SzQjdblu4DsP6VaTW7M0m9lc8/wBY1HfdMzLciMHA3bsfqao3Ot20SbGhDcc7lBrX8T6pBqahIIcRjur7q8/1m0ggUu2MntyM1Dutj1aMYzSUkLrWrrL/AKqONB2VFxXNSOXYsetLsZ3xGpJJwBVuLR9SkXclnMy+oXiuebnI7Vyw0Rnsx9K7nwBp/gK80u8fxnrOp2F6rkQx2sW5WXHXODznPFct/ZN6Hw9vIPqtXIdAPHmXUMRwchwQRU8ktyZq63Op/s34Zf8AQd1//wABl/worN/4RW0/6CUVFXyvsZ2X8z/r5HnecYB64p2/I96ayjHp3pCfY/jWFrnDzOJPCwVsEVftbhIn3FC3pg4rMHqMHFPXI/izTUnHY6KdSysei+GdYs53EVwEgOfvSSgA/nXdNoFnqMYaHUbR5HwBtJP8q8FRiT7V0Wia5qttcwR29/cxIzqmEbPf0rohVTVmhTpSl70HY9m8Q+HxZeGI7FyJdxzujBUCuc0aHUNKcfZJ1lHHyeXuOK6rxrpHi/8Asy2uH0xHsI0DNK92A7YHUiuC0LxX9nvAWsEmwfmzI+D+OK30TOampzpu2v3HpujeKnt1Vb3RdVlfu6QqFNdRbeJdJukzLazwEj/lqyAj9areFPE+jalChvrC1jYDkZdsenat+5n8FTxssltZE46eQx/pTdQ4nTV7WsctqL6VeyFoJCSOQolB/lTrRjDgpHIyr2VcmsDxrc6PpyNLol/FbPzhIYip/lXmzfEnW7O42i/nnRTwPM2/0qXUS3OmlhJ1VeJ7xN4hiRNs1hfM2OCFA4rzH4l+JvDt/G1jcWOoNdLypEiqFPv/AIVzr/FW+eIq9s7EgjLXJJ/lXFXd3LqN/JcyDDOc4zmuLEVItWiexl2CcZ3mixbRBj8gIHua3rVIQiguVOOhbpVbSggg/eQZOeuf6VakjhdRhwD6CvHqJ30Pu8LZLYnKQg5Mg9OGFZ2ttEIkRWJI7BulMuIdo+SRWz0ArJvQwX/61VTcrhippQbSMq7KmU4P61Qn+8NvNXRIis3mQh/TJxVGVtznHyj0r3MMuVXufBY2fM3puRt2z/OliRSTuyQenNMYgk8nr0pNzAYxtxWrryWp5/LG+pajQKcrkfjVy3nJkVZGyOg5rK8wgcE4HpThJkDg1g68jphOC0SPa/hV9ihjv5C8RJTkb1zjHpXLarHprzzOnlsXcn5dpPWuc8G3KQ3dyrH55IWVFHVj6VllpEkdTlGBwRT9pomOlH3nPudVHpdlOflOMd84rRtdFhVxiVQPQMOa5C3vJ0HF0V9jzWjY6i0UgaUfaOegbBqlKLN3Gb6nXLo8ShSqsxB5Awf5VPD4VnvXAt18vnPzgqP5VX0vxlbaYqmPRpkkU/eE4/qK3bf4l39wVRkngTPcoRj8quLick1XXwoc/he9sIt5Mcq8YCsWZvwFT6XpWu3FyIrK0XJ/5+FdU+vSt7wn4x0/7ejalcoxJyN0gTb+Qr2bTPHWhC3VUurYDHJM61cpW+E5XOqtJxPMdO+Eev36pLqF4kSMc7ba6dcfgRWq/wAFbKBDJPf6i7Y/iuA38xXdXvxG0K1iLG9tDjsLlM15z4y+NGn/AGeSKyZHJB6SowrJSfUF7aWkbmdf/DzTrNzm7u+O3mpiuev/AArolw3lie5YjjO1D+przPXvGd3qVy74QAn+4v8ASsh9Xfb84DZ7DjFU5xOuGFq7yke+aRpmg6LbBfsUV3yATJboxH41zvjXxho0MJgtbK2hIyMLAy5/EV4xdXhm+7uX1GeDVTJcnHOATUSrW0RccHGL5pyubFx4gneV2jRBk8ZJOK7Lwf8AE+10PSms9Q8JaXq8pz/pFwSHIPboa8xDCvQ/AXw2Pi7RbjUj4i0bTEiZl8q7lw5wOuOwrHmk9ma1fZte/sav/C0rP/oStH/77b/CisX/AIV9F/0N/hz/AL//AP1qKfvf1Yj9x2/M8xc8DbRyOuMUrYHoTTDgj73XvUHC9GOB2jkD86dn/wDXSdcAdRSkZHXk0ilfoOErL0xViO5IxkH1FVcDkcU3vx24pp9jRVJQ6nSWOv3sNzDN9pkmMRDKkzl1/ImvT9L+OGsLCltLaaWIxwNlso/rXhy8d6eJDng/lVKpKOhblCp8cdT688F+MNJ1yJJNTKi467YPLRR+ua7P7PoVypBeVR3xOv8AjXw1a3s1rKs1vK0ci8hlPSt6Hx14hgUCPVbgDtwp/pWyrrqck8Gm7xZ9PeJfAWh6nG7W17FExH3pbzAzXlOr/B2YXOYfE3h1EbjD3WDXm1x461+aMiXUpmB6ghef0rAuL6W5cyTMWc9STUTqKXQ6KMXSVuf9TsPE/gu80G+S2t72x1iRhkjTXMxX6gDiqcOheIFww0PUyPX7I5H8qyvD/iXVfD07T6Ney2czjDNGRyK6gfF/x0ECjxJeY9ML/hWElF9Drp4mpD4WFnBrzny10bUGx1VbJ/8ACtBINQUlZ9I1JSvJH2RgR+lZtv8AF3xzbyl4/EV3ubqWCt/MU+b4veOJ2Yv4huiWGDhVHH5Vl7KHVHo084xEF0/EhudXto5njkidHU4KsuCD71R1G/heAeQ64PJUnvXQ3nj3wvehHvPAtrLdcGWY3rgyN3J46mp77xx4Hm0sQW/gCCKfvKLts/nitoUqUdyK2dYiorcv5f5nmszbmYk/lVfBOeOa9Qs/GvgWCxeKXwBFLMRje163+FY//CS+EtzZ8FxkE/8AP9JxXQvZ2tF2/r0PHnOcneS/L/M4Uq3JPr2NAAwc55rvD4k8HHr4KHvi/f8Awp3/AAk3gofe8E8f9f7/AOFRJRf2vzITa+z+X+ZwKoBnFS2tvNcSeVbQyzPjO2NSx/Su4j8T+CwDv8ELnt/xMH/wp6+PNI0uCWTwr4fk0fUXXYLpLtpCoz6MKjlj3He3S33GD4Z064t9at5Lywu1iDc5gb0rI1Ftt7MOQN5xnr1rp5Pip4xkjaJ9cmZG4IKJ0/KuNubqSeZpZyXkc7mY9ye9DelkUqqUbMkilUck1aS72keWxBHPAxWcG3dqkQnjjFTdo0p1n0LbXEhYnkk9yetL9smA4YqB23GqzSnqKC+PSlzM1dXzLIu7gvkSOD0zuNamn3Goy4C3cyp0yZsD9TWGsmOg5pzStjrzVRnbccZrdnVSlIhm4vPNPo3OfasW6kgwfLZjnsQBWaWP1PrSdRnNU6jY1V7E7SgHgV6D8N/h3P4otZdU1OSSz0OMMPtETKXZx2Ck9OvNeb/Q5r13wHrvw8GkWdn4lsdZbUF4eSO58uHPrgMMfiKVO1/eMatSbj7p5lrEUVrqVzBbO7QxyMqM+MkA8E4p+g2lvf6tawahd/ZLN3AmuNu7y07nHeupv9J0LxV45ey8LSx6Tp7BiZtTuRt46kH37CtP4U6TZ2fxVSzu9Rspra23/wClJMqxuQOCpbrRb3vIcp6N+Qnj/wABaNpehw6x4Q1ifWNP8zyppJIwm1vQdCfyrzswSrnMUgHupr6j8e6prPhSKTXINa8J3sURAis9odsH0APJrgpf2hvEjxun9kaCcjGTak/pmifL0Jpym43Wvz/4B4tj3H5UV6N/wtnxD/z5aL/4L1oqbR/pf8E2/edvx/4B5S/OOQMUEADnH4UMp4HH0ox6cUzzt3sGQG6cUuAQf59KMDI4xj2oK45/HmgaAgDPakJ6getBHc80DpkcduaAY4kYIP40gOMcUpBxjAH1FKoJGeOBSK1bEwAKQHHbmnYIA75ppBzjGDTB6AcEDPSnZGSeKRhxSEHjAx9aA1QDgDAzSk/N7Z/GhQRjGcUdDnpkelIBST2zQGNNOegP1o2Z9cUWC7voSA8Yz096fkeufeoGXsKQ5PuDRyle0a6EjMOoP5U0MQTzTdpA6c/0oUEtz29KLE8zbJAw7/WgsPx96ax9aQc5z3FA+boI7DHB5PpSHgetBQ9B/KnKpxjaOlMz1bBeTnAx71INmRmkUE8EE0DcCeo/CkapWJgU7AZ9alWMHoODUAduMHn0qdA7Acj8aEjqptPoKYwFzxTGCY6U8wDbliD7ZoMSLir5GW0+iIkAzipNi/U0w4UYWo2J3DBqLWI5lFaolKhaj3DtTDu+tGD1J+ooM3PshQc9DkU8HjGKYqgHPepQq4pWHBMOuARSjg80EYBApo3ZAIosaXsShgcbjmuy8LfDrxV4o0iXVNC0trqzjLKXEirkjrgE81xW0nsAa0rDV9UsIHgstRvLaB85jimZFP4A01p0KcpW0Nr/AIQzxX/0Brz8h/jRXOfa77/n7n/7+n/Gii68/v8A+AHPU7/h/wAExCxx1P50m5v7x/OiiqPJQpZsn5j+dJub+8fzooplMNzf3j+dG446n86KKBAHb+8fzpVdtw+Y/nRRSKQM7huGb86VWY9SfzoooDqNLNj7x/Ojc3PzH86KKYmG5v7x/Ojc3qfzoooEAZv7x/Ojc394/nRRQNbBub1P50bj6miigl7hub+8fzpxZt33j+dFFIsXc3949PWkdj6n86KKENgGbB+Y/nSqx8tjk5+tFFDBDyzeWvJ6+tLGxKnJJ/GiikbEidRViMnI5PSiihbm1EcGIGQTmoZGPqaKKDWexEzHJ5PT1prE5HJoooOaQm4+p/OgMfU9PWiikyUICdw5PWpQxz1NFFDHAduOOpoLHHU0UUjZkgY+pr0PwDYWd14U1aa6tLeaVGIV5IwzL8o6EjiiiqhuVLY47yo/+eafkKKKKZJ//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     V: umbilical vein; A: umbilical artery.",
"    </div>",
"    <div class=\"reference\">",
"     <br>",
"      Courtesy of Ana Monteagudo, MD.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9425=[""].join("\n");
var outline_f9_13_9425=null;
var title_f9_13_9426="MR fetal liver herniation";
var content_f9_13_9426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging (MRI) of fetal liver position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrafast fetal MRI using HASTE technique demonstrates (left) liver intraabdominal and (right) liver herniation into left chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Holly L Hedrick, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9426=[""].join("\n");
var outline_f9_13_9426=null;
var title_f9_13_9427="MPS I cord compression B";
var content_f9_13_9427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spinal cord compressions in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome) B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sagittal T1-weighted MR image of the cervical spine in a patient with Hurler-Scheie syndrome showing the grossly abnormal vertebrae and intervertebral discs. Note the abnormal spinus processes of the upper cervical vertebrae and constriction of the cord due to soft tissue thickening and meningeal storage. An enlarged cisterna magna with small cerebellum is also evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emil Kakkis, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9427=[""].join("\n");
var outline_f9_13_9427=null;
var title_f9_13_9428="Five-grass pollen sublingual tablet: Patient drug information";
var content_f9_13_9428=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Five-grass pollen sublingual tablet: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/40/18053?source=see_link\">",
"     see \"Five-grass pollen sublingual tablet: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16055480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oralair&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F16059153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4131944",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The first dose will be given in a doctor&rsquo;s office.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16059155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4131949",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a grass pollen allergy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16059154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4131945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to grass pollen allergen extract or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4131952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, autoimmune disease, cancer, or swelling in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to lactose, talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16059159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16059160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4131956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sneezing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16059161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16059157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4131955",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 4 months before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3370402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place under tongue and let melt all the way. Do not chew, suck or swallow tablet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F16059158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F16059162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699403",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in foil pouch until ready for use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16059163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87802 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-3636CB1C0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9428=[""].join("\n");
var outline_f9_13_9428=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055480\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059153\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059155\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059154\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059159\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059160\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059161\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059157\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059158\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059162\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059163\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/40/18053?source=related_link\">",
"      Five-grass pollen sublingual tablet: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_13_9429="Normal and abnormal plethysmographic digit waveforms";
var content_f9_13_9429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal and abnormal plethysmographic digit waveforms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 670px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With photoplethysmography (PPG), infrared light is emitted onto a defined area of skin. More or less light is absorbed depending upon changes in blood volume, which is determined by measuring the light reflected from the skin. A normal PPG waveform consists of a short rise in the upstroke during systole (A), a gradual decline during diastole (B), and a dicrotic notch in the diastolic downstroke (C). Moderate arterial obstruction results in loss of the dicrotic notch, flattening of the upstroke and downstroke, and rounding of the peaks of the waveform. Severe obstruction flattens the waveform.",
"    <div class=\"footnotes\">",
"     mV: millivolts; V: volts; PPG: photoplethysmography; HR: heartrate; FP: finger pressure.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kesselman P. Non-Invasive Arterial Vascular Testing: Providing these diagnostic services benefits both the patient and your bottom line. Podiatry Management Nov/Dec 2006. Copyright &copy; 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9429=[""].join("\n");
var outline_f9_13_9429=null;
var title_f9_13_9430="Hetastarch: Drug information";
var content_f9_13_9430=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hetastarch: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/47/19187?source=see_link\">",
"    see \"Hetastarch: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/0/31748?source=see_link\">",
"    see \"Hetastarch: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hespan&reg;;",
"     </li>",
"     <li>",
"      Hextend&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hextend&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F179076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Plasma Volume Expander, Colloid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F179046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Plasma volume expansion:",
"     </b>",
"     I.V. infusion: 500-1000 mL (up to 1500 mL/day) or 20 mL/kg/day (up to 1500 mL/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Leukapheresis  (Hespan&reg;):",
"     </b>",
"     I.V. infusion: 250-700 mL;",
"     <b>",
"      Note:",
"     </b>",
"     Citrate anticoagulant is added before use.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F179047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F179048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution. Use is contraindicated in renal failure with oliguria or anuria (not related to hypovolemia).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS: 6% (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hespan&reg;: 6% (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in lactated electrolyte solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hextend&reg;: 6% (500 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Sodium chloride infusion",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F179027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Volume expansion: Administer I.V. only; may be administered via infusion pump or pressure infusion. Administration rates vary depending upon the extent of blood loss, age, and clinical condition of patient but,",
"     <i>",
"      in general",
"     </i>",
"     , should not exceed 1.2 g/kg/hour (20 mL/kg/hour);",
"     <i>",
"      however,",
"     </i>",
"     <b>",
"      rates up to 1000 mL over 7-8 minutes via pressure infusion have been studied in otherwise healthy subjects (McIlroy, 2003)",
"     </b>",
"     .  Anaphylactoid reactions can occur, have epinephrine and resuscitative equipment available. If administered by pressure infusion, air should be withdrawn or expelled from bag prior to infusion to prevent air embolus. Do not administer Hextend&reg; with blood through the same administration set. Change I.V. tubing or flush copiously with normal saline before administering blood through the same line. Change I.V. tubing at least every 24 hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Leukapheresis: Mix Hespan&reg; and citrate well. Administer to the input line of the centrifuge apparatus at a ration of 1:8 to 1:13 to venous whole blood.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F179082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hespan&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Cimetidine, diltiazem, doxycycline, enalaprilat, ertapenem, nicardipine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amikacin, cefamandole, cefoperazone, cefotaxime, cefoxitin, gentamicin, ranitidine, theophylline, tobramycin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ampicillin, cefazolin, doxycycline, ranitidine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hextend&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alfentanil, amikacin, aminophylline, amiodarone, ampicillin, ampicillin-sulbactam, atracurium, azithromycin, aztreonam, bumetanide, butorphanol, calcium gluconate, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisatracurium, clindamycin, dexamethasone sodium phosphate, digoxin, diltiazem, diphenhydramine, dobutamine, dolasetron, dopamine, doxycycline, droperidol, enalaprilat, ephedrine, epinephrine, erythromycin, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, furosemide, gentamicin, granisetron, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, inamrinone, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, lorazepam, magnesium, mannitol, meperidine, methylprednisolone sodium succinate, metoclopramide, metronidazole, midazolam, milrinone, morphine, nalbuphine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, palonosetron, pancuronium, phenylephrine, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, ranitidine, rocuronium, succinylcholine, sufentanil, sulfamethoxazole/trimethoprim, theophylline, thiopental, ticarcillin/clavulanate, tobramycin, vancomycin, vecuronium, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, diazepam, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F179026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood volume expander used in treatment of hypovolemia; adjunct in leukapheresis to improve harvesting and increase the yield of granulocytes by centrifugation (Hespan&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F179073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Priming fluid in pump oxygenators during cardiopulmonary bypass; plasma volume expansion during cardiopulmonary bypass",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hespan&reg; may be confused with heparin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F179074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, circulatory overload, heart failure, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache, intracranial bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching, pruritus (dose dependent; may be delayed), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amylase levels increased (transient), metabolic acidosis, parotid gland enlargement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding, bleeding time prolonged, clotting time prolonged, dilutional coagulopathy, disseminated intravascular coagulopathy (rare), factor VIII:C plasma levels decreased, hemolysis (rare), plasma aggregation decreased, PT prolonged, PTT prolonged, thrombocytopenia, von Willebrand factor decreased, wound hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (indirect)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, pulmonary edema (noncardiac)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, flu-like syndrome (mild), hypersensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Hypotension, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F179030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxyethyl starch or any component of the formulation; renal failure with oliguria or anuria (not related to hypovolemia); any fluid overload condition (eg, pulmonary edema, congestive heart failure); pre-existing coagulation or bleeding disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hextend&reg; is also contraindicated; in the treatment of lactic acidosis and in leukapheresis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F179014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Anaphylactic/anaphylactoid reactions have been reported; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy. Patients allergic to corn may be allergic to hetastarch.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid overload: Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young,  elderly patients, or those with HF).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic: Large volumes of hetastarch may cause a reduction in hemoglobin concentration, coagulation factors, and other plasma proteins due to hemodilution; coagulation may be impaired (eg, prolonged PT, PTT, and clotting times) and a transient prolongation of bleeding time may be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders (eg, von Willebrand&rsquo;s disease): Use caution in severe bleeding disorders; may increase the risk of more bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Critically-ill patients: The use of hydroxyethyl starches (HES), including hetastarch, is associated with an increased risk of acute kidney injury (Reinhart, 2012). Additionally, in a meta-analysis of mixed critically-ill patient populations, the use of HES did not demonstrate statistically significant differences in mortality compared to crystalloid therapy (Perel, 2011). In review of clinical trials including patients with severe sepsis or septic shock, a meta-analysis of HES trials demonstrated a trend toward increased mortality (Zarychanski, 2009). In patients with severe sepsis, a trend towards higher mortality at 90 days was observed in one clinical trial comparing HES 200/0.5 (pentastarch) to Ringer&rsquo;s lactate (Brunkhorst, 2008). In addition, the use of HES 130/0.42 (Tetraspan&reg;; similar to tetrastarch) has been shown to increase mortality in patients with severe sepsis as compared to Ringer&rsquo;s acetate (Perner, 2012).  The Society of Critical Care Medicine has recommended either crystalloid or iso-oncotic colloid (natural or artificial) therapy for fluid resuscitation in patients with septic shock (Dellinger, 2008). Hyperoncotic solutions should not be used for fluid resuscitation (Reinhart, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; may result in further reduction of coagulation factors, increasing the risk of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: The risk of adverse reactions may be increased in patients with renal impairment; monitor fluid status, urine output, and infusion rate. Larger hetastarch molecules may leak into urine in patients with glomerular damage; may elevate urine specific gravity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Use with caution in patients with thrombocytopenia; large volumes may interfere with platelet function and transiently prolong bleeding time. Observe for bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hextend&reg;: Contains calcium, lactate and potassium; use with caution in situations where electrolyte and/or acid-base disturbances may be exacerbated (renal impairment, respiratory alkalosis, metabolic alkalosis). Do not use in leukapheresis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13888219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F179052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hespan Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-0.9% (500 mL): $15.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hetastarch-NaCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-0.9% (500 mL): $16.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hextend Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6% (500 mL): $37.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F179023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Volume expansion: Blood pressure, heart rate, capillary refill time, CVP, RAP, MAP, urine output; if pulmonary artery catheter in place, monitor cardiac index, PCWP, SVR, and PVR; hemoglobin, hematocrit, serum electrolytes, renal function, acid-base balance, coagulation parameters",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Leukapheresis: CBC, total leukocyte and platelet counts, leukocyte differential count, hemoglobin, hematocrit, PT, PTT",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Elo Hes (ES);",
"     </li>",
"     <li>",
"      Elohaes (HR, NL);",
"     </li>",
"     <li>",
"      Elohaest (AT);",
"     </li>",
"     <li>",
"      Expafusin (ES);",
"     </li>",
"     <li>",
"      Haes Esteril (ES);",
"     </li>",
"     <li>",
"      HAES-steril (BE, HR, LU, NL, PL);",
"     </li>",
"     <li>",
"      Haes-Steril (BG, CH, CL, CZ, DE, GB, GR, HN, ID, IL, IN, PH, RU, SG, TH);",
"     </li>",
"     <li>",
"      Hemohes (AR, CN, LU, NL);",
"     </li>",
"     <li>",
"      Hespander (JP);",
"     </li>",
"     <li>",
"      Hestar-200 (CO, ID);",
"     </li>",
"     <li>",
"      Hesteril (ES);",
"     </li>",
"     <li>",
"      Hydroksyetyloskrobia (PL);",
"     </li>",
"     <li>",
"      Hyper HAES (DK, EE, FI, NO, SE);",
"     </li>",
"     <li>",
"      Hyperhes (AT, FR);",
"     </li>",
"     <li>",
"      Infukoll HES (PL);",
"     </li>",
"     <li>",
"      Plasmasteril (BE, PL, TR);",
"     </li>",
"     <li>",
"      StarQuin (NZ);",
"     </li>",
"     <li>",
"      Temo (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F179013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces plasma volume expansion by virtue of its highly colloidal starch structure",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F179029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Volume expansion: I.V.: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Molecules &gt;50,000 daltons require enzymatic degradation by the reticuloendothelial system or amylases in the blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (33% to 40% within 24 hours; ~62% within 72 hours); smaller molecular weight molecules readily excreted",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bick RL, &ldquo;Evaluation of a New Hydroxyethyl Starch Preparation (Hextend&trade;) on Selected Coagulation Parameters,&rdquo;",
"      <i>",
"       Clin Appl Thrombosis/Hemostasis",
"      </i>",
"      , 1995, 1(3):215-29.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brunkhorst FM, Engel C, Bloos F, et al, &ldquo;Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      ,  2008, 358(2):125-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/18184958/pubmed\" id=\"18184958\" target=\"_blank\">",
"        18184958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brutocao D, Bratton SL, Thomas JR, et al, &ldquo;Comparison of Hetastarch With Albumin for Postoperative Volume Expansion in Children After Cardiopulmonary Bypass,&rdquo;",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 1996, 10(3):348-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/8725415/pubmed\" id=\"8725415\" target=\"_blank\">",
"        8725415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canver CC and Nichols RD, &ldquo;Use of Intraoperative Hetastarch Priming During Coronary Bypass,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2000, 118(6):1616-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/11115448/pubmed\" id=\"11115448\" target=\"_blank\">",
"        11115448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327; published erratum appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Bennett-Guerrero E, Phillips-Bute B, et al &ldquo;Hextend&reg;, a Physiologically Balanced Plasma Expander for Large Volume Use in Major Surgery: A Randomized Phase III Clinical Trial,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1999, 88(5):992-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/10320157/pubmed\" id=\"10320157\" target=\"_blank\">",
"        10320157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Wright D, Robertson C, et al, &ldquo;Randomized Comparison of the Coagulation Profile When Hextend&reg; or 5% Albumin is Used for Intraoperative Fluid Resuscitation,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2001, 95:A193.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knutson JE, Deering JA, Hall FW, et al, &ldquo;Does Intraoperative Hetastarch Administration Increase Blood Loss and Transfusion Requirements After Cardiac Surgery?&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2000, 90(4):801-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/10735779/pubmed\" id=\"10735779\" target=\"_blank\">",
"        10735779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Niemi TT, Miyashita R, and Yamakage M, &ldquo;Colloid Solutions: A Clinical Update,&rdquo;",
"      <i>",
"       J Anesth",
"      </i>",
"      , 2010, 24(6):913-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/20953964/pubmed\" id=\"20953964\" target=\"_blank\">",
"        20953964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perel P and Roberts I, &ldquo;Colloids versus Crystalloids for Fluid Resuscitation in Critically Ill Patients,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2012, 6:CD000567.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/22696320/pubmed\" id=\"22696320\" target=\"_blank\">",
"        22696320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perner A, Haase N, Guttormsen AB, et al, &ldquo;Hydroxyethyl Starch 130/0.4 versus Ringer&rsquo;s Acetate in Severe Sepsis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(2):124-34; published erratum appears in",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(5):481.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/22738085/pubmed\" id=\"22738085\" target=\"_blank\">",
"        22738085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reinhart K, Perner A, Sprung CL, et al, &ldquo;Consensus Statement of the ESICM Task Force on Colloid Volume Therapy in Critically Ill Patients,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2012, 38(3):368-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/22323076/pubmed\" id=\"22323076\" target=\"_blank\">",
"        22323076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      University Health System Consortium.",
"      <i>",
"       Technology Assessment: Albumin, Nonprotein Colloid, and Crystalloid Solutions",
"      </i>",
"      , May 2000.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilkes NJ, Woolf RL, Powanda MC, et al, &ldquo;Hydroxyethyl Starch in Balanced Electrolyte Solution (Hextend&reg;) - Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2002, 94(3):538-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/11867371/pubmed\" id=\"11867371\" target=\"_blank\">",
"        11867371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zarychanski R, Turgeon AF, Fergusson DA, et al, &ldquo;Renal Outcomes and Mortality Following Hydroxyethyl Starch Resuscitation of Critically Ill Patients: Systematic Review and Meta-Analysis of Randomized Trials&rdquo;",
"      <b>",
"       ATTENTION:",
"      </b>",
"      The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia's retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia's press release.",
"      <i>",
"       Open Med",
"      </i>",
"      , 2009, 3(4):e196-209.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/13/9430/abstract-text/21688756/pubmed\" id=\"21688756\" target=\"_blank\">",
"        21688756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8522 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9430=[""].join("\n");
var outline_f9_13_9430=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179043\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179044\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179076\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179046\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179047\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179048\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897476\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179025\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179010\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179027\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179082\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179026\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179073\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179084\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179074\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179030\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179014\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299443\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220790\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179020\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888219\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179052\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323182\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179023\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038650\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179013\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179029\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8522\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8522|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/47/19187?source=related_link\">",
"      Hetastarch: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/0/31748?source=related_link\">",
"      Hetastarch: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_13_9431="Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm";
var content_f9_13_9431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9431/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9431/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9431/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9431/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9431/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9431/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9431/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/13/9431/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of myocardial infarction (MI) is typically suspected from the history of chest pain and may be confirmed by the electrocardiogram (ECG) and elevations in serum troponins and CK-MB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ECG diagnosis of an acute MI in patients with right or left bundle branch block (RBBB or LBBB) or a paced rhythm will be reviewed here. Other issues related to RBBB and LBBB are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=see_link\">",
"     \"Right bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG diagnosis of MI is more difficult when the baseline ECG shows a bundle branch block pattern that may precede or be a complication of the infarct or the patient has a paced rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The frequency of bundle branch block was best assessed in a review of almost 300,000 infarctions from the National Registry of Myocardial Infarction 2 investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/6\">",
"     6",
"    </a>",
"    ]. Right bundle branch block was present in approximately 6 percent and left bundle branch block in 7 percent of infarctions. Patients with bundle branch block were significantly less likely than those without bundle branch block to receive appropriate therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or beta blockers, had more comorbid disease, and had a significant increase in in-hospital mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RIGHT BUNDLE BRANCH BLOCK WITH MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of right bundle branch block (RBBB) must be considered in both Q wave (ST elevation) and non-Q wave (non-ST elevation) infarctions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Q wave MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right bundle branch block does not usually interfere with the diagnosis of a Q wave MI. Myocardial infarction most often involves the left ventricle and therefore affects the initial phase of ventricular depolarization, sometimes producing abnormal Q waves. In contrast, RBBB primarily affects the terminal phase of ventricular depolarization, producing a wide R' wave in the right chest leads and a wide S wave in the left chest leads (",
"    <a class=\"graphic graphic_waveform graphicRef65619 graphicRef64393 \" href=\"UTD.htm?43/16/44298\">",
"     waveform 1A-B",
"    </a>",
"    ). These changes are due to delayed depolarization of the right ventricle, while depolarization of the left ventricle is not affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=see_link\">",
"     \"Right bundle branch block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net effect is that the ECG patterns are combined when complete RBBB and a Q wave infarct occur together, and the criteria for the diagnosis of a Q wave MI are the same as in patients with normal conduction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Due to the bundle branch block, the QRS complex will be abnormally wide (0.12 sec or more), lead V1 will show a terminal positive deflection, and lead V6 will show a terminal negative deflection (wide S wave)",
"     </li>",
"     <li>",
"      If the infarction is anterior, there will be a loss of R wave progression with abnormal Q waves in the anterior leads and characteristic ST-T changes; if the infarction is inferior, Q waves will appear in leads II, III and aVF",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are, however, problems that can occur with interpretation of the ECG in patients with RBBB and acute MI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large clinical trials in which serial ECGs are performed have shown both false-positive and false-negative diagnoses of MI in the presence of RBBB [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/7\">",
"       7",
"      </a>",
"      ]. After revascularization, for example, Q wave durations in patients who develop RBBB can shorten significantly, primarily in the inferior leads, suggesting that the initial orientation of wavefronts can change and that false-negative results may be obtained in patients with inferior infarctions [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There has been a case report of a woman with an acute anterior MI in whom the initial ECG revealed a small R wave in leads V1 and V4 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/9\">",
"       9",
"      </a>",
"      ]. These R waves were replaced by Q waves after the development of RBBB associated with PR-interval prolongation, suggesting extension of the infarction. However, the Q waves disappeared with resolution of the RBBB.",
"     </li>",
"     <li>",
"      The coexistence of left anterior fascicular block with or without RBBB can be associated with Q waves suggestive of an anterior MI; in this setting, the altered initial vector is attributed to the left anterior fascicular block [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/10\">",
"       10",
"      </a>",
"      ]. These Q waves can often be distinguished from pathologic Q waves in an acute MI by their short duration (0.02 sec versus 0.04 to 0.05 sec with an infarction) and their presence in only leads V2",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      V3.",
"     </li>",
"     <li>",
"      A new posterior wall infarct in the presence of RBBB might be expected to increase the anterior forces in the right precordial leads but this has not been systematically studied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Non-Q wave MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be some diagnostic difficulties in interpreting the ECG in patients with RBBB who have a non-Q wave MI. RBBB is typically associated with secondary ST-T changes due to abnormal right ventricular repolarization. Thus, leads with an R' wave (leads V1, V2, and sometimes V3) will show T wave inversions. In contrast, ST depressions or T wave inversions in leads with a terminal S wave (leads V5 and V6) cannot be attributed to the RBBB alone. Such ST-T changes may be due to ischemia, or to other factors such as drug effects or electrolyte abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LEFT BUNDLE BRANCH BLOCK WITH MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left bundle branch block (LBBB) is present in approximately 7 percent of acute infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/6\">",
"     6",
"    </a>",
"    ]. The diagnosis of MI in the presence of LBBB is considerably more complicated and confusing than that of RBBB. The reason is that LBBB alters both the early and the late phases of ventricular depolarization and produces secondary ST-T changes (",
"    <a class=\"graphic graphic_waveform graphicRef52836 graphicRef61594 \" href=\"UTD.htm?43/24/44426\">",
"     waveform 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Two issues need to be addressed: the impact of LBBB on the diagnosis of acute MI; and the effect on diagnosis of a prior MI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. There are issues that vary with the site of the infarct and there are changes that are independent of the site of the infarct, such as the ST-T changes that can occur. Because of these difficulties, careful attention to the strength of the clinical history and confirmation of the diagnosis of an acute MI by cardiac enzyme elevations is essential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequence of repolarization is altered in LBBB, with the ST segment and T wave vectors being directed",
"    <strong>",
"     opposite",
"    </strong>",
"    to the QRS complex. These changes may mask the ST segment depression and T wave inversion induced by ischemia. On the other hand, the diagnosis of an acute MI or ischemia can occasionally be made in a patient with underlying LBBB if certain ST-T changes are seen, particularly if the ST-T vectors are in the same direction as the QRS complex as in the Sgarbossa criteria described below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of deep T wave inversions in leads with a predominantly negative QRS complex (eg, V1-V3) is highly suggestive of evolving ischemia or MI.",
"     </li>",
"     <li>",
"      ST elevations in leads with a predominant R wave (as opposed to QS or rS waves) are also strongly suggestive of acute ischemia.",
"     </li>",
"     <li>",
"      Pseudonormalization of previously inverted T waves is suggestive but not diagnostic of ischemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of accurate diagnosis in patients with LBBB is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of patients with LBBB and acute chest pain having an acute MI in different studies has been between 13 to 32 percent, with a lower incidence in community-based studies compared to clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. As a result, inaccurate diagnosis can lead to both undertreatment of patients with an MI and unnecessary overtreatment of patients without an MI [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/11,13\">",
"       11,13",
"      </a>",
"      ]. In one report, for example, thrombolysis was given to only 73 percent of eligible patients with LBBB and an acute MI and to 48 percent of patients with LBBB and chest pain but no biochemical evidence of infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/13\">",
"       13",
"      </a>",
"      ]. None of the latter patients satisfied the Sgarbossa criteria described below for an acute MI.",
"     </li>",
"     <li>",
"      In addition to difficulties in ECG interpretation, approximately one-half of patients with LBBB and an acute MI do not have chest pain [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/14\">",
"       14",
"      </a>",
"      ]. These patients are much less likely to receive appropriate medical therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , beta blockers) or reperfusion therapy than LBBB patients with chest pain [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Attempts to improve ECG diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have systematically evaluated the value of different ECG findings of acute MI in LBBB. An analysis by Wackers correlated ECG changes in LBBB with localization of the infarct by thallium scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/2\">",
"     2",
"    </a>",
"    ]. The most useful ECG criteria were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serial ECG changes &mdash; 67 percent sensitivity",
"     </li>",
"     <li>",
"      ST segment elevation &mdash; 54 percent sensitivity",
"     </li>",
"     <li>",
"      Abnormal Q waves &mdash; 31 percent sensitivity",
"     </li>",
"     <li>",
"      Initial positivity in V1 with a Q wave in V6 &mdash; 20 percent sensitivity but 100 percent specificity for anteroseptal MI",
"     </li>",
"     <li>",
"      Cabrera's sign &mdash; 27 percent sensitivity overall, 47 percent for anteroseptal MI",
"      <br/>",
"      <br/>",
"      Cabrera's sign refers to prominent (0.05 sec) notching in the ascending limb of the S wave in leads V3 and V4; a similar finding is prominent notching of the ascending limb of the R wave in lead V5 or V6 (Chapman's sign) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/2\">",
"       2",
"      </a>",
"      ]. These signs have a specificity that approaches 90 percent. However, there may be a high degree of interobserver variability in accurate identification and their sensitivity is quite low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sgarbossa criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large trial of thrombolytic therapy for acute MI (GUSTO-1) provided an opportunity to revisit the issue of the electrocardiographic diagnosis of evolving acute MI in the presence of LBBB [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/3\">",
"     3",
"    </a>",
"    ]. Among 26,003 North American patients who had a myocardial infarction confirmed by enzyme studies, 131 (0.5 percent) had LBBB. A scoring system, often called the Sgarbossa criteria, was developed from the coefficients assigned by a logistic model for each independent criterion, on a scale of 0 to 5.",
"   </p>",
"   <p>",
"    The three ECG criteria with an independent value in the diagnosis of acute infarction and the score for each were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ST segment elevation of 1 mm or more that was in the same direction (concordant) as the QRS complex in any lead &mdash; score 5.",
"     </li>",
"     <li>",
"      ST segment depression of 1 mm or more in any lead from V1 to V3 &mdash; score 3.",
"     </li>",
"     <li>",
"      ST segment elevation of 5 mm or more that was discordant with the QRS complex (ie, associated with a QS or rS complex) &mdash; score 2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A minimal score of 3 was required for a specificity of 90 percent. The first two criteria are similar to those described above since the ST segment is concordant rather than discordant with the QRS complex. However, the third finding requires further validation, since a high take-off of the ST segment in leads V1 to V3 has been described with uncomplicated LBBB, particularly if there is underlying left ventricular hypertrophy. In a substudy from the ASSENT 2 and 3 trials, the third criteria added little diagnostic or prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of the other criteria, including those of Wackers mentioned above [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/2\">",
"     2",
"    </a>",
"    ], were not found to be useful. A difference may be that the GUSTO criteria were applied within hours of the MI as part of the GUSTO-1 trial, while those of Wackers were often applied much longer after the acute event. Furthermore, only the Wackers study attempted to localize the infarct.",
"   </p>",
"   <p>",
"    A Sgarbossa score of &ge;3 was highly specific (ie, few false positives) but much less sensitive (36 percent) in the validation sample in the original report [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/3\">",
"     3",
"    </a>",
"    ]. Similar findings were noted in a subsequent meta-analysis of 10 studies of 1614 patients in which a Sgarbossa score of &ge;3 had a sensitivity of 20 percent and a specificity of 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/16\">",
"     16",
"    </a>",
"    ]. The sensitivity may increase if serial or previous ECGs are available [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to their utility in diagnosis, the Sgarbossa criteria may also predict prognosis in patients with acute MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link&amp;anchor=H16#H16\">",
"     \"Conduction abnormalities after myocardial infarction\", section on 'Mortality and heart blocks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ventricular pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar problem is the diagnosis of an acute MI in the presence of a ventricular paced rhythm, which is usually associated with a left bundle branch block pattern. Thirty-two patients in the GUSTO-1 trial (0.1 percent of enrolled patients) had a ventricular paced rhythm. The only ECG criterion with a high specificity and statistical significance for the diagnosis of an acute MI was ST segment elevation &ge;5 mm in leads with a negative QRS complex [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/5\">",
"     5",
"    </a>",
"    ]. Two other criteria with acceptable specificity were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ST elevation &ge;1 mm in leads with concordant QRS polarity",
"     </li>",
"     <li>",
"      ST depression &ge;1 mm in leads V1, V2, or, V3",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prior infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the sequence of depolarization in LBBB can also mask typical findings associated with prior transmural (Q wave) infarctions. Certain ECG patterns, however may suggest prior infarction despite LBBB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Left ventricular free wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infarction of the left ventricular free (or lateral) wall ordinarily results in abnormal Q waves in the midprecordial to lateral precordial leads (and selected limb leads). However, the initial septal depolarization forces with LBBB are directed from right to left. These leftward forces produce an initial R wave in the mid- to lateral precordial leads, usually masking the loss of potential (Q waves) caused by the infarction. As a result, acute or chronic left ventricular free wall infarction by itself will not usually produce diagnostic Q waves in the presence of LBBB.",
"   </p>",
"   <p>",
"    If, however, the loss of lateral force is sufficiently large, late rightward forces generated by other portions of the left ventricle may predominate, possibly resulting in S waves in I, aVL and V6. Thus, an anterolateral MI should be suspected in the appropriate clinical setting if new S waves appear in leftward leads in a patient with preexisting common LBBB. This is an old concept that makes electrophysiologic and vectorcardiographic sense; however, it requires further clinical validation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Anteroseptal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of LBBB has a variable effect on the ECG changes that can occur with anteroseptal MI. Perhaps most important, the leftward shift in the initial vector in LBBB causes the loss of normal septal q waves in the left-right leads, I, aVL, and V6. Furthermore, the leftward and posterior orientation of the initial vector often results in a QS pattern in the anterior leads, V1 and sometimes in V2. These changes can mask the presence of an anteroseptal MI.",
"   </p>",
"   <p>",
"    There are, however, other changes that can occur that may suggest the presence of an anteroseptal or septal MI. The infarct may cause the leftwardly directed initial vector of LBBB to shift to the right, resulting in \"pseudonormalization\" of the initial vector and the reappearance of q waves in I, aVL and V6. If enough of the septum is infarcted, abnormal QR, QRS, or qrS types of complexes may appear in the mid- to lateral precordial leads in conjunction with the LBBB pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Free wall and septal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute or chronic infarction involving both the free wall and the septum may produce abnormal Q waves (usually as part of QRS or QrS types of complexes) in leads V4 to V6. These initial Q waves probably reflect posterior and superior forces from the spared basal portion of the septum. Small q waves (0.03 sec or less) may be seen in leads I and V5 to V6 with uncomplicated LBBB. Thus, wide Q waves (0.04 sec) in one or more of these leads are a more reliable sign of underlying infarction. As an example, wide Q waves (as part of QR complexes) in V6, particularly with an R wave in V1, appear to be a specific, although relatively insensitive, marker of anterior infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Inferior wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective analysis, 35 patients with LBBB and an unequivocal inferior MI on thallium imaging were compared to 131 patients with LBBB without an inferior wall MI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/17\">",
"     17",
"    </a>",
"    ]. Two ECG findings were most useful for the diagnosis of an inferior wall MI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Q or QS wave in lead aVF, found in 29 percent of those with a documented MI versus only 3 percent of those without an inferior MI",
"     </li>",
"     <li>",
"      Diagnostic T wave inversion (compete or biphasic with an initial negative deflection), present in 66 percent with and 6 percent without a MI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of either finding was 86 percent sensitive and 91 percent specific for the diagnosis of an inferior wall MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following points summarize the electrocardiographic signs of myocardial infarction in LBBB.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Sgarbossa criteria have high specificity but low sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/3,11-13,18\">",
"       3,11-13,18",
"      </a>",
"      ]; thus, their presence is highly suggestive of acute infarction but their absence has little value.",
"     </li>",
"     <li>",
"      A QS pattern, slow R wave progression, or loss of R waves in the anterior precordial leads or a QS pattern in II, III, aVF, or aVL can occur with uncomplicated LBBB.",
"     </li>",
"     <li>",
"      LBBB characteristically masks the Q waves of pure lateral and free wall infarction; it may also mask the Q waves of inferior or anteroseptal infarction.",
"     </li>",
"     <li>",
"      ST segment elevation with tall positive T waves are frequently seen in the right precordial leads with uncomplicated LBBB. Secondary T wave inversions are characteristically seen in the lateral precordial leads. However, the appearance of concordant ST elevations in the lateral leads or ST depression or deep T wave inversions in leads V1-V3 suggests underlying ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9431/abstract/3\">",
"       3",
"      </a>",
"      ]. Thus, close attention should be paid to serial ST-T changes. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Sgarbossa criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of QR complexes in leads I, V5, or V6, or in II, III, and aVF with LBBB strongly suggests underlying infarction.",
"     </li>",
"     <li>",
"      An anterolateral MI should be suspected if new S waves appear in leftward leads (I, aVL, and V6) in a patient with preexisting common LBBB.",
"     </li>",
"     <li>",
"      Underlying MI, due to fibrosis and scarring, is also suggested by notching of the ascending part of a wide S waves in the mid-precordial leads (Cabrera's sign), or of the ascending limb of a wide R wave in V5 or V6 (Chapman's sign).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Goldberger AL. Myocardial infarction: Electrocardiographic differential diagnosis, 7th, Elsevier/Mosby, St Louis 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/2\">",
"      Wackers FJ. The diagnosis of myocardial infarction in the presence of left bundle branch block. Cardiol Clin 1987; 5:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/3\">",
"      Sgarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. N Engl J Med 1996; 334:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/4\">",
"      Wellens HJ. Acute myocardial infarction and left bundle-branch block--can we lift the veil? N Engl J Med 1996; 334:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/5\">",
"      Sgarbossa EB, Pinski SL, Gates KB, Wagner GS. Early electrocardiographic diagnosis of acute myocardial infarction in the presence of ventricular paced rhythm. GUSTO-I investigators. Am J Cardiol 1996; 77:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/6\">",
"      Go AS, Barron HV, Rundle AC, et al. Bundle-branch block and in-hospital mortality in acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. Ann Intern Med 1998; 129:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/7\">",
"      Gussak I, Wright RS, Bjerregaard P, et al. False-negative and false-positive ECG diagnoses of Q wave myocardial infarction in the presence of right bundle-branch block. Cardiology 2000; 94:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/8\">",
"      Gussak I, Zhou SH, Rautaharju P, et al. Right bundle branch block as a cause of false-negative ECG classification of inferior myocardial infarction. J Electrocardiol 1999; 32:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/9\">",
"      Ortega-Carnicer J, G&oacute;mez-Grande ML, Ambr&oacute;s A. Right bundle branch block-induced Q waves simulating anterior myocardial infarction extension. J Electrocardiol 2000; 33:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/10\">",
"      Shettigar UR, Pannuri A, Barbier GH, Appunn DO. Significance of anterior Q waves in left anterior fascicular block--a clinical and noninvasive assessment. Clin Cardiol 2002; 25:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/11\">",
"      Kontos MC, McQueen RH, Jesse RL, et al. Can myocardial infarction be rapidly identified in emergency department patients who have left bundle-branch block? Ann Emerg Med 2001; 37:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/12\">",
"      Shlipak MG, Lyons WL, Go AS, et al. Should the electrocardiogram be used to guide therapy for patients with left bundle-branch block and suspected myocardial infarction? JAMA 1999; 281:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/13\">",
"      Sgarbossa EB. Value of the ECG in suspected acute myocardial infarction with left bundle branch block. J Electrocardiol 2000; 33 Suppl:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/14\">",
"      Shlipak MG, Go AS, Frederick PD, et al. Treatment and outcomes of left bundle-branch block patients with myocardial infarction who present without chest pain. National Registry of Myocardial Infarction 2 Investigators. J Am Coll Cardiol 2000; 36:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/15\">",
"      Al-Faleh H, Fu Y, Wagner G, et al. Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. Am Heart J 2006; 151:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/16\">",
"      Tabas JA, Rodriguez RM, Seligman HK, Goldschlager NF. Electrocardiographic criteria for detecting acute myocardial infarction in patients with left bundle branch block: a meta-analysis. Ann Emerg Med 2008; 52:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/17\">",
"      Laham CL, Hammill SC, Gibbons RJ. New criteria for the diagnosis of healed inferior wall myocardial infarction in patients with left bundle branch block. Am J Cardiol 1997; 79:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9431/abstract/18\">",
"      Gunnarsson G, Eriksson P, Dellborg M. ECG criteria in diagnosis of acute myocardial infarction in the presence of left bundle branch block. Int J Cardiol 2001; 78:167.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2104 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9431=[""].join("\n");
var outline_f9_13_9431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RIGHT BUNDLE BRANCH BLOCK WITH MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Q wave MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Non-Q wave MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LEFT BUNDLE BRANCH BLOCK WITH MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Attempts to improve ECG diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sgarbossa criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prior infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Left ventricular free wall",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Anteroseptal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Free wall and septal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Inferior wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2104\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2104|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?7/46/7909\" title=\"waveform 1A\">",
"      Right bundle branch block 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/12/43210\" title=\"waveform 1B\">",
"      Right bundle branch block 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/51/12085\" title=\"waveform 2A\">",
"      Left bundle branch block 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/28/43466\" title=\"waveform 2B\">",
"      Left bundle branch block 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=related_link\">",
"      Right bundle branch block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_13_9432="Treatment of latent tuberculosis infection in HIV-negative adults";
var content_f9_13_9432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of latent tuberculosis infection in HIV-negative adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9432/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9432/contributors\">",
"     C Robert Horsburgh, Jr, MD, MUS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9432/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9432/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9432/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/13/9432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of individuals with active tuberculosis (TB) is the first priority for TB control; an important second priority is identification and treatment of individuals with latent TB infection (LTBI).",
"   </p>",
"   <p>",
"    In most individuals, Mycobacterium tuberculosis infection is contained initially by host defenses, and the infection remains latent. However, latent infection has the potential to develop into active infection at any time. Identification and treatment of LTBI greatly reduces the likelihood of reactivation, and so has potential to protect the health of the individuals as well as the public by reducing the number of potential sources of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following LTBI treatment, the durability of protection against reactivation is variable and depends upon regional prevalence of TB and risk for reexposure. LTBI treatment may confer lifelong protection against disease; among Alaskan Eskimos, for example, the protective effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH) prophylaxis has been shown to persist for more than 19 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of LTBI should be initiated only once active TB has been excluded. The approach to treatment of LTBI in HIV-negative patients will be reviewed here. LTBI in children and diagnostic testing for LTBI in HIV-negative patients are discussed in detail separately, as is management of LTBI for patients with HIV or receiving tumor necrosis factor-alpha inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=see_link\">",
"     \"Latent tuberculosis infection in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14135196\">",
"    <span class=\"h1\">",
"     WHOM TO TREAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of testing for latent tuberculosis infection (LTBI) is to identify individuals who are at increased risk for the development of TB and therefore would benefit from treatment of LTBI. Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive. This is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens for treatment of latent tuberculosis infection (LTBI) include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH), INH with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    (RPT),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (RIF), or INH with RIF (",
"    <a class=\"graphic graphic_table graphicRef65944 \" href=\"UTD.htm?16/61/17373\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]. RIF with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    was previously recommended as a two-month regimen for treatment of LTBI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/1\">",
"     1",
"    </a>",
"    ], although revised guidelines advise against the use of this combination because of substantial hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10167569\">",
"    <span class=\"h2\">",
"     Isoniazid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH) for reducing the incidence of active TB (compared with placebo) is 60 to 90 percent. However, because not all patients complete the course of therapy, the efficacy of treatment is only about 60 percent (range 25 to 92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the only study comparing the efficacy of different durations of INH therapy, six months of treatment was 65 percent effective and 12 months of treatment was 75 percent effective (but not statistically different from six months) in preventing TB among patients with radiographic abnormalities suggestive of inactive infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/11\">",
"     11",
"    </a>",
"    ]. By extrapolation of data from randomized trials, the optimal duration of INH treatment for LTBI has been determined to be nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important side effect of INH is hepatitis; the incidence is about 1 per 1000 persons, although asymptomatic, mild liver enzyme abnormalities are relatively common [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The most important risk factor for the development of INH-induced hepatitis is alcohol consumption; patients should be advised to abstain from alcohol while taking INH. In addition, all individuals on INH should be educated about the symptoms of hepatitis and instructed to seek prompt evaluation of symptoms to reduce risk for progression to severe disease. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Peripheral neuropathy occurs in up to 2 percent of patients taking INH [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/16\">",
"     16",
"    </a>",
"    ]. It is caused by interference with metabolism of pyridoxine and can be prevented with pyridoxine supplementation (25 to 50 mg daily). This is especially important for patients with conditions that can predispose to neuropathy (including diabetes, uremia, alcoholism, malnutrition, and HIV infection) as well as in the setting of pregnancy and seizure disorders. Pyridoxine should also be administered to infants of breastfeeding mothers receiving INH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26951774\">",
"    <span class=\"h2\">",
"     Isoniazid and rifapentine",
"    </span>",
"    &nbsp;&mdash;&nbsp;RPT is a rifamycin derivative with a long half-life and greater potency against M. tuberculosis than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    . A three-month regimen of weekly INH and RPT given as directly observed therapy (",
"    <a class=\"graphic graphic_table graphicRef65944 \" href=\"UTD.htm?16/61/17373\">",
"     table 1",
"    </a>",
"    ) has been shown to be noninferior to a nine-month self-administered regimen of daily INH in a randomized, open label trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/17\">",
"     17",
"    </a>",
"    ]. The trial included 7731 predominantly HIV-negative individuals at high risk for progression from latent to active TB infection in four low-incidence countries (Brazil, Canada, Spain, and the United States) for up to 33 months of follow-up. Patients were required to be at least 12 years of age and belong to one of the following four high-risk categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Close contact of patient with culture-confirmed contagious TB and positive tuberculin test",
"     </li>",
"     <li>",
"      Conversion from negative to positive tuberculin test result",
"     </li>",
"     <li>",
"      HIV-positive patients not on antiretroviral medications with positive tuberculin test or who have had close contact with known TB case (regardless of tuberculin test status)",
"     </li>",
"     <li>",
"      Positive tuberculin test with fibrotic changes on chest x-ray consistent with previously untreated TB",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most participants in the trial were presumed to be recently infected; infected contacts of infectious cases and recent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    converters made up approximately 96 percent of patients. TB developed in 7 of 3986 patients in the combination therapy group (cumulative rate 0.19 percent) and 15 of 3745 patients in the INH only group (cumulative rate 0.43 percent). Hepatoxicity was observed more frequently in the INH group than the combination therapy group (2.7 versus 0.4 percent; p&lt;0.001), while &ldquo;hypersensitivity&rdquo; was observed more frequently in the combination therapy group than the INH group (3.8 versus 0.5 percent; p&lt;0.001).",
"   </p>",
"   <p>",
"    The completion rate was 82 percent for the combination therapy group and 69 percent for INH (p&lt;0.01). At least some of the higher completion rate for combination therapy (and thus, some of the efficacy) can be attributed to administration of combination therapy via directly observed therapy (DOT), while INH was administered without DOT. Further study of the combination regimen is needed with respect to completion and efficacy when the regimen is not given by DOT, durability of protection, efficacy and toxicity in the setting of HIV infection, efficacy and toxicity in other patient groups who have not been recently infected (including patients who are to receive TNF-alpha inhibitors), and utility in regions where the incidence of TB is high.",
"   </p>",
"   <p>",
"    Use of INH-RPT for treatment of LTBI has NOT been demonstrated to be effective in patients in the following categories: children &lt;2 years of age, HIV infected persons on antiretroviral therapy, presumed infection with INH- or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    -resistant TB, and pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are important and potentially prolonged drug interactions with rifamycins, including with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ; oral contraceptives; some antihypertensives, antiarrhythmics, antidepressants, and anticonvulsants;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ; and the protease inhibitor class of antiretroviral drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link\">",
"     \"Rifampin and other rifamycins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rifampin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (RIF) for reducing the incidence of active TB is estimated to be similar to that of INH [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Although data are limited, RIF appears to be well tolerated, with a low rate of hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/19\">",
"     19",
"    </a>",
"    ]. In a study of 679 patients with silicosis, the efficacy of RIF as a single agent for treatment of LTBI (duration three months) was equivalent to that of INH administered daily for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/19\">",
"     19",
"    </a>",
"    ]. In another study of 847 patients randomized to four months of RIF or nine months of INH, fewer adverse effects and better adherence were observed among those who received RIF, although the study did not evaluate efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barriers to adoption of routine use of RIF for treatment of LTBI include the possibility of inadvertent treatment of active TB resulting in RIF-resistant disease, concerns about efficacy, and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are important and potentially prolonged drug interactions with rifamycins, including with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ; oral contraceptives; some antihypertensives, antiarrhythmics, antidepressants, and anticonvulsants;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ; and the protease inhibitor class of antiretroviral drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link\">",
"     \"Rifampin and other rifamycins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22706927\">",
"    <span class=\"h2\">",
"     Isoniazid and rifampin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on use of INH and RIF in HIV-negative patients are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. In a prospective randomized trial among HIV-infected individuals, a three-month regimen of daily INH and RIF provided 60 percent protection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/24\">",
"     24",
"    </a>",
"    ]. Although this regimen has not been studied in a large trial among HIV-uninfected persons, a meta-analysis of small studies in this population suggests that it is equally efficacious and not more toxic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/4\">",
"     4",
"    </a>",
"    ]. For circumstances in which RPT is not available",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    directly observed therapy for INH-RPT is not feasible, a three-month daily regimen of INH-RIF may be an acceptable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SELECTING A REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred treatment regimen for most individuals with latent tuberculosis infection (LTBI) is nine months of daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH), as recommended by the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2011, the three-month once-weekly regimen of isoniazid (INH) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    (RPT) (given by directly observed therapy) (",
"    <a class=\"graphic graphic_table graphicRef65944 \" href=\"UTD.htm?16/61/17373\">",
"     table 1",
"    </a>",
"    ) was recommended by CDC as an equal alternative to nine months of INH for treatment of LTBI in otherwise healthy patients aged &ge;12 years who fall within the four high-risk groups studied [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/1,2,5,17,18\">",
"     1,2,5,17,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26951774\">",
"     'Isoniazid and rifapentine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The choice between combination INH-RPT and the other regimens depends on feasibility of directly observed therapy by a trained provider, resources for drug procurement and patient preference. In general, when directly observed therapy is feasible, we favor use of INH-RPT for treatment of LTBI for patients within the four high-risk groups studied, given its noninferiority to INH and the higher treatment completion rate demonstrated in these groups [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are insufficient to support use of INH-RPT for treatment of LTBI for patients in the following categories: children &lt;2 years of age, HIV infected persons on antiretroviral therapy, presumed infection with INH- or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    -resistant TB, and pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If INH is used, daily therapy for nine months is preferred. A six-month course of treatment with INH also provides substantial protection; in the setting of difficulty with adherence, providers may prefer to concentrate efforts in ensuring six months of therapy. However, regimens shorter than nine months are not recommended for children or for patients with fibrotic lesions on chest radiograph. For patients with poor adherence to treatment, directly observed therapy (DOT) may be the optimal approach; this may be implemented daily or twice weekly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10341?source=see_link\">",
"     \"Adherence to tuberculosis treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pyridoxine supplementation (25 to 50 mg daily) should be administered together with INH for patients with conditions that can predispose to neuropathy (including diabetes, uremia, alcoholism, malnutrition, and HIV infection). It should also be administered in the setting of pregnancy and to infants of breastfeeding mothers receiving INH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=see_link\">",
"     \"Tuberculosis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other regimens (INH for six months,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (RIF) for four months or INH plus RIF for three months) are acceptable alternatives. Some experts favor four months of self-administered RIF over nine months of self-administered INH because of increased completion and decreased hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the alternative regimens, RIF should be used for patients who are intolerant of INH or who are presumed to have infection with INH-resistant, RIF-sensitive strains of tuberculosis (TB) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/2,25-29\">",
"     2,25-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7497?source=see_link\">",
"     \"Epidemiology and molecular mechanisms of drug-resistant tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10341?source=see_link\">",
"     \"Adherence to tuberculosis treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RIF with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    should NOT for treatment of LTBI be used because of the possibility of severe hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients exposed to (and presumed to be infected with) multidrug-resistant TB (MDR-TB), treatment should be individualized based on the susceptibility profile of the index case [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Two drugs to which the organism is sensitive should be chosen, such as a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    or a fluoroquinolone with antituberculous activity (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Duration of treatment has not been studied; 6 to 12 months is reasonable. Patients with MDR-TB LTBI should be treated with DOT and monitored closely for hepatotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of LTBI in pregnancy and in children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=see_link\">",
"     \"Tuberculosis in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=see_link\">",
"     \"Latent tuberculosis infection in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Continuation of LTBI treatment after presumptive treatment for TB disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;LTBI may be inferred for patients initiated on presumptive therapy (based on positive Mantoux or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    , epidemiologic exposure, etc) but subsequent negative cultures and no clinical response to treatment. The time of initial phase combination therapy administered can be applied to the total duration of treatment for LTBI. Options include stopping treatment if RIF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    have been given for at least two months, continuing treatment with RIF for a total of four months (with or without INH), or continuing treatment with INH for a total of nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interrupted LTBI therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, it is preferable that patients do not interrupt therapy. For circumstances in which the specified number of doses cannot be administered within the target period, a determination should be made regarding continuing the same regimen for the remaining duration of time or restarting treatment from the beginning. The earlier the interruption in the course of treatment and the longer the duration of the interruption, the more serious the effect and the greater the need to restart therapy from the beginning.",
"   </p>",
"   <p>",
"    In general, for treatment of LTBI with INH (nine or six month regimen), treatment may be resumed where it was left off if less than three months were missed; treatment for LTBI should be reinitiated from the beginning if more than three months are missed. For treatment of LTBI with three- or four-month regimens, treatment may be resumed where left off if less than two months are missed; treatment for LTBI should be reinitiated from the beginning if more than two months are missed. There are no data regarding the impact of treatment interruptions on the effectiveness of the three month, once-weekly INH-RPT regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving latent tuberculosis infection (LTBI) treatment should be monitored at least monthly for clinical symptoms of hepatitis. Such individuals should also be educated about the symptoms of hepatitis and instructed to stop the medication and seek prompt evaluation of symptoms to reduce risk for progression to severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/36\">",
"     36",
"    </a>",
"    ]. Symptoms include anorexia, nausea, vomiting, dark urine, icterus, rash, persistent paresthesias of the hands and feet, persistent fatigue, weakness or fever lasting three or more days, abdominal pain (particularly right upper quadrant discomfort), easy bruising or bleeding, or arthralgias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients receiving treatment by directly observed therapy, including the three month once-weekly INH-RPT regimen, should be questioned at each dose about possible side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/17\">",
"     17",
"    </a>",
"    ]. Persons with signs or symptoms suggesting toxicity should be evaluated clinically and with liver function testing.",
"   </p>",
"   <p>",
"    Baseline liver enzyme testing is appropriate for the following individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with underlying liver disease (eg, hepatitis C)",
"     </li>",
"     <li>",
"      Patients with HIV infection",
"     </li>",
"     <li>",
"      Pregnant and postpartum women within three months of delivery",
"     </li>",
"     <li>",
"      Patients who consume alcohol regularly",
"     </li>",
"     <li>",
"      Patients on other medication(s) with potential hepatotoxicity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Baseline liver enzyme testing may also be considered on an individual basis for other patients; it does not need to be performed routinely. Active hepatitis and end-stage liver disease are relative contraindications to the use of hepatotoxic agents for LTBI treatment. For patients with baseline serum transaminase levels greater than three times the upper limit of normal, LTBI treatment should be delayed pending evaluation of the underlying cause. LTBI treatment should be discontinued for symptomatic patients with serum transaminase levels greater than three times the upper limit of normal or for asymptomatic patients with serum transaminase levels greater than five times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/9\">",
"     9",
"    </a>",
"    ]. Treatment with the offending agent should not be resumed, even after liver function tests have improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adherence to prolonged therapy is a major challenge for treatment of LTBI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9432/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10341?source=see_link\">",
"     \"Adherence to tuberculosis treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUBSEQUENT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, individuals with ongoing potential tuberculosis (TB) exposure who have a history of a positive test for latent tuberculosis infection (LTBI) and have completed a course of LTBI treatment should undergo baseline chest x-ray. If symptoms develop that raise the possibility of active TB, evaluation should be pursued with chest x-ray and other investigation as outlined in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with documented positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) should never have repeat TST; once the test is positive, it generally remains positive. Repeating the test has some risk of severe reaction and no clinical utility. There are no additional mechanisms to evaluate for subsequent TB exposure in these individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"       \"Patient information: Tuberculosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For treatment of latent tuberculosis infection (LTBI) in HIV-negative adults, we suggest either nine months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      (INH) or, in recently-infected individuals (including infected contacts to infectious cases and recent tuberculin test converters), three months of weekly INH and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"       rifapentine",
"      </a>",
"      (RPT) given by direct observation (",
"      <a class=\"graphic graphic_table graphicRef65944 \" href=\"UTD.htm?16/61/17373\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternative regimens include daily INH for six months, daily RIF for four months, or daily INH and RIF for three months. There are important and potentially prolonged drug interactions with rifamycins, including with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , oral contraceptives, some antihypertensives, antiarrhythmics, antidepressants, anticonvulsants, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Selecting a regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hepatitis can be an important adverse effect of INH. Patients should be advised to abstain from alcohol and have monthly monitoring for clinical symptoms of hepatitis. Patients should also be educated about the symptoms of hepatitis and instructed to stop their medication and seek prompt evaluation if they develop. Baseline liver enzyme testing is appropriate for certain individuals as outlined above (see",
"      <a class=\"local\" href=\"#H10167569\">",
"       'Isoniazid'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Monitoring'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Treatment should be discontinued for symptomatic patients with serum transaminase levels greater than three times the upper limit of normal or for asymptomatic patients with serum transaminase levels greater than five times the upper limit of normal. Treatment should not be resumed, even after liver function tests have improved. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral neuropathy can occur among patients taking INH due to interference with metabolism of pyridoxine and can be prevented with pyridoxine supplementation (25 to 50 mg daily). This is especially important for patients with conditions that can predispose to neuropathy (including diabetes, uremia, alcoholism, malnutrition, and HIV infection) as well as in the setting of pregnancy and seizure disorders. Pyridoxine should also be administered to infants of breastfeeding mothers receiving INH. (See",
"      <a class=\"local\" href=\"#H10167569\">",
"       'Isoniazid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients exposed to multidrug-resistant tuberculosis (MDR-TB), treatment should be individualized based on the susceptibility profile of the index case. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Selecting a regimen'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"       \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend against the use of RIF with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      for treatment of latent tuberculosis infection because of the possibility of severe hepatotoxicity (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Selecting a regimen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/1\">",
"      Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/2\">",
"      Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011; 364:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/3\">",
"      Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979; 119:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/4\">",
"      Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005; 40:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC), American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/6\">",
"      From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. JAMA 2001; 286:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/7\">",
"      McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005; 41:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/8\">",
"      Ijaz K, Jereb JA, Lambert LA, et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2006; 42:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/9\">",
"      Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002; 347:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/10\">",
"      Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; :CD001363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/11\">",
"      Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982; 60:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/12\">",
"      Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/13\">",
"      Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/14\">",
"      Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA 1979; 241:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/15\">",
"      Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976; 84:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/16\">",
"      OESTREICHER R, DRESSLER SH, MIDDLEBROOK G. Peripheral neuritis in tuberculous patients treated with isoniazid. Am Rev Tuberc 1954; 70:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/17\">",
"      Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/19\">",
"      A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992; 145:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/20\">",
"      Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997; 155:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/21\">",
"      Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/22\">",
"      Aspler A, Long R, Trajman A, et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010; 65:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/23\">",
"      Young H, Wessolossky M, Ellis J, et al. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. Clin Infect Dis 2009; 49:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/24\">",
"      Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/25\">",
"      Polesky A, Farber HW, Gottlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996; 154:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/26\">",
"      Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002; 347:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/27\">",
"      Lardizabal A, Passannante M, Kojakali F, et al. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/28\">",
"      Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2004; 170:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/29\">",
"      Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009; 49:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/30\">",
"      Fraser A, Paul M, Attamna A, Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2006; :CD005435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/31\">",
"      Schaaf HS, Vermeulen HA, Gie RP, et al. Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases. Pediatr Infect Dis J 1999; 18:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/32\">",
"      Schaaf HS, Gie RP, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002; 109:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/33\">",
"      Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 1992; 41:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/34\">",
"      Younossian AB, Rochat T, Ketterer JP, et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/35\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/36\">",
"      Centers for Disease Control and Prevention (CDC). Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010; 59:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/37\">",
"      Menzies D, Dion MJ, Rabinovitch B, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/38\">",
"      Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9432/abstract/39\">",
"      Menzies D, Dion MJ, Francis D, et al. In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection. Int J Tuberc Lung Dis 2005; 9:1343.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8017 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9432=[""].join("\n");
var outline_f9_13_9432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14135196\">",
"      WHOM TO TREAT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10167569\">",
"      Isoniazid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26951774\">",
"      Isoniazid and rifapentine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rifampin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22706927\">",
"      Isoniazid and rifampin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SELECTING A REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Continuation of LTBI treatment after presumptive treatment for TB disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interrupted LTBI therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adherence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUBSEQUENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8017\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8017|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/61/17373\" title=\"table 1\">",
"      Dosing regimens for treatment of latent TB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10341?source=related_link\">",
"      Adherence to tuberculosis treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7497?source=related_link\">",
"      Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=related_link\">",
"      Latent tuberculosis infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=related_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=related_link\">",
"      Tuberculosis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_13_9433="Diagnosis of and screening for autosomal dominant polycystic kidney disease";
var content_f9_13_9433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of and screening for autosomal dominant polycystic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9433/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9433/contributors\">",
"     Vicente E Torres, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9433/contributors\">",
"     William M Bennett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9433/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9433/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/13/9433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant polycystic kidney disease (ADPKD) is a common disorder, occurring in approximately 1 in every 400 to 1000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It is estimated that less than one-half of these cases will be diagnosed during the patient's lifetime, as the disease is often clinically silent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 85 percent of families with ADPKD have an abnormality on chromosome 16 (PKD1 locus) that is tightly linked to the alpha-globin gene locus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/4\">",
"     4",
"    </a>",
"    ]. The remaining patients have a different defect that involves a gene on chromosome 4 (the PKD2 locus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with PKD2 have a less severe phenotype than those with PKD1, but neither disorder is benign [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/5\">",
"     5",
"    </a>",
"    ]. Cysts occur later in PKD2 disease, as does end-stage renal disease (mean age 74.0 versus 54.3 years in PKD1) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/6\">",
"     6",
"    </a>",
"    ]. As a result, false negative results are more likely when screening young subjects with PKD2 disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of and screening for ADPKD will be reviewed here. The course and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ADPKD relies principally upon imaging of the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/7\">",
"     7",
"    </a>",
"    ]. Typical findings include large kidneys and extensive cysts scattered throughout both kidneys. Because of cost and safety, ultrasonography is most commonly used as the imaging modality. In certain settings, genetic testing is required for a definitive diagnosis.",
"   </p>",
"   <p>",
"    Important issues related to the diagnosis of ADPKD include the presence or absence of a family history of the disease, the number and types of renal cysts, and the age of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POSITIVE FAMILY HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Screening and diagnosis of asymptomatic individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for the diagnosis of ADPKD in an asymptomatic individual at risk because of a positive family history usually relies upon imaging of the kidney. Among at risk individuals, ultrasonography of the kidneys is usually the initial modality used for screening and diagnosis. Since this technique is less reliable in younger individuals, genetic diagnosis using linkage or DNA analysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an alternative imaging modality can be performed when a definitive diagnosis is required. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Genetic testing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'Other imaging modalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In children (less than 18 years of age), we recommend NOT screening. This is principally because the adverse consequences associated with a positive diagnosis prior to symptoms in young individuals (such as career, educational, emotional, and insurability issues) far outweigh any benefits since effective therapies are not yet available. Nevertheless, children at risk for ADPKD should be monitored for early disease presentations that require treatment. Among these, hypertension is underrecognized.",
"   </p>",
"   <p>",
"    In adults (greater than 18 years of age), we recommend screening in potential living related kidney donors given the adverse medical consequences of transplanting a kidney from a donor with ADPKD. It is important to realize, however, that all potential kidney donors undergo imaging of the kidneys. In other at-risk adults, the decision to screen for the disease should be based upon patient's preferences and values after the benefits and adverse consequences of certainty concerning the diagnosis are fully understood.",
"   </p>",
"   <p>",
"    Prior to testing, counseling by experienced staff must be performed. The benefits derived from testing include knowledge concerning the diagnosis, appropriate family planning, the ability to detect and treat complications associated with the disease, reassurance of unaffected individuals, and appropriate selection of unaffected relatives as possible donors for kidney transplantation. Adverse consequences with testing, including possible difficulties with insurability and employment due to a positive diagnosis, must be discussed.",
"   </p>",
"   <p>",
"    There has been a trend for earlier diagnosis of ADPKD in patients at risk for the disease. In one cohort of patients, for example, the age at diagnosis was significantly lower among those born between 1951 and 1974 compared to those born before 1951 (27 versus 39 years, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Ultrasonographic criteria for adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal ultrasonography is usually used for screening because it is safe, effective, and inexpensive. There have been no studies that adequately compared ultrasonography with other imaging modalities for screening and diagnosis of ADPKD.",
"   </p>",
"   <p>",
"    The criteria for diagnosis varies based upon whether the familial genotype is known. In the vast majority of cases, the individual at risk for ADPKD is from a family with an unknown genotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77995158\">",
"    <span class=\"h4\">",
"     At risk but unknown familial genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use the following ultrasonographic criteria for the diagnosis of ADPKD for at risk individuals from families of unknown genotype:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among individuals between 15 and 39 years of age, at least three unilateral or bilateral kidney cysts. The specificity and positive predictive value of this criterion for individuals of this age is 100 percent. By comparison, this criteria is associated with a sensitivity of 82 and 96 percent for individuals between 15 and 29 years, and between 30 to 39 years of age, respectively.",
"     </li>",
"     <li>",
"      Among individuals 40 to 59 years of age, at least two cysts in each kidney. This finding is associated with a sensitivity, specificity, and positive predictive value of 90, 100, and 100 percent, respectively.",
"     </li>",
"     <li>",
"      Among individuals 60 years or older, at least four cysts in each kidney. This is associated with 100 percent sensitivity and specificity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria are based upon a well-designed study of 948 individuals at risk for either PKD1 or PKD2, in which the performance of different ultrasound criteria was evaluated among at-risk individuals who subsequently underwent molecular genotyping [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/9\">",
"     9",
"    </a>",
"    ]. A statistical resampling method termed \"bootstrapping\" was used to obtain the best estimate for the accuracy of different ultrasonographic diagnostic criteria for various age groups and also ensure that the analysis involved a constant ratio of 85:15 of patients with PKD1 to those with PKD2. This latter feature was performed to simulate the case mix observed in a general clinic assessing at-risk individuals of all age groups.",
"   </p>",
"   <p>",
"    This study also provided some guidance concerning the ability of specific ultrasonographic findings to exclude the diagnosis of ADPKD among at-risk individuals from families of unknown genotype:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among individuals 40 years of age or older, ultrasonographic evidence of zero or only one renal cyst excludes the disease, since these findings are associated with a negative predictive value of 100 percent.",
"     </li>",
"     <li>",
"      Among those 30 to 39 years of age, the disease is essentially excluded if ultrasonography reveals the absence of any renal cysts, which is associated with a false negative rate of 2 percent. The finding of no renal cysts with more sensitive modalities, such as CT scanning or magnetic resonance imaging, would provide further support that the disease is not present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Other imaging modalities'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Among patients less than 30 years of age, ultrasonographic imaging is limited in its ability to help exclude the disease. The approach to such patients is discussed in other sections in this topic review. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Other imaging modalities'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H7\">",
"       'Approach after equivocal ultrasound results'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H8\">",
"       'Infant/child'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129629707\">",
"    <span class=\"h4\">",
"     At risk for type 1 ADPKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some asymptomatic patients at risk for ADPKD are from families with known and well-characterized pathogenic mutations in the PKD1 locus. In this setting, testing for the known mutation is more definitive and may be more cost-effective than ultrasonography.",
"    <br/>",
"    <br/>",
"    However, if genetic testing is not available or less desirable, ultrasonographic imaging may be used for individuals who are known to be at risk for type 1 ADPKD. Among such patients, the following age-dependent ultrasonographic criteria have been used for the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among individuals between 15 and 30 years of age, at least two unilateral or bilateral cysts",
"     </li>",
"     <li>",
"      Among individuals 30 to 59 years of age, two cysts in each kidney",
"     </li>",
"     <li>",
"      Among individuals 60 years or older, four cysts in each kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria were derived from an ultrasonographic study of 128 individuals at risk for PKD1 that compared imaging findings with genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/10\">",
"     10",
"    </a>",
"    ]. The specificity of these criteria was found to be 100 percent for all patients at risk for type 1 ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. By comparison, the sensitivity of these findings varies by patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. Among patients between 15 and 30 years of age at risk for type 1 disease, the sensitivity of these criteria is 95 percent. The sensitivity increases to 97 to 100 percent for those older than 30 years of age. Thus, a negative ultrasound can definitely exclude type 1 disease when the patient is older than 30 years, although the false negative rate at age 20 is only about 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129629736\">",
"    <span class=\"h4\">",
"     At risk for type 2 ADPKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some asymptomatic patients at risk for ADPKD are from families with known and well-characterized pathogenic mutations in the PKD2 locus. In this setting, testing for the known mutation is more definitive and may be more cost-effective than ultrasonography.",
"    <br/>",
"    <br/>",
"    If genetic testing is not available or less desirable, established ultrasonographic criteria are less sensitive for patients who are known to be at risk for type 2 ADPKD. In this setting, some clinicians would use the ultrasonographic criteria created for those at risk for ADPKD but of unknown familial genotype, as noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other imaging modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because CT and magnetic resonance imaging (MRI) are more sensitive than ultrasonography, the sonographic criteria listed above are not applicable to these modalities. Contrast enhanced CT scanning or MRI or heavy-weighted unenhanced T2 MR images can reliably detect small cysts of 2 to 3 mm diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not formally evaluated and only studied in small case series and reports, we believe that a negative test (no cysts in either the kidneys or the liver) found with these techniques by 20 years of age virtually excludes the presence of PKD, at least for type 1 disease.",
"   </p>",
"   <p>",
"    Conversely, among patients with equivocal ultrasonographic studies, these techniques may demonstrate numerous small cysts, thereby possibly precluding the need for genetic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Approach after equivocal ultrasound results",
"    </span>",
"    &nbsp;&mdash;&nbsp;No formal studies have compared CT or MRI techniques, or genetic testing among at risk adult patients with equivocal ultrasonographic results. In the setting of an equivocal ultrasound, some clinicians prefer genetic testing, while others choose either a CT scan or MR study with genetic testing performed if the diagnosis remains uncertain after additional radiologic evaluation. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Infant/child",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an",
"    <span class=\"nowrap\">",
"     infant/child",
"    </span>",
"    at 50 percent risk for ADPKD, ultrasonography of the kidney is less useful than in adults, with inconclusive results being noted in one-half of those at risk (particularly children less than five years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/13\">",
"     13",
"    </a>",
"    ]. As previously mentioned, we recommend NOT screening in children. However, if desired, we use renal ultrasonography for initial evaluation because it is safe and inexpensive.",
"   </p>",
"   <p>",
"    The finding of large echogenic kidneys without distinct macroscopic cysts in infants is highly suggestive of the disease. The presence of one cyst is adequate for the diagnosis in an at-risk child (0 to 15 years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic testing can be used when the imaging results are equivocal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when a definite diagnosis is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14\">",
"     'Genetic testing'",
"    </a>",
"    below.) Prenatal screening in the fetus at risk for ADPKD is discussed separately. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prenatal and preimplantation genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis of symptomatic individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is easy to establish in patients with symptomatic disease who have a family history of ADPKD. In such patients, the diagnosis is certain with the finding of large kidneys with multiple bilateral cysts on ultrasonography or CT scanning (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76800 \" href=\"UTD.htm?43/36/44623\">",
"     image 1",
"    </a>",
"    ). The specific number of cysts per kidney detected by ultrasonography that will definitively establish the diagnosis of ADPKD depends upon patient age and is the same as the criteria used in patients with asymptomatic disease. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Ultrasonographic criteria for adults'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Affected patients may present with flank pain or renal insufficiency, and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/2\">",
"     2",
"    </a>",
"    ]. Cysts may also be seen in the liver and pancreas. Hepatic cysts, for example, can be detected in over half of cases and are more commonly seen in women and in patients over the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/14\">",
"     14",
"    </a>",
"    ]. Additional manifestations may include intracranial aneurysms, decreased urinary concentrating ability, and abdominal wall hernias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NEGATIVE FAMILY HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In up to 25 percent of cases, the clinical presentation and imaging studies suggest a diagnosis of ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/2\">",
"     2",
"    </a>",
"    ]; however, no one else in the family is known to have the disease.",
"   </p>",
"   <p>",
"    In most such cases, the disease is inherited, but the affected parent has died without a diagnosis or is alive with a mild form of the disease that has gone undetected. In this case, reviewing medical information or obtaining imaging studies on the parents or other family members may prove helpful. In up to five percent of cases, the disease may be due to a new mutation.",
"   </p>",
"   <p>",
"    In the absence of a family history, there is no definitive number of cysts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyst location that provides an unequivocal diagnosis of ADPKD. The diagnosis should be strongly suspected in the presence of multiple and bilateral cysts (arbitrarily defined as 10 or more cysts in each kidney) in the absence of findings suggestive of a different renal cystic disease, particularly if renal enlargement or liver cysts are also present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders other than ADPKD must be considered in the patient without a family history of the disease. The age of the patient, a family history of other genetic disorders, and the presence of associated manifestations help in the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Adults and older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired disorders that should be considered in adults and older children (greater than 10 years of age) in the absence of a family history of ADPKD include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple benign simple cysts &mdash; Multiple benign simple cysts are relatively common in the general adult population and increase in number with age. Since they may be difficult to differentiate from a mild form of ADPKD, knowledge concerning the relative prevalence of simple cysts in the general population can help distinguish ADPKD from benign simple cysts. The prevalence of such cysts was evaluated in a study in which renal ultrasonography was performed in 729 individuals with normal renal function who were referred for the investigation of symptoms unrelated to the urinary tract [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/16\">",
"       16",
"      </a>",
"      ]. Ultrasonography detected at least one cyst in 0, 1.7, 11.5, and 22.1 percent of individuals aged 15 to 29 years, 30 to 49 years, 50 to 70 years, and 70 years and above, respectively. Bilateral renal cysts (at least one cyst in each kidney) were detected in 1, 4, and 9 percent of those aged 30 to 49, 50 to 70 years, and over 70 years, respectively.",
"      <br/>",
"      <br/>",
"      CT and MRI are more sensitive than ultrasonography. Spiral CT detects renal cysts in approximately 50 percent of men (mean age, 66 years) and 35 percent of women (mean age, 63 years) with a total number of cysts ranging from 1 to 10 per patient [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Thus, since the diagnosis of ADPKD is a possibility in some patients of the appropriate age with multiple cysts detected via abdominal ultrasonographic imaging but without a family history of ADPKD, the number and location of cysts may favor one diagnosis over the other:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Simple renal cysts are uncommon in patients younger than 30 years and are rarely multiple or bilateral.",
"     </li>",
"     <li>",
"      It is uncommon for patients aged 30 to 59 years to have at least two cysts in each kidney.",
"     </li>",
"     <li>",
"      In patients over age 60, the finding of four or more cysts in each kidney is rarely due to multiple simple cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In problem cases, further evaluation with more sensitive imaging techniques (such as contrast-enhanced CT scanning or MRI or heavy-weighted unenhanced T2 MRI), and the presence of extrarenal manifestations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      enlarged kidneys can further help establish the diagnosis of ADPKD.",
"      <br/>",
"      <br/>",
"      Renal ultrasonography in parents and family members can also help detect asymptomatic ADPKD, if present [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized renal cystic disease &mdash; Localized cystic disease of the kidney is an uncommon benign condition that can be confused with polycystic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. In one series of 18 patients, the age at diagnosis ranged from 24 to 83 (average 54), and none had a family history of polycystic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/22\">",
"       22",
"      </a>",
"      ]. Imaging studies revealed multiple cysts of various sizes separated by normal or atrophic parenchyma involving one kidney. In contrast to polycystic kidney disease, localized cystic disease is neither bilateral nor progressive [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acquired renal cystic disease &mdash; Chronic renal failure (particularly patients on maintenance hemodialysis or peritoneal dialysis) is frequently associated with the development of multiple and bilateral small cysts; these cysts are usually less than 0.5 cm in diameter but can be as large as 2 to 3 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/23\">",
"       23",
"      </a>",
"      ]. The diagnosis of acquired cystic disease in renal failure is established by ultrasonography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CT scanning, although each procedure can have false negative results. A positive test requires involvement of both kidneys with four or more cysts being present.",
"      <br/>",
"      <br/>",
"      Acquired cystic disease is usually easily distinguished from autosomal dominant polycystic kidney disease (ADPKD), since there is no family history of ADPKD and the kidneys are small to normal in size with a smooth contour as opposed to usually extreme renal enlargement with a cystic contour [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/23\">",
"       23",
"      </a>",
"      ]. Rarely, however, the kidneys in those with acquired renal cystic disease may enlarge and resemble those of ADPKD. In such cases, acquired renal cystic disease can be distinguished by the absence of the extrarenal features of ADPKD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=see_link\">",
"       \"Acquired cystic disease of the kidney in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"       \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medullary sponge kidney &mdash; Medullary sponge kidney is characterized by tubular dilatation of the collecting ducts confined to the medullary pyramids. The urographic appearance of the kidneys in this disorder can mimic those in ADPKD, but the renal cortex is spared on CT or MRI. Autosomal dominant inheritance has been reported in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=see_link\">",
"       \"Medullary sponge kidney\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bilateral parapelvic cysts &mdash; Bilateral parapelvic cysts (eg, cystic disease of the renal sinus) may distort the renal pelvis, infundibula, and calyces, and can be confused with ADPKD on excretory urography [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/25\">",
"       25",
"      </a>",
"      ]. The lack of cysts in the",
"      <span class=\"nowrap\">",
"       cortex/medulla",
"      </span>",
"      distinguishes this disorder from ADPKD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic disorders that should be considered in adults and older children (over the age of 10 years) in the absence of a family history of ADPKD include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal recessive polycystic kidney disease &mdash; In older children or young adults, autosomal recessive polycystic kidney disease (ARPKD) is associated with collecting duct ectasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      macrocystic changes, frequently with nephrolithiasis, hypertension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      impairment of renal function. Patients also often present with symptoms and signs of hepatic fibrosis and portal hypertension or ascending cholangitis, while neonates may present with enlarged echogenic kidneys and pulmonary hypoplasia.",
"      <br/>",
"      <br/>",
"      The ultrasonographic appearance of the kidney may not distinguish autosomal recessive PKD from autosomal dominant disease. Extrarenal (hepatic, pancreatic) cysts also favor the presence of autosomal dominant disease, while portal fibrosis or signs of portal hypertension, cholangitis, or biliary dysgenesis favor the diagnosis of autosomal recessive disease.",
"      <br/>",
"      <br/>",
"      A careful family history and analysis of the parents is often helpful. Ultrasonography of parents of children with autosomal recessive polycystic kidney disease will not show cysts while autosomal dominant disease is often first discovered in a parent at the time of diagnosis in the child. However, affected parents with autosomal dominant polycystic kidney disease under the age of 25 to 30 may not yet have cysts detectable on ultrasonography and establishing the diagnosis may require evaluation of the grandparents.",
"      <br/>",
"      <br/>",
"      Genetic testing may also be helpful in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Genetic testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Autosomal dominant tuberous sclerosis complex &mdash; Patients with tuberous sclerosis can also present with multiple renal cysts. The diagnosis of tuberous sclerosis is usually confirmed by noting the presence of other features of the disease.",
"      <br/>",
"      <br/>",
"      The diagnosis requires two major features (renal angiomyolipoma, facial angiofibromas or forehead plaques, nontraumatic ungual or periungual fibroma, three or more hypomelanotic macules, shagreen patch, multiple retinal nodular hamartomas, cortical tuber, subependymal nodule, subependymal giant cell astrocytoma, cardiac rhabdomyoma, lymphangioleiomyomatosis) or one major plus two minor features (multiple renal cysts, nonrenal hamartoma, hamartomatous rectal polyps, retinal achromic patch, cerebral white matter radial migration tracts, bone cysts, gingival fibromas, \"confetti\" skin lesions, multiple enamel pits). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=see_link\">",
"       \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autosomal dominant von Hippel-Lindau disease &mdash; In addition to renal cysts, patients with von Hippel-Lindau disease may have retinal hemangiomas, clear cell carcinomas of the kidney, cerebellar and spinal hemangioblastomas, pheochromocytoma, endocrine pancreatic tumors,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epididymal cystadenoma.",
"      <br/>",
"      <br/>",
"      Infrequently, patients with renal cysts but without the other manifestations of the disorder may be misdiagnosed with autosomal dominant polycystic kidney disease. The correct diagnosis is eventually uncovered with the development of a manifestation that is unique to von Hippel-Lindau disease, such as a hemangioblastoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"       \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autosomal dominant medullary cystic disease &mdash; Unlike those with autosomal dominant polycystic kidney disease, patients with medullary cystic disease have renal cysts at the corticomedullary junction, small to normal size kidneys, and, particularly in type 2 disease, hyperuricemia and gout. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=see_link&amp;anchor=H2#H2\">",
"       \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\", section on 'Uromodulin-associated kidney disease (UAKD)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autosomal dominant polycystic liver disease &mdash; Autosomal dominant polycystic liver disease is distinct from polycystic kidney disease, since it is not associated with kidney involvement. However, it may be difficult to distinguish the patient with autosomal dominant polycystic liver disease plus simple renal cysts from the patient with ADPKD. Although family history may be helpful, genetic testing may be required to make a definitive diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8104?source=see_link\">",
"       \"Diagnosis and management of cystic lesions of the liver\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      X-linked dominant orofaciodigital syndrome type I &mdash; Affected females with X-linked dominant orofaciodigital syndrome type I (OFD1) (prenatal lethality in males) may have kidneys that are indistinguishable from autosomal dominant polycystic kidneys. Distinguishing features are extrarenal manifestations that include oral (hyperplastic frenula, cleft tongue, cleft palate or lip and malposed teeth), facial (broad nasal root with hypoplasia of nasal alae and malar bone) and digital (brachy, syn, clino, campto, polydactyly) anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Young children and infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of a family history of ADPKD, the differential diagnosis of severe presentations in infants or young children (up to 10 years of life) include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal recessive polycystic kidney disease &mdash; As previously mentioned, imaging of the kidneys cannot definitively distinguish autosomal recessive polycystic kidney disease from a severe early presentation of ADPKD. Genetic testing by direct mutational analysis of the culprit genes will clarify the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/26\">",
"       26",
"      </a>",
"      ]. (See above and (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"       \"Autosomal recessive polycystic kidney disease in children\"",
"      </a>",
"      )).",
"     </li>",
"     <li>",
"      Contiguous PKD1-TSC2 contiguous syndrome &mdash; Deletions that inactivate both the TSC2 and PKD1 genes are associated with severe polycystic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. This disorder is usually diagnosed in the first year of life and leads to ESRD at an earlier age than ADPKD alone. The presence of manifestations unique to tuberous sclerosis helps clarify the diagnosis. Multiplex ligation-dependent probe amplification (MLPA), which detects large gene rearrangements, may allow for definitive diagnosis of this syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Genetic testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Meckel-Gruber syndrome &mdash; Meckel-Gruber syndrome includes occipital encephalocele, polycystic kidneys, biliary dysgenesis and polydactyly. By comparison, patients with ADPKD do not have encephalocele or polydactyly.",
"     </li>",
"     <li>",
"      Other multiple malformation syndromes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link\">",
"     \"Renal cystic diseases in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with equivocal imaging results",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when a definite diagnosis is required (such as a potential living related donor, only with informed consent), genetic testing should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Methods used to perform genetic testing are linkage or sequence analysis of DNA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Linkage analysis uses microsatellite markers that flank the PKD1 and PKD2 genes. The technique requires the accurate diagnosis in an adequate number of known family members (at least four) who are willing to be tested. Linkage analysis is therefore suitable in less than one-half of families.",
"     </li>",
"     <li>",
"      Direct DNA analysis of the PKD1 and PKD2 genes is hampered by their immense size, complexity, and allelic heterogeneity. With both genes, mutation detection rates of approximately 65 to 70 percent have been reported with denaturing high-performance liquid chromatography (DHPLC) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Direct sequencing is associated with rates of approximately 85 to 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. High-throughput next generation sequencing may allow for the genetic characterization of large populations of patients with ADPKD [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether a mutation is associated with pathogenicity is unclear since most changes are unique and missense changes in PKD1 constitute nearly one-third of all mutations. Sequence analysis of the PKD1 and PKD2 genes is currently clinically available.",
"   </p>",
"   <p>",
"    Approximately 2 to 3 percent of PKD1 mutations are large deletion mutations in which multiple exons may be removed. Multiplex ligation-dependent probe amplification (MLPA) is a quantitative method that detects large gene rearrangements and may allow for rapid screening for this syndrome. This method was evaluated using the well-characterized consortium for radiological imaging studies of PKD (CRISP) population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/31\">",
"     31",
"    </a>",
"    ]. Large gene rearrangements were detected in 4 percent of the ADPKD patients in the CRISP study, accounting for one-third of families without a known causative mutation. In addition, the MLPA method allowed for the detection and characterization of six, one, and seven mutations involving the PKD1, PKD2, and the",
"    <span class=\"nowrap\">",
"     PKD1/TSC2",
"    </span>",
"    region.",
"   </p>",
"   <p>",
"    The choice of performing either linkage or sequence analysis largely depends upon whether the particular technique is feasible as well as the availability of the modality.",
"   </p>",
"   <p>",
"    A combined approach using both modalities may be most effective. This was shown in a study in which genetic linkage and direct DNA analysis was performed in patients from families with and without a history of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/38\">",
"     38",
"    </a>",
"    ]. Among two prospective kidney donors with a positive family history, the use of both linkage and DNA sequencing was required to definitively exclude the presence of ADPKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PRENATAL AND PREIMPLANTATION GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal testing for ADPKD is clinically available if the mutation has been identified in an affected family member or if linkage has been established in the family. However, it is rarely considered for adult-onset conditions such as ADPKD that do not affect intellect and have some effective therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/39\">",
"     39",
"    </a>",
"    ]. A possible exception may be in rare families where severe, early-onset disease in one child suggests a significant risk of recurrence of severe disease in a sibling. Preimplantation genetic testing has been performed in a few cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9433/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional information about PKD for patients can be obtained from:",
"   </p>",
"   <p>",
"    &nbsp;PKD Foundation",
"   </p>",
"   <p>",
"    &nbsp;9221 Ward Parkway, Suite 400",
"   </p>",
"   <p>",
"    &nbsp;Kansas City, MO 64114-3367",
"   </p>",
"   <p>",
"    &nbsp;Telephone: 800-PKD-CURE, 816-931-2600",
"   </p>",
"   <p>",
"    &nbsp;FAX: 816-931-8655",
"   </p>",
"   <p>",
"    e-mail:",
"    <a class=\"external\" href=\"mailto:pkdcure@pkdcure.org\">",
"     pkdcure@pkdcure.org",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp;Website:",
"    <a class=\"external\" href=\"file://www.pkdcure.org/\">",
"     www.pkdcure.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 85 percent of families with autosomal dominant polycystic kidney disease (ADPKD) have an abnormality on chromosome 16 (PKD1 locus), while the remaining patients have a different defect that involves a gene on chromosome 4 (the PKD2 locus). Patients with PKD2 have a less severe phenotype than those with PKD1, but neither disorder is benign. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Counseling should be done prior to testing among asymptomatic patients with a family history of autosomal dominant polycystic kidney disease (ADPKD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In children at 50 percent risk for the disease (age less than 18 years), we do NOT screen children at risk since the adverse effects from a presymptomatic diagnosis outweigh the current benefits. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Screening and diagnosis of asymptomatic individuals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adults at 50 percent risk for the disease (age greater than 18 years), we recommend screening potential living related kidney donors (only with informed consent) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In other at-risk adults, the decision to screen for the disease should be based upon patient's preferences and values after the benefits and adverse consequences of certainty concerning the diagnosis are fully understood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If screening is performed among asymptomatic patients with a family history of ADPKD, we recommend imaging of the kidney (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Because of safety and cost, ultrasonography is usually the initial modality.",
"     </li>",
"     <li>",
"      Sonographic diagnostic criteria for the diagnosis of ADPKD for at risk individuals greater than 15 years of age who are from families of",
"      <strong>",
"       unknown",
"      </strong>",
"      genotype:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among individuals between 15 and 39 years of age, at least three unilateral or bilateral cysts.",
"     </li>",
"     <li>",
"      Among individuals 40 to 59 years of age, two cysts in each kidney.",
"     </li>",
"     <li>",
"      Among individuals 60 years or older, four cysts in each kidney.",
"      <br/>",
"      <br/>",
"      The sensitivity and specificity of these ultrasonographic findings varies by patient age. A discussion of these issues in patients greater than 15 years of age can be found elsewhere (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ultrasonographic criteria for adults'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some asymptomatic patients at risk for ADPKD are from families with known and well-characterized pathogenic mutations in the PKD1 or PKD2 locus. In this setting, testing for the known mutation is more definitive and may be more cost-effective than ultrasonography. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ultrasonographic criteria for adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children (less than 18 years of age), we recommend NOT screening. However, if performed in an",
"      <span class=\"nowrap\">",
"       infant/child",
"      </span>",
"      (less than 18 years of age) at risk for ADPKD, ultrasonography of the kidney is less diagnostically useful than in adults. The finding of large echogenic kidneys without distinct macroscopic cysts in infants is highly suggestive of the disease, while the presence of one cyst is adequate for the diagnosis in young children. Genetic testing can be used when the imaging results are equivocal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      when a definite diagnosis is required. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Infant/child'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with symptomatic disease who have a family history of ADPKD, the specific number of cysts per kidney that will definitively establish the diagnosis of ADPKD depends upon patient age and is the same as the criteria used in patients with asymptomatic disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis of symptomatic individuals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In up to 25 percent of cases, the clinical presentation and imaging studies suggest a diagnosis of ADPKD but there is no family history of the disease. In this case, reviewing medical information or obtaining imaging studies on the parents or other family members may prove helpful. In up to five percent of cases, the disease may be due to a new mutation. In the absence of a family history, there is no definitive number of cysts",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cyst location that provides an unequivocal diagnosis of ADPKD. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Negative family history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disorders other than ADPKD must be considered in a patient without a family history of the disease. The age of the patient, a family history of other genetic disorders, and the presence of associated manifestations help in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing, which can be performed by linkage or sequence analysis, can be used when the imaging results are equivocal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      when a definitive diagnosis is required. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although prenatal testing is clinically available if the mutation has been identified in an affected family member or if linkage has been established in the family, it is rarely considered for adult-onset conditions such as ADPKD. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prenatal and preimplantation genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/1\">",
"      Davies F, Coles GA, Harper PS, et al. Polycystic kidney disease re-evaluated: a population-based study. Q J Med 1991; 79:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/2\">",
"      Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/3\">",
"      Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58:925.",
"     </a>",
"    </li>",
"    <li>",
"     Harris, PC, Torres, VE. Autosomal dominant polycystic kidney disease. Gene Clinics Online Reviews at Gene Tests-Gene Clinics (University of Washington, Seattle, 2002).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/5\">",
"      Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/6\">",
"      Hateboer N, v Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/7\">",
"      Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/8\">",
"      Taylor M, Johnson AM, Tison M, et al. Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis 2005; 46:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/9\">",
"      Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/10\">",
"      Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/11\">",
"      Nicolau C, Torra R, Badenas C, et al. Autosomal dominant polycystic kidney disease types 1 and 2: assessment of US sensitivity for diagnosis. Radiology 1999; 213:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/12\">",
"      Zand MS, Strang J, Dumlao M, et al. Screening a living kidney donor for polycystic kidney disease using heavily T2-weighted MRI. Am J Kidney Dis 2001; 37:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/13\">",
"      Chapman AB. Autosomal dominant polycystic kidney disease: time for a change? J Am Soc Nephrol 2007; 18:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/14\">",
"      Bae KT, Zhu F, Chapman AB, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006; 1:64.",
"     </a>",
"    </li>",
"    <li>",
"     Ecder, T, Fick-Brosnahan, et al. Polycystic kidney disease. In: Diseases of the Kidney and Urinary Tract, 8th ed, Shrier, RW (Eds), Lippincott, Williams, and Wilkins, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/16\">",
"      Ravine D, Gibson RN, Donlan J, Sheffield LJ. An ultrasound renal cyst prevalence survey: specificity data for inherited renal cystic diseases. Am J Kidney Dis 1993; 22:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/17\">",
"      Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol 2003; 58:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/18\">",
"      Clayman RV, Surya V, Miller RP, et al. Pursuit of the renal mass. Is ultrasound enough? Am J Med 1984; 77:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/19\">",
"      Kimberling WJ, Fain PR, Kenyon JB, et al. Linkage heterogeneity of autosomal dominant polycystic kidney disease. N Engl J Med 1988; 319:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/20\">",
"      Bisceglia M, Cret&igrave; G. AMR series unilateral (localized) renal cystic disease. Adv Anat Pathol 2005; 12:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/21\">",
"      Fick-Brosnahan G, Johnson AM, Strain JD, Gabow PA. Renal asymmetry in children with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1999; 34:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/22\">",
"      Slywotzky CM, Bosniak MA. Localized cystic disease of the kidney. AJR Am J Roentgenol 2001; 176:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/23\">",
"      Levine E. Acquired cystic kidney disease. Radiol Clin North Am 1996; 34:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/24\">",
"      Gambaro G, Feltrin GP, Lupo A, et al. Medullary sponge kidney (Lenarduzzi-Cacchi-Ricci disease): a Padua Medical School discovery in the 1930s. Kidney Int 2006; 69:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/25\">",
"      Murray KK, McLellan GL. Renal peripelvic lymphangiectasia: appearance at CT. Radiology 1991; 180:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/26\">",
"      Zerres K, Senderek J, Rudnik-Sch&ouml;neborn S, et al. New options for prenatal diagnosis in autosomal recessive polycystic kidney disease by mutation analysis of the PKHD1 gene. Clin Genet 2004; 66:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/27\">",
"      Thauvin-Robinet C, Coss&eacute;e M, Cormier-Daire V, et al. Clinical, molecular, and genotype-phenotype correlation studies from 25 cases of oral-facial-digital syndrome type 1: a French and Belgian collaborative study. J Med Genet 2006; 43:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/28\">",
"      Brook-Carter PT, Peral B, Ward CJ, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet 1994; 8:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/29\">",
"      Sampson JR, Maheshwar MM, Aspinwall R, et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet 1997; 61:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/30\">",
"      Martignoni G, Bonetti F, Pea M, et al. Renal disease in adults with TSC2/PKD1 contiguous gene syndrome. Am J Surg Pathol 2002; 26:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/31\">",
"      Consugar MB, Wong WC, Lundquist PA, et al. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int 2008; 74:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/32\">",
"      Huang E, Samaniego-Picota M, McCune T, et al. DNA testing for live kidney donors at risk for autosomal dominant polycystic kidney disease. Transplantation 2009; 87:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/33\">",
"      Rossetti S, Strmecki L, Gamble V, et al. Mutation analysis of the entire PKD1 gene: genetic and diagnostic implications. Am J Hum Genet 2001; 68:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/34\">",
"      Rossetti S, Chauveau D, Walker D, et al. A complete mutation screen of the ADPKD genes by DHPLC. Kidney Int 2002; 61:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/35\">",
"      Harris PC, Bae KT, Rossetti S, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2006; 17:3013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/36\">",
"      Rossetti S, Consugar MB, Chapman AB, et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/37\">",
"      Rossetti S, Hopp K, Sikkink RA, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol 2012; 23:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/38\">",
"      Zhao X, Paterson AD, Zahirieh A, et al. Molecular diagnostics in autosomal dominant polycystic kidney disease: utility and limitations. Clin J Am Soc Nephrol 2008; 3:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/39\">",
"      Sujansky E, Kreutzer SB, Johnson AM, et al. Attitudes of at-risk and affected individuals regarding presymptomatic testing for autosomal dominant polycystic kidney disease. Am J Med Genet 1990; 35:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9433/abstract/40\">",
"      De Rycke M, Georgiou I, Sermon K, et al. PGD for autosomal dominant polycystic kidney disease type 1. Mol Hum Reprod 2005; 11:65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1678 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9433=[""].join("\n");
var outline_f9_13_9433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POSITIVE FAMILY HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Screening and diagnosis of asymptomatic individuals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Ultrasonographic criteria for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H77995158\">",
"      At risk but unknown familial genotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H129629707\">",
"      At risk for type 1 ADPKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H129629736\">",
"      At risk for type 2 ADPKD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other imaging modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Approach after equivocal ultrasound results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Infant/child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis of symptomatic individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NEGATIVE FAMILY HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Adults and older children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Young children and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PRENATAL AND PREIMPLANTATION GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1678|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/36/44623\" title=\"diagnostic image 1\">",
"      CT scan in PKD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=related_link\">",
"      Acquired cystic disease of the kidney in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=related_link\">",
"      Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8104?source=related_link\">",
"      Diagnosis and management of cystic lesions of the liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=related_link\">",
"      Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=related_link\">",
"      Medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=related_link\">",
"      Patient information: Polycystic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=related_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=related_link\">",
"      Renal cystic diseases in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=related_link\">",
"      Renal manifestations of tuberous sclerosis and renal angiomyolipoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_13_9434="Anemia of chronic disease (anemia of chronic inflammation)";
var content_f9_13_9434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anemia of chronic disease (anemia of chronic inflammation)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9434/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9434/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9434/contributors\">",
"     Clara Camaschella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9434/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9434/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/13/9434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/13/9434/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/13/9434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of chronic disease (ACD, anemia of [chronic] inflammation, hypoferremia of inflammation), was initially thought to be associated primarily with infectious, inflammatory, or neoplastic disease. However, other observations have shown that ACD can be seen in a variety of conditions, including severe trauma, diabetes mellitus, anemia of the elderly, and in those with acute or chronic immune activation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. The anemia is typically normochromic, normocytic, and hypoproliferative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link\">",
"     \"Hematologic manifestations of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link&amp;anchor=H2#H2\">",
"     \"Impact of anemia in patients with heart failure\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis, laboratory findings, and treatment of ACD will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/9\">",
"     9",
"    </a>",
"    ]. An overview of the approach to the adult patient with anemia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other medical settings that share some of the features of ACD are discussed separately. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia secondary to malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"       \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia secondary to chronic renal disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the management of chronic kidney disease in adults\", section on 'Anemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6486?source=see_link\">",
"       \"Anemia and left ventricular hypertrophy in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia secondary to HIV infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3098?source=see_link\">",
"       \"Hematologic manifestations of HIV infection: Anemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia in the presence of heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link&amp;anchor=H3#H3\">",
"       \"Impact of anemia in patients with heart failure\", section on 'Increased circulating cytokines and the anemia of inflammation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia in the older adult. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22538?source=see_link\">",
"       \"Anemia in the older adult\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of chronic disease (ACD) is thought to primarily reflect a reduction in red blood cell (RBC) production by the bone marrow. There may also be a small component due to mild shortening of RBC survival. A number of factors are thought to contribute to this hypoproliferative state [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal iron metabolism with trapping of iron in macrophages. This results in reduced plasma iron levels (hypoferremia), making iron unavailable for new hemoglobin synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hepcidin'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Inability to increase erythropoiesis in response to anemia. Serum erythropoietin (EPO) levels are somewhat elevated in ACD, but there is virtually no increase in erythropoiesis, perhaps due to increased apoptotic death of red cell precursors within the bone marrow [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/2,10,15,16\">",
"       2,10,15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A relative decrease in EPO production. The inverse relationship between hematocrit levels and serum EPO seen in most anemic conditions (",
"      <a class=\"graphic graphic_figure graphicRef53916 \" href=\"UTD.htm?34/53/35677\">",
"       figure 1",
"      </a>",
"      ) is not maintained in ACD [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/14\">",
"       14",
"      </a>",
"      ]. As an example, patients with ACD have lower levels of EPO than do patients with iron deficiency and a similar degree of anemia.",
"     </li>",
"     <li>",
"      A minor component of ACD is due to decreased red cell survival. Shortening of red cell life span may occur in cases of acute inflammation characterized by increased erythrophagocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/5,17\">",
"       5,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     The role of cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Why the above-noted changes occur is becoming increasingly understood. It has been suggested that the underlying inflammatory medical condition causes the release of cytokines such as the interleukins (eg, IL-1 and IL-6) and tumor necrosis factor (TNF-alpha) by activated monocytes; these cytokines may then unleash a cascade including the secretion of interferon (IFN)-beta and IFN-gamma by T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As an example, IFN-gamma when given to experimental animals, or when its formation is stimulated in vivo, can produce the picture of ACD with most of the abnormalities noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/10,20-23\">",
"     10,20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decreased bone marrow responsiveness to erythropoietin is mediated by inflammatory cytokines, especially IL-1 beta and TNF-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/5\">",
"     5",
"    </a>",
"    ], which may induce apoptosis of red cells precursors as well as downregulation of erythropoietin receptors on progenitor cells. Cytokines may also decrease erythropoietin expression by renal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/4,24,25\">",
"     4,24,25",
"    </a>",
"    ]. In vitro treatment of cultured cells with proinflammatory cytokines can also alter ferritin and transferrin receptor expression and iron-responsive protein activity in macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/13\">",
"     13",
"    </a>",
"    ]. However, iron metabolism in ACD is mainly altered via overproduction of hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In support of these mechanisms are three clinical observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of patients with rheumatoid arthritis using an anti-TNF-alpha antibody led to a reduction in IL-6 levels, a decrease in the proportion of apoptotic red cell precursors, and an improvement in anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/16,27,28\">",
"       16,27,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute phase reactants\", section on 'Induction by cytokines'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link&amp;anchor=H3#H3\">",
"       \"Hematologic manifestations of rheumatoid arthritis\", section on 'Anemia of chronic disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of children with systemic juvenile idiopathic arthritis (formerly called systemic onset juvenile rheumatoid arthritis or Still&rsquo;s disease) using the anti-IL-6 receptor antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      resulted in clinical improvement along with significant, profound reduction in C-reactive protein levels and reduced incidences of anemia, thrombocytosis, and hyperferritinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link&amp;anchor=H9#H9\">",
"       \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\", section on 'Laboratory findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Doses of the erythropoiesis-stimulating agent darbepoetin required to reverse anemia in pre-dialysis elderly patients were higher in the presence of elevated levels of IL-6 and TNF-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hepcidin",
"    </span>",
"    &nbsp;&mdash;&nbsp;One acute phase protein that appears to be most directly involved in iron metabolism is hepcidin, which appears to be a component of the innate immune response to acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The complex relationships between hepcidin and different types of infections have been reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/33\">",
"     33",
"    </a>",
"    ]. Evidence from transgenic mouse models and human genetic disorders indicates that hepcidin is the predominant negative regulator of iron absorption in the small intestine, iron transport across the placenta, as well as iron release from macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/34\">",
"     34",
"    </a>",
"    ], secondary to its effect on internalization and degradation of the iron export protein ferroportin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"     \"Regulation of iron balance\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Animal models of inflammation shed further light on the importance of hepcidin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, a single injection of turpentine induced an acute sixfold increase in liver hepcidin mRNA and a twofold decrease in serum iron [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/35\">",
"       35",
"      </a>",
"      ]. The latter effect was completely blunted in hepcidin-deficient mice [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study performed in mice, the anemia of inflammation was induced via injection of heat-killed bacteria, resulting in iron-deficient erythropoiesis and resistance to treatment with supraphysiologic doses of an erythropoiesis-stimulating agent (ESA, darbepoetin) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/37\">",
"       37",
"      </a>",
"      ]. Treatment of the anemic animals with an antibody to hepcidin corrected the hypoferremia and restored their responsiveness to the ESA. The relevance of this model (and its treatment) to the human disorder is unknown.",
"     </li>",
"     <li>",
"      In an established rat model of the anemia of inflammation, pharmacologic inhibition of hepcidin expression resulted in mobilization of iron from macrophages, stimulation of erythropoiesis, and correction of anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/38\">",
"       38",
"      </a>",
"      ]. Similar results were obtained in a murine model of inflammation using the same bone morphogenetic pathway signaling inhibitory agents [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In other murine studies, direct injection of human hepcidin induced hypoferremia within four hours, while implantation of tumor xenografts overexpressing human hepcidin resulted in more severe anemia, lower serum iron levels, and increased hepatic iron compared with mice harboring control tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an acute cynomolgus monkey model of IL-6-induced hypoferremia, NOX-H94, a structured oligoribonucleotide that binds human hepcidin with high affinity, inhibited serum iron reduction completely [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the few human studies reported to date, increased hepcidin production, increased urinary excretion of hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/31\">",
"     31",
"    </a>",
"    ], and increased serum levels of prohepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/14\">",
"     14",
"    </a>",
"    ] and hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/42-44\">",
"     42-44",
"    </a>",
"    ] have been noted in patients with infections, malignancy, or inflammatory states (eg, C-reactive protein levels &gt;10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/42\">",
"     42",
"    </a>",
"    ]). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In experimental infection with P. falciparum in normal subjects, low-density parasitemia and its treatment induced an increase in IL-6 and serum hepcidin concentrations, along with hypoferremia, an increase in serum ferritin, and a reduced hemoglobin content of emerging reticulocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some patients with type 1a glycogen storage disease, secretion of hepcidin by hepatic adenomas leads to anemia with low serum iron levels and iron sequestration by macrophages, reminiscent of ACD [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/46\">",
"       46",
"      </a>",
"      ]. This pattern is reversible after adenoma resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of Interleukin (IL)-6 in this hepcidin pathway was shown by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect of an injection of turpentine on liver hepcidin mRNA and serum iron, as noted above, was completely blunted in Interleukin (IL)-6 knockout mice [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The acute increase in hepcidin mRNA in cultured hepatocytes following stimulation with bacterial lipopolysaccharide (LPS) was completely blunted when LPS was combined with an antibody to IL-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infusion of IL-6 into normal human volunteers acutely raised urinary excretion of hepcidin along with a significant drop in serum iron [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Following injection of bacterial LPS into 10 healthy human volunteers, IL-6 was dramatically induced within 3 hours; urinary hepcidin peaked 3 hours later, followed by a significant decrease in serum iron [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, serum levels of IL-6 and C-reactive protein in patients with ACD were raised more than 10-fold over those in controls or in patients with iron deficiency anemia and similar levels of hemoglobin [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of the anti-IL-6 receptor antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      reduced the hepcidin levels in patients with Castleman's disease, a disorder characterized by a clinical picture similar to that seen in ACD, including high levels of both IL-6 and hepcidin [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/49\">",
"       49",
"      </a>",
"      ]. Such treatment resulted in progressive normalization of iron-related parameters and symptomatic improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link&amp;anchor=H23#H23\">",
"       \"Castleman's disease\", section on 'Inhibition of interleukin-6'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with ACD, production of hepcidin has been detected in circulating monocytes as an autocrine mechanism to increase macrophage iron sequestration [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/14,51\">",
"       14,51",
"      </a>",
"      ]. Hepcidin mRNA levels were significantly correlated with serum IL-6 concentrations, and were associated with decreased expression of ferroportin as well as increased monocyte iron retention [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepcidin plasma levels were significantly higher in 65 patients with Hodgkin lymphoma than in controls, and showed a positive correlation with IL-6 levels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/44\">",
"       44",
"      </a>",
"      ]. Hepcidin and IL-6 levels were significantly higher in those with more aggressive disease characteristics (eg, stage IV disease, presence of B symptoms, International Prognostic Score &gt;2). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link&amp;anchor=H11#H11\">",
"       \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\", section on 'Cytokine responses'",
"      </a>",
"      .) Increased hepcidin levels have also been documented in patients with multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/52\">",
"       52",
"      </a>",
"      ], inflammatory bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/53\">",
"       53",
"      </a>",
"      ], and Castleman&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/50,54\">",
"       50,54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although IL-6 and urinary hepcidin levels do not always correlate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/55\">",
"     55",
"    </a>",
"    ], these studies suggest that IL-6 is required for the induction of hepcidin and hypoferremia during inflammation in both animals and humans (",
"    <a class=\"graphic graphic_figure graphicRef78381 \" href=\"UTD.htm?8/45/8916\">",
"     figure 2",
"    </a>",
"    ), although hepcidin can also be upregulated by the cytokine IL-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/56\">",
"     56",
"    </a>",
"    ]. While the molecular mechanisms responsible for this activation are only partially understood, IL-6 appears to be involved in regulation of hepcidin levels through the",
"    <span class=\"nowrap\">",
"     JAK/STAT-3",
"    </span>",
"    signaling pathway (",
"    <a class=\"graphic graphic_figure graphicRef64022 \" href=\"UTD.htm?1/56/1927\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"     \"Regulation of iron balance\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Activation of hepcidin by IL-6 requires a BMP-SMAD intact pathway. Inhibition of BMP receptor type 1 by specific inhibitors ameliorates the anemia of inflammation in mice treated with IL-6 or turpentine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/39\">",
"     39",
"    </a>",
"    ] as well as in mouse models of inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21195242\">",
"    <span class=\"h3\">",
"     Hepcidin assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepcidin assays are not yet routinely available for clinical use. It is possible that in the future hepcidin levels might aid in the differential diagnosis of iron deficiency anemia alone or in combination with other tools [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/61\">",
"     61",
"    </a>",
"    ]. In one study, reticulocyte hemoglobin content, along with measurement of hepcidin-25 levels by mass spectrometry, has been proposed as a potential tool for the differential diagnosis of ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute variant of ACD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute event-related anemia, such as that occurring after surgery, major trauma, myocardial infarction, or sepsis, a condition called the \"anemia of critical illness\", shows many of the features of ACD (ie, low serum iron, high ferritin, blunted response to EPO), presumably secondary to tissue damage and acute inflammatory changes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. It appears to be an acute variant of ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A mouse model of the acute variant of ACD has been created using injections of lipopolysaccharide and zymosan. These animals develop anemia along with increased messenger RNA levels for both IL-6 and hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 92 consecutive patients admitted for sepsis, hepcidin levels at admission were high, increased with the number of systemic inflammatory response syndrome (SIRS) criteria, correlated with IL-6 and with the hemoglobin decrease in the following days [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/68\">",
"     68",
"    </a>",
"    ]. Similarly, in a series of 150 patients with severe trauma, urinary hepcidin levels were extremely high on admission; hepcidin was positively correlated with the Injury Severity Score (ISS) and the duration of anemia, and negatively correlated with hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the underlying mechanisms are similar, anemia of acute and chronic inflammatory disorders may be considered together under the term \"anemia of inflammation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     General findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia in ACD is of variable severity. Many patients have a mild anemia, with a hemoglobin concentration of 10 to 11",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    The anemia is usually normocytic and normochromic, although it may become microcytic and hypochromic in long-standing cases.",
"   </p>",
"   <p>",
"    More severe anemia, with a hemoglobin concentration &lt;8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    occurs in approximately 20 percent of cases. The absolute reticulocyte count is frequently low",
"    <span class=\"nowrap\">",
"     (&lt;25,000/microL),",
"    </span>",
"    a reflection of the overall decrease in RBC production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H38#H38\">",
"     \"Approach to the adult patient with anemia\", section on 'Reticulocyte count'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anemia may be accompanied by an elevation in cytokines (eg, IL-6) as well as acute phase reactants (eg, fibrinogen, erythrocyte sedimentation rate, C-reactive protein) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Iron studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum iron concentration and transferrin level (also measured as total iron binding capacity, TIBC) are both low and the percent saturation of transferrin is usually normal, which should distinguish ACD from iron deficiency anemia, in which transferrin saturation is low. However, approximately 20 percent of patients with ACD have low transferrin saturations in the iron deficiency range (as low as 10 percent), even though only about one-quarter of such patients are truly iron deficient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/2\">",
"     2",
"    </a>",
"    ]. In the remaining patients, the reduced ability to release iron from macrophages is presumably responsible for the low serum iron levels and low transferrin saturation (",
"    <a class=\"graphic graphic_figure graphicRef78381 \" href=\"UTD.htm?8/45/8916\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66578 \" href=\"UTD.htm?38/11/39088\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H29#H29\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Serum iron and transferrin (TIBC)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum ferritin concentration, which is usually normal or elevated in ACD, may be a poor index of iron stores in chronic inflammatory diseases because ferritin is also an acute phase reactant. In addition, the destruction of hepatic or splenic tissue due to the primary disease may release relatively large amounts of ferritin into the circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H28#H28\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Inflammatory states'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the bone marrow for its content and distribution of iron is instructive. In the most classical presentation of ACD, bone marrow macrophages contain normal or increased amounts of storage iron, reflecting reduced macrophage iron export. In addition, erythroid precursors show decreased or absent staining for iron (ie, decreased numbers of sideroblasts), reflecting reduced availability of iron for red cell production (",
"    <a class=\"graphic graphic_picture graphicRef70226 \" href=\"UTD.htm?6/57/7064\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Bone marrow examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Normocytic hypoproliferative anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACD usually presents as a normocytic hypoproliferative anemia that does not affect other blood cell lines. The most common disorder presenting with similar findings is chronic kidney disease. However, several endocrine disorders, including hyperthyroidism, hypothyroidism, panhypopituitarism, and primary and secondary hyperparathyroidism may also present with a similar anemic picture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the management of chronic kidney disease in adults\", section on 'Anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6486?source=see_link\">",
"     \"Anemia and left ventricular hypertrophy in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Microcytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with more severe anemia (eg, hemoglobin concentration &lt;8",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    along with hypochromic and microcytic red cells, the differential diagnosis is wider (",
"    <a class=\"graphic graphic_table graphicRef59035 \" href=\"UTD.htm?0/26/428\">",
"     table 1",
"    </a>",
"    ). The most common conditions, which need to be excluded, include iron deficiency anemia, the thalassemic disorders, and the sideroblastic variants of the myelodysplastic syndrome. Further discussion of distinguishing among the various causes of a microcytic anemia can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=see_link&amp;anchor=H19#H19\">",
"     \"Mean corpuscular volume\", section on 'Causes of microcytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum EPO levels are lower in ACD than in patients with iron deficiency anemia and comparable degrees of anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/14\">",
"     14",
"    </a>",
"    ]. However, serum EPO levels in anemic subjects scatter too broadly to be of diagnostic use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/74\">",
"     74",
"    </a>",
"    ]. This is illustrated the figure, which shows that the correlation between EPO levels and hematocrit is semi-logarithmic, with wide scatter of EPO levels for any particular level of hematocrit (",
"    <a class=\"graphic graphic_figure graphicRef53916 \" href=\"UTD.htm?34/53/35677\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As noted above, measurement of serum iron, transferrin (total iron binding capacity), and ferritin may not clearly distinguish among these disorders. In this setting, a history of an acute or chronic inflammatory disease with no evidence of occult blood loss is suggestive of ACD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     ACD with coexisting iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognizing coexisting iron deficiency in patients with ACD is challenging. Such patients tend to have more microcytic red cells and may be detected through assays for soluble transferrin receptor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of special erythrocyte indices (see below). Alternatively, one may monitor the response to a trial of iron supplementation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H28#H28\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Inflammatory states'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Soluble transferrin receptor assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the differentiation between iron deficiency anemia (IDA) and ACD is clinically important and sometimes difficult, measurement of serum levels of soluble transferrin receptor (sTfR) may help distinguish between the two. The biologic principle is that in iron deficiency states, cellular membrane transferrin receptor density increases, with the result that truncated forms of transferrin receptors (sTfR) appear in the serum in increased amounts.",
"   </p>",
"   <p>",
"    While some authors have claimed that measurement of sTfR can distinguish between IDA and ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], another study noted that sTfR levels were no more useful than measurement of total iron binding capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of the ratio of sTfR to the logarithm of ferritin (TfR-ferritin index) may overcome these limitations. A TfR-ferritin index &lt;1.0 suggests the diagnosis of ACD, while an index &gt;2.0 suggests either IDA or the combination of IDA and ACD (",
"    <a class=\"graphic graphic_figure graphicRef79053 \" href=\"UTD.htm?15/36/15950\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H32#H32\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'TfR-ferritin index'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link&amp;anchor=H4#H4\">",
"     \"Hematologic manifestations of rheumatoid arthritis\", section on 'Iron deficiency anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Erythrocyte indices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the percentage of hypochromic red cells and reticulocyte hemoglobin content can help in the identification of true iron deficient erythropoiesis in patients with ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. As an example, in two studies, a reticulocyte hemoglobin content &lt;26",
"    <span class=\"nowrap\">",
"     pg/cell",
"    </span>",
"    was a stronger predictor of iron deficiency and iron deficiency anemia than routine iron studies (eg, serum iron, transferrin, transferrin saturation, ferritin, circulating transferrin receptor). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H35#H35\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Reticulocyte indices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In difficult cases, the diagnosis can often be established by bone marrow examination. Findings in the most common disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACD &mdash; Bone marrow macrophages contain normal to increased iron, while erythroid precursors show decreased to absent amounts of iron (ie, decreased to absent sideroblasts) (",
"      <a class=\"graphic graphic_picture graphicRef70226 \" href=\"UTD.htm?6/57/7064\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Iron deficiency &mdash; Stainable iron is absent from both macrophages and erythroid precursors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H38#H38\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myelodysplastic syndrome &mdash; Single or multi-lineage dysplastic changes with or without increased number of sideroblasts, including ring forms, are commonly seen in patients with myelodysplasia (",
"      <a class=\"graphic graphic_picture graphicRef65887 \" href=\"UTD.htm?0/44/705\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Pathologic features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Initial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred therapy for ACD is correction of the underlying disorder, rather than replacement therapy with red cell transfusions or use of an erythropoiesis-stimulating agent (eg, erythropoietin, darbepoetin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with ACD have mild anemia that produces no symptoms, being compatible with the patient's often limited lifestyle. It has been suggested that ACD is a biologically adaptive response in which, for example, low serum iron levels serve to inhibit the growth of iron-requiring microorganisms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients have more severe anemia, leading to impaired function and an impaired quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/1,2,82\">",
"     1,2,82",
"    </a>",
"    ]. Since ACD can complicate the course of aging-related disorders, its presence has considerable importance, since anemia negatively influences the outcome of several associated disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the adult patient with anemia\", section on 'Older adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4120?source=see_link\">",
"     \"Evaluation of health-related quality of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other complicating factors (eg, blood loss, deficiencies of iron, folate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin B12) should be appropriately treated, if present, and may obviate the need for blood transfusions or erythropoietin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the anemia is due to underlying malignancy, successful treatment with combinations of surgery, chemotherapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy may, in the long term, improve the anemia. However, anemia may be transiently or permanently exacerbated by the myelosuppressive effects of chemotherapy and radiation. Treatment of cancer-associated anemia is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the plasma erythropoietin (EPO) concentration may be helpful in ACD. Patients with cancer, rheumatoid arthritis, or AIDS who have EPO levels &lt;500",
"    <span class=\"nowrap\">",
"     mU/mL",
"    </span>",
"    (although some authors suggest a cut-off of 100",
"    <span class=\"nowrap\">",
"     mU/mL)",
"    </span>",
"    may respond to the administration of recombinant human EPO [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/85-89\">",
"     85-89",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link&amp;anchor=H2#H2\">",
"     \"Hematologic manifestations of rheumatoid arthritis\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EPO can be given once per week, while darbepoetin has an effectiveness equal to that of EPO when given once every two or three weeks. Supplemental iron should be given to maintain a transferrin saturation &ge;20 percent and a serum ferritin &ge;100",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Such use of erythropoiesis-stimulating agents is considered \"unlabeled or investigational\" in the United States, and may not be reimbursed. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Supplemental iron'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dosage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although one of the hallmarks of ACD is a reduced erythropoietic response to both endogenous as well as exogenous EPO, high doses of EPO may overcome this hyporesponsiveness. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link&amp;anchor=H2#H2\">",
"     \"Hematologic manifestations of rheumatoid arthritis\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EPO may be given in a starting dose of 100 to 150",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    subcutaneously three times weekly along with supplemental oral iron. Responders may show a rise in the hemoglobin concentration of at least 0.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    by two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/88,90\">",
"     88,90",
"    </a>",
"    ]. If there is no elevation in the hemoglobin concentration by six to eight weeks, the regimen can be intensified to daily therapy or 300",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    three times weekly. It is not worthwhile to continue EPO in patients who do not have a clinically meaningful response by 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, most clinicians use 30,000 to 40,000 units of EPO given SQ once per week, a single dose which is numerically equivalent to a dose of 140 to 190",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    three times per week for a 70 kg person [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. This dose can be increased to 60,000 units if there is no response (ie, hemoglobin rise &lt;1",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    at four weeks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This simplified, well-tolerated dosing regimen has also been recommended for treatment of the anemia associated with HIV infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3098?source=see_link&amp;anchor=H30#H30\">",
"       \"Hematologic manifestations of HIV infection: Anemia\", section on 'Recombinant human erythropoietin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is conflicting evidence regarding the benefits versus risks of using EPO in critically ill patients. This subject is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=see_link&amp;anchor=H5#H5\">",
"       \"Use of blood products in the critically ill\", section on 'RBC alternatives'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse side effects of EPO treatment in patients with ACD have not been rigorously studied, although there is considerable information available on adverse side effects of EPO in patients with cancer-related anemia. Accordingly, it would seem reasonable to minimize side effects by keeping hemoglobin levels at or below 12",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H7#H7\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'ESAs: efficacy, side effects, and clinical use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Darbepoetin",
"    </span>",
"    &nbsp;&mdash;&nbsp;While darbepoetin is capable of reversing anemia due to chronic inflammatory disease in experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/93\">",
"     93",
"    </a>",
"    ], it has had limited use in the treatment of ACD in humans. A dose of darbepoetin equivalent to the above-noted dose of erythropoietin is in the range of 60 to 100",
"    <span class=\"nowrap\">",
"     mcg/week,",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Supplemental iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;To",
"    achieve and maintain target hemoglobin levels noted above with either erythropoietin or darbepoetin, sufficient body iron stores are required. Supplemental iron should be administered, as needed, to maintain a transferrin saturation of &ge;20 percent, and a serum ferritin level of &ge;100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/94\">",
"     94",
"    </a>",
"    ]. Two factors associated with increased hepcidin production in ACD may limit the ability to achieve these levels with oral iron preparations alone (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Hepcidin'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suboptimal intestinal iron absorption is expected when hepcidin levels are increased.",
"     </li>",
"     <li>",
"      Subjects with ACD have functional iron deficiency due to hepcidin-mediated inhibition of the transfer of iron from macrophages to the developing erythron [",
"      <a class=\"abstract\" href=\"UTD.htm?9/13/9434/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, if the patient has not responded to treatment with oral iron preparations, parenteral iron should be administered before considering the patient to be a nonresponder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H34#H34\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Iron monitoring and supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=see_link\">",
"       \"Patient information: Anemia of chronic disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     When to suspect ACD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of chronic disease (ACD) is suspected in a patient with a chronic infectious, inflammatory, or malignant condition who has a mild to moderate normocytic, normochromic anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diagnosis of ACD",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACD is most likely when all of the following are present (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Iron studies'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low serum iron",
"     </li>",
"     <li>",
"      Normal to low serum transferrin (total iron binding capacity)",
"     </li>",
"     <li>",
"      Normal to increased serum ferritin",
"     </li>",
"     <li>",
"      Elevated erythrocyte sedimentation rate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the following test results may also be helpful in diagnosing ACD. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'General findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal to increased levels of serum erythropoietin",
"     </li>",
"     <li>",
"      A reduced reticulocyte response for the degree of anemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Coexisting iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Co-existing iron deficiency is common in patients with ACD. Its presence is suggested by the finding of low serum ferritin levels, absence of stainable iron on bone marrow",
"    <span class=\"nowrap\">",
"     aspiration/biopsy,",
"    </span>",
"    response to a therapeutic trial of oral iron,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increased transferrin",
"    <span class=\"nowrap\">",
"     receptor/ferritin",
"    </span>",
"    index. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'ACD with coexisting iron deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the differential diagnosis of mild to moderate anemia is wide, the following conditions should be considered. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoproliferative anemias (eg, renal disease, endocrine disorders)",
"     </li>",
"     <li>",
"      Iron deficiency anemia, thalassemia, sideroblastic variants of the myelodysplastic syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Appropriate initial studies for patients with suspected ACD include the following. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Laboratory findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count, reticulocyte percentage, white blood cell differential, and examination of the peripheral smear",
"     </li>",
"     <li>",
"      Serum iron studies (ie, serum iron, total iron binding capacity (transferrin), ferritin)",
"     </li>",
"     <li>",
"      Serum creatinine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with ACD have mild anemia that produces no symptoms, being compatible with the patient's often limited lifestyle. Accordingly, treatment should be limited to those with symptomatic anemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First-line therapy is directed at the underlying cause of the ACD.",
"     </li>",
"     <li>",
"      For most patients with ACD who continue to have symptomatic anemia despite treatment of the underlying cause, we suggest use of an erythropoiesis-stimulating agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Erythropoietin and darbepoetin are equally acceptable options. In order to achieve maximal response, supplemental iron should be administered, as needed, to maintain a transferrin saturation of &ge;20 percent, and a serum ferritin level of &ge;100",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Red cell transfusion is warranted when patients with ACD continue to have symptomatic anemia despite both treatment of the underlying cause and use of an erythropoiesis-stimulating agent.",
"     </li>",
"     <li>",
"      The hemoglobin concentration at which treatment should be initiated must be individualized to the patient's symptoms and comorbidities. However, for all patients, we suggest that a hemoglobin level of 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      be the endpoint for both erythropoiesis-stimulating therapy and red cell transfusion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Initial approach'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H36#H36\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/1\">",
"      Cash JM, Sears DA. The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am J Med 1989; 87:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/2\">",
"      Schilling RF. Anemia of chronic disease: a misnomer. Ann Intern Med 1991; 115:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/3\">",
"      Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002; 16:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/4\">",
"      Means RT Jr. Recent developments in the anemia of chronic disease. Curr Hematol Rep 2003; 2:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/5\">",
"      Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/6\">",
"      Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005; 26:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/7\">",
"      Silverberg DS, Wexler D, Palazzuoli A, et al. The anemia of heart failure. Acta Haematol 2009; 122:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/8\">",
"      Price EA, Schrier SL. Unexplained aspects of anemia of inflammation. Adv Hematol 2010; 2010:508739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/9\">",
"      Cullis JO. Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol 2011; 154:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/10\">",
"      Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/11\">",
"      Roy CN. Anemia of inflammation. Hematology Am Soc Hematol Educ Program 2010; 2010:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/12\">",
"      Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol 1999; 70:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/13\">",
"      Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003; 101:4148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/14\">",
"      Theurl I, Mattle V, Seifert M, et al. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood 2006; 107:4142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/15\">",
"      Papadaki HA, Kritikos HD, Gemetzi C, et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 2002; 99:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/16\">",
"      Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 2002; 100:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/17\">",
"      Moldawer LL, Marano MA, Wei H, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989; 3:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/18\">",
"      Raj DS. Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum 2009; 38:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/19\">",
"      Boutou AK, Pitsiou GG, Stanopoulos I, et al. Levels of inflammatory mediators in chronic obstructive pulmonary disease patients with anemia of chronic disease: a case-control study. QJM 2012; 105:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/20\">",
"      Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 1993; 91:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/21\">",
"      Means RT Jr, Krantz SB, Luna J, et al. Inhibition of murine erythroid colony formation in vitro by interferon gamma and correction by interferon receptor immunoadhesin. Blood 1994; 83:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/22\">",
"      Voulgari PV, Kolios G, Papadopoulos GK, et al. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 1999; 92:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/23\">",
"      Libregts SF, Guti&eacute;rrez L, de Bruin AM, et al. Chronic IFN-&gamma; production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis. Blood 2011; 118:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/24\">",
"      Wang CQ, Udupa KB, Lipschitz DA. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J Cell Physiol 1995; 162:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/25\">",
"      Taniguchi S, Dai CH, Price JO, Krantz SB. Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood 1997; 90:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/26\">",
"      Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 2006; 46:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/27\">",
"      Davis D, Charles PJ, Potter A, et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol 1997; 36:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/28\">",
"      Doyle MK, Rahman MU, Han C, et al. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Semin Arthritis Rheum 2009; 39:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/29\">",
"      De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/30\">",
"      Neves PL, Morgado E, Fa&iacute;sca M, et al. Nutritional and inflammatory status influence darbepoetin dose in pre-dialysis elderly patients. Int Urol Nephrol 2006; 38:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/31\">",
"      Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/32\">",
"      Armitage AE, Eddowes LA, Gileadi U, et al. Hepcidin regulation by innate immune and infectious stimuli. Blood 2011; 118:4129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/33\">",
"      Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012; 338:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/34\">",
"      Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117:4425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/35\">",
"      Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/36\">",
"      Roy CN, Custodio AO, de Graaf J, et al. An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice. Nat Genet 2004; 36:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/37\">",
"      Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010; 115:3616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/38\">",
"      Theurl I, Schroll A, Sonnweber T, et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 2011; 118:4977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/39\">",
"      Steinbicker AU, Sachidanandan C, Vonner AJ, et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 2011; 117:4915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/40\">",
"      Rivera S, Liu L, Nemeth E, et al. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005; 105:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/41\">",
"      Schwoebel F, van Eijk LT, Zboralski D, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 2013; 121:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/42\">",
"      Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 2008; 112:4292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/43\">",
"      Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009; 113:5277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/44\">",
"      Hohaus S, Massini G, Giachelia M, et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010; 28:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/45\">",
"      de Mast Q, van Dongen-Lases EC, Swinkels DW, et al. Mild increases in serum hepcidin and interleukin-6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection. Br J Haematol 2009; 145:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/46\">",
"      Weinstein DA, Roy CN, Fleming MD, et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002; 100:3776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/47\">",
"      Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/48\">",
"      Kemna E, Pickkers P, Nemeth E, et al. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/49\">",
"      Kawabata H, Tomosugi N, Kanda J, et al. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 2007; 92:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/50\">",
"      Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010; 116:3627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/51\">",
"      Theurl I, Theurl M, Seifert M, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 2008; 111:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/52\">",
"      Maes K, Nemeth E, Roodman GD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 2010; 116:3635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/53\">",
"      Sasu BJ, Li H, Rose MJ, et al. Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI). Blood Cells Mol Dis 2010; 45:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/54\">",
"      Arlet JB, Hermine O, Darnige L, et al. Iron-deficiency anemia in Castleman disease: implication of the interleukin 6/hepcidin pathway. Pediatrics 2010; 126:e1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/55\">",
"      Ferrucci L, Semba RD, Guralnik JM, et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood 2010; 115:3810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/56\">",
"      Truksa J, Peng H, Lee P, Beutler E. Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol 2007; 139:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/57\">",
"      Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006; 108:3204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/58\">",
"      Verga Falzacappa MV, Vujic Spasic M, Kessler R, et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007; 109:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/59\">",
"      Pietrangelo A, Dierssen U, Valli L, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 2007; 132:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/60\">",
"      Wang L, Trebicka E, Fu Y, et al. The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/61\">",
"      Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116:4754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/62\">",
"      Thomas C, Kobold U, Thomas L. Serum hepcidin-25 in comparison to biochemical markers and hematological indices for the differentiation of iron-restricted erythropoiesis. Clin Chem Lab Med 2011; 49:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/63\">",
"      van Iperen CE, van de Wiel A, Marx JJ. Acute event-related anaemia. Br J Haematol 2001; 115:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/64\">",
"      Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/65\">",
"      Rodriguez RM, Corwin HL, Gettinger A, et al. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001; 16:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/66\">",
"      Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002; 288:2827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/67\">",
"      Lasocki S, Millot S, Andrieu V, et al. Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia. Crit Care Med 2008; 36:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/68\">",
"      van Eijk LT, Kroot JJ, Tromp M, et al. Inflammation-induced hepcidin-25 is associated with the development of anemia in septic patients: an observational study. Crit Care 2011; 15:R9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/69\">",
"      Sihler KC, Raghavendran K, Westerman M, et al. Hepcidin in trauma: linking injury, inflammation, and anemia. J Trauma 2010; 69:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/70\">",
"      Vreugdenhil G, L&ouml;wenberg B, van Eijk HG, Swaak AJ. Anaemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis. Rheumatol Int 1990; 10:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/71\">",
"      Macci&ograve; A, Madeddu C, Massa D, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005; 106:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/72\">",
"      ELLIS LD, JENSEN WN, WESTERMAN MP. MARROW IRON. AN EVALUATION OF DEPLETED STORES IN A SERIES OF 1,332 NEEDLE BIOPSIES. Ann Intern Med 1964; 61:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/73\">",
"      GARDNER DL, ROY LM. Tissue iron and the reticulo-endothelial system in rheumatoid arthritis. Ann Rheum Dis 1961; 20:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/74\">",
"      Chaves PH, Xue QL, Guralnik JM, et al. What constitutes normal hemoglobin concentration in community-dwelling disabled older women? J Am Geriatr Soc 2004; 52:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/75\">",
"      Suominen P, M&ouml;tt&ouml;nen T, Rajam&auml;ki A, Irjala K. Single values of serum transferrin receptor and transferrin receptor ferritin index can be used to detect true and functional iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum 2000; 43:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/76\">",
"      Fitzsimons EJ, Houston T, Munro R, et al. Erythroblast iron metabolism and serum soluble transferrin receptor values in the anemia of rheumatoid arthritis. Arthritis Rheum 2002; 47:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/77\">",
"      Wians FH Jr, Urban JE, Keffer JH, Kroft SH. Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status vs transferrin receptor concentration. Am J Clin Pathol 2001; 115:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/78\">",
"      Punnonen K, Irjala K, Rajam&auml;ki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997; 89:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/79\">",
"      Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002; 48:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/80\">",
"      Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003; 49:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/81\">",
"      Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ 2008; 179:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/82\">",
"      Lind M, Vernon C, Cruickshank D, et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002; 86:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/83\">",
"      Culleton BF, Manns BJ, Zhang J, et al. Impact of anemia on hospitalization and mortality in older adults. Blood 2006; 107:3841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/84\">",
"      Denny SD, Kuchibhatla MN, Cohen HJ. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 2006; 119:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/85\">",
"      Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994; 84:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/86\">",
"      Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/87\">",
"      Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med 1992; 117:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/88\">",
"      Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/89\">",
"      Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002; 20:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/90\">",
"      Gonz&aacute;lez-Bar&oacute;n M, Ord&oacute;&ntilde;ez A, Franquesa R, et al. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy. Cancer 2002; 95:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/91\">",
"      Soignet S. Management of cancer-related anemia: epoetin alfa and quality of life. Semin Hematol 2000; 37:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/92\">",
"      Cazzola M, Beguin Y, Kloczko J, et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/93\">",
"      Coccia MA, Cooke K, Stoney G, et al. Novel erythropoiesis stimulating protein (darbepoetin alfa) alleviates anemia associated with chronic inflammatory disease in a rodent model. Exp Hematol 2001; 29:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/13/9434/abstract/94\">",
"      Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22:1301.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7149 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-07C7D38949-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9434=[""].join("\n");
var outline_f9_13_9434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      The role of cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hepcidin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21195242\">",
"      - Hepcidin assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute variant of ACD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      General findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Iron studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Normocytic hypoproliferative anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Microcytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ACD with coexisting iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Soluble transferrin receptor assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Erythrocyte indices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Initial approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dosage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Darbepoetin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Supplemental iron",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      When to suspect ACD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diagnosis of ACD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Coexisting iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7149\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7149|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/53/35677\" title=\"figure 1\">",
"      Serum EPO and anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/45/8916\" title=\"figure 2\">",
"      Mechanism for anemia of chronic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/56/1927\" title=\"figure 3\">",
"      Hepcidin regulatory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/11/39088\" title=\"figure 4\">",
"      Ferroportin hepcidin function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/36/15950\" title=\"figure 5\">",
"      TfR ferritin index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7149|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/57/7064\" title=\"picture 1\">",
"      Anemia chron dis marrow iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/705\" title=\"picture 2\">",
"      Ring sideroblasts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7149|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/26/428\" title=\"table 1\">",
"      Causes of microcytic anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6486?source=related_link\">",
"      Anemia and left ventricular hypertrophy in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22538?source=related_link\">",
"      Anemia in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4120?source=related_link\">",
"      Evaluation of health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3098?source=related_link\">",
"      Hematologic manifestations of HIV infection: Anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=related_link\">",
"      Hematologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=related_link\">",
"      Patient information: Anemia of chronic disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=related_link\">",
"      The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_13_9435="Physiologic values in postop";
var content_f9_13_9435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expected hemodynamic variables in the immediate post-operative period",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expected value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mean arterial pressure (MAP)",
"       </td>",
"       <td>",
"        60 - 90 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systolic blood pressure (SBP)",
"       </td>",
"       <td>",
"        90 - 140 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right atrial pressure (RAP)",
"       </td>",
"       <td>",
"        5 - 15 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary artery wedge pressure (PAWP)",
"       </td>",
"       <td>",
"        10 - 15 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac index (CI)",
"       </td>",
"       <td>",
"        2.2 - 4.4 L/min/M2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic vascular resistance (SVR)",
"       </td>",
"       <td>",
"        1400 - 2800 dyn-s-cm5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9435=[""].join("\n");
var outline_f9_13_9435=null;
var title_f9_13_9436="Elements comp geri assess";
var content_f9_13_9436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Elements of a comprehensive geriatric assessment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter assessed",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elements of the assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Function",
"       </td>",
"       <td>",
"        Performance status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activities of daily living",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Instrumental activities of daily living",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Timed Get Up and Go",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Comorbidity",
"       </td>",
"       <td>",
"        Number of comorbid conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severity of comorbid conditions (comorbidity index)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Socioeconomic conditions",
"       </td>",
"       <td>",
"        Living conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence and adequacy of a caregiver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Cognition",
"       </td>",
"       <td>",
"        Folstein's Mini-mental Status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emotional conditions",
"       </td>",
"       <td>",
"        Geriatric Depression Scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Pharmacy",
"       </td>",
"       <td>",
"        Number of medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appropriateness of medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of drug interactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutrition",
"       </td>",
"       <td>",
"        Mini-Nutritional Assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Geriatric syndromes",
"       </td>",
"       <td>",
"        Dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delirium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Falls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neglect and abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous bone fractures",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced and modified with permission from: Kohne CH, Folprecht G, Goldberg RM, et al. Chemotherapy in Elderly Patients with Colorectal Cancer. The Oncologist 2008; 13:390. Copyright &copy; 2008 AlphaMed Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9436=[""].join("\n");
var outline_f9_13_9436=null;
var title_f9_13_9437="DDx of rash by appearance 2";
var content_f9_13_9437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of fever and rash based upon appearance of the rash",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Macules, papules, nodules, or plaques",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vesicles, bullae, or pustules",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purpuric macules, purpuric papules, or purpuric vesicles",
"       </td>",
"       <td class=\"subtitle1\">",
"        Widespread erythema with or without edema followed by desquamation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Blastomyces dermatitidis*",
"        </p>",
"        <p>",
"         Candida spp",
"        </p>",
"        <p>",
"         Coccidioides immitis",
"        </p>",
"        <p>",
"         Cryptococcus neoformans",
"        </p>",
"        <p>",
"         Histoplasma capsulatum",
"        </p>",
"        <p>",
"         Other disseminated deep fungal infections in immunocompromised patients",
"        </p>",
"       </td>",
"       <td>",
"        Histoplasma capsulatum",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Adenovirus",
"        </p>",
"        <p>",
"         Arbovirus",
"        </p>",
"        <p>",
"         Atypical measles*",
"        </p>",
"        <p>",
"         Colorado tick fever",
"        </p>",
"        <p>",
"         Coxsackieviruses A and B",
"        </p>",
"        <p>",
"         Cytomegalovirus, primary infection",
"        </p>",
"        <p>",
"         Dengue virus",
"        </p>",
"        <p>",
"         Epstein-Barr virus, primary infection",
"        </p>",
"        <p>",
"         Echoviruses",
"        </p>",
"        <p>",
"         Hepatitis B (urticaria)*",
"        </p>",
"        <p>",
"         Human herpesvirus 6 (exanthem subitum)*",
"        </p>",
"        <p>",
"         Human immunodeficiency virus (HIV-1)*",
"        </p>",
"        <p>",
"         Kawasaki syndrome (presumed viral)",
"        </p>",
"        <p>",
"         Molluscum contagiosum",
"        </p>",
"        <p>",
"         Orf",
"        </p>",
"        <p>",
"         Parvovirus B19 (erythema infectiosum {fifth disease})",
"        </p>",
"        <p>",
"         Rubella (German measles)*",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Rubeola (measles)*",
"        </p>",
"        <p>",
"         Varicella (chickenpox)*",
"        </p>",
"        <p>",
"         Varicella zoster (disseminated)",
"        </p>",
"        <p>",
"         Viral hemorrhagic fevers (many)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Colorado tick fever",
"        </p>",
"        <p>",
"         Coxsackie A5, 9, 10, 16, B2, 7",
"        </p>",
"        <p>",
"         Echoviruses",
"        </p>",
"        <p>",
"         Eczema herpeticum",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Herpes simplex (disseminated)",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Varicella (chickenpox)",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Varicella-zoster (disseminated)",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Adenovirus (rare)",
"        </p>",
"        <p>",
"         Atypical measles*",
"        </p>",
"        <p>",
"         Colorado tick fever",
"        </p>",
"        <p>",
"         Congenital cytomegalovirus",
"        </p>",
"        <p>",
"         Coxsackie A and B (rare, types A-9, B2-5)",
"        </p>",
"        <p>",
"         Dengue fever",
"        </p>",
"        <p>",
"         Epstein-Barr virus (rare)",
"        </p>",
"        <p>",
"         Echoviruses (rare, types 3, 4, 9)",
"        </p>",
"        <p>",
"         Rubella*",
"        </p>",
"        <p>",
"         Varicella zoster virus",
"        </p>",
"        <p>",
"         Yellow fever",
"        </p>",
"       </td>",
"       <td>",
"        Kawasaki syndrome (presumed viral)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Reportable disease.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      May have arthralgia or musculoskeletal pain.",
"      <br>",
"       &Delta; Umbilicated papule or vesicle a characteristic of these exanthems.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. Originally modified with permission from Fitzpatrick TB, et al: Color Atlas &amp; Synopsis of Clinical Dermatology - Common and Serious Diseases. Fitzgerald TB, et al (Eds), McGraw-Hill, New York, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9437=[""].join("\n");
var outline_f9_13_9437=null;
var title_f9_13_9438="Wernicke-Lichtheim model";
var content_f9_13_9438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Wernicke Lichtheim model",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 317px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Mendez, MF, Clark, DG. Neuropsychiatric aspects of aphasia and related disorders. In: The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences, 5th ed, Yudofsky, SC, Hales, RH (Eds), American Psychiatric Publishing, Washington, DC 2007. p.521.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_13_9438=[""].join("\n");
var outline_f9_13_9438=null;
var title_f9_13_9439="Contents: Blood disorders";
var content_f9_13_9439=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Blood disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Blood disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Anemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/49/30484\">",
"           Patient information: Anemia caused by low iron (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/53/19281\">",
"           Patient information: Anemia caused by low iron (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/15/20721\">",
"           Patient information: Anemia of chronic disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/4/30785\">",
"           Patient information: Aplastic anemia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/51/12081\">",
"           Patient information: Autoimmune hemolytic anemia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/57/7057\">",
"           Patient information: Pernicious anemia (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Anticoagulation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/11/14515\">",
"           Patient information: Latest medicines to prevent blood clots (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/43/28337\">",
"           Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21747\">",
"           Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/44/2755\">",
"           Patient information: Warfarin (Coumadin) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antiphospholipid syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/16/16642\">",
"           Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Blood clots in the legs or lungs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/44/12998\">",
"           Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/3/1075\">",
"           Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24067\">",
"           Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Blood donation and transfusion",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/52/22338\">",
"           Patient information: Blood donation (giving blood) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/12/26820\">",
"           Patient information: Blood donation and transfusion (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Blood tests",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/26/5537\">",
"           Patient information: Complete blood count (CBC) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bone marrow transplant",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/47/2802\">",
"           Patient information: Bone marrow transplant (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/4/34886\">",
"           Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disseminated intravascular coagulation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/62/994\">",
"           Patient information: Disseminated intravascular coagulation (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Factor V Leiden",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/60/24514\">",
"           Patient information: Factor V Leiden (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         G6PD deficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/41/12946\">",
"           Patient information: Glucose-6-phosphate dehydrogenase deficiency (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemochromatosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/15/40179\">",
"           Patient information: Hemochromatosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/41/2709\">",
"           Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemophilia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/24/29058\">",
"           Patient information: Hemophilia (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         ITP",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29970\">",
"           Patient information: Immune thrombocytopenia (ITP) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Leukemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/15/15602\">",
"           Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/34/17955\">",
"           Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/4/14402\">",
"           Patient information: Acute myeloid leukemia (AML) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34275\">",
"           Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/39/12914\">",
"           Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/10/6309\">",
"           Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/58/12194\">",
"           Patient information: Chronic myeloid leukemia (CML) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/60/37829\">",
"           Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/12/13506\">",
"           Patient information: Hairy cell leukemia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/13/38098\">",
"           Patient information: Leukemia in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24194\">",
"           Patient information: Leukemia in children (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lymphoma and Hodgkin's disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/19/26930\">",
"           Patient information: Diffuse large B-cell lymphoma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27588\">",
"           Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/23/18802\">",
"           Patient information: Follicular lymphoma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/9/8339\">",
"           Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/37/13908\">",
"           Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23714\">",
"           Patient information: Hodgkin lymphoma in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/50/31523\">",
"           Patient information: Hodgkin lymphoma in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40386\">",
"           Patient information: Lymphoma (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple myeloma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/23/16754\">",
"           Patient information: Monoclonal gammopathy of undetermined significance (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29090\">",
"           Patient information: Multiple myeloma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/16/12547\">",
"           Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/40/31366\">",
"           Patient information: Multiple myeloma treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myelodysplastic syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/1/9234\">",
"           Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/26/6564\">",
"           Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neutropenia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/59/25521\">",
"           Patient information: Neutropenia (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polycythemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/14/12513\">",
"           Patient information: Polycythemia vera (PV) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Porphyrias",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/25/27025\">",
"           Patient information: Porphyrias (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary embolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/3/1075\">",
"           Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/29/2517\">",
"           Patient information: Pulmonary embolism (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24067\">",
"           Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sepsis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/50/33569\">",
"           Patient information: Sepsis in adults (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sickle cell disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/8/4227\">",
"           Patient information: Sickle cell anemia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/12/22723\">",
"           Patient information: When your child has sickle cell disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thalassemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/14/7394\">",
"           Patient information: Thalassemia (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         von Willebrand disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/55/6002\">",
"           Patient information: von Willebrand disease (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/32/39425\">",
"           Patient information: von Willebrand disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E4E7EDA024-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f9_13_9439=[""].join("\n");
var outline_f9_13_9439=null;
